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The endolysosome and autophagy−mediated quality control systems maintain the homeostasis 
and physiology of epithelial cells lining the kidney tubules. Defects in the autophagy-
endolysosome degradation system leads to kidney tubule dysfunction and chronic kidney 
disease. The mechanisms linking endolysosomal dysfunction and tubular cell damage remain 
unknown, slowing down the development of novel therapies. Studies of inherited kidney 
diseases, through the use of in vitro and in vivo genetically-modified model organisms, help to 
decipher the pathways that regulate the endolysosomal system in kidney tubule cells. In turn, 
novel pathogenic cascades can help to design targeted treatments. Drug repurposing, which 
identifies new uses for already approved drugs, offers crucial advantages compared to the 
development of new compounds, for instance in reducing costs and risk of failure, or improving 
safety. Over the past years, identification of repurposed drugs has often been successful in the 
field of rare diseases. Taking these advantages into account, we applied a strategy of drug 
repurposing in two rare diseases targeting the endolysosomal and autophagy pathways in the 
kidney.  
In the first part of thesis, we characterized a new OCRL-deficient mouse model for Lowe 
syndrome/Dent disease 2 and the derived primary cultures of proximal tubule (PT) cells, in 
order to decipher the role of OCRL in the reabsorptive function of PT cells and its involvement 
in endocytic trafficking. Novel pathogenic cascades linking PI(4,5)P2, aberrant actin 
polymerization, endocytic trafficking and PT cell function were identified. These findings led 
us to test class I PI3K inhibitors, already developed for cancer therapy, thus potentially 
amenable for drug repurposing. In the second part, we used cell and animal-based models to 
study the pathophysiology of Methylmalonic acidemia (MMA) and we described the 
mechanism linking methylmalonyl-coenzyme A mutase deficiency, PINK1/Parkin-mediated 
mitophagy, mitochondria homeostasis and the integrity of tubular cells. We integrated these 
findings into a drug-disease network-based computational modeling approach and identified 
targetable pathways to predict drug repurposing. We validated the in silico analysis by showing 
a beneficial effect of targeting mitochondria function, which reversed cellular dysfunction 
associated with MMA. Taken together, these studies improved our understanding of alterations 
of endomembrane trafficking and cellular homeostasis in a disease context, and identified 
promising candidates for drug repurposing in rare genetic diseases affecting the kidneys. 
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List of abbreviations 
AMN: amnionless  
AMPK: adenosine monophosphate-activated protein kinase  
AKI: acute kidney disease 
AP2: adaptor protein-2  
ATG: autophagy related protein 
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1. The proximal tubule of the kidney 
The kidneys maintain the body fluid and electrolyte homeostasis through the appropriate 
handling of water and solutes (van der Wijst et al. 2019). The nephron, the structural and 
functional unit of the kidney, is composed of a filtering component named glomerulus and a 
long tubule formed by differentiated segments, including the proximal tubule (PT), the loop of 
Henle, the distal tubule, the connecting tubule and the collecting duct (Figure 1). The human 
kidneys filter approximatively 180 L of fluid per day, but only 1,5 L of final urine is excreted, 
demonstrating the major role of this organ in the control of homeostasis via the reabsorption of 
essential nutrients (Zhuo and Li 2013). The ultrafiltrate is modified along the tubular passage; 
however, it is well known that the PT is the largest contributor to these changes. In fact, the PT 
is able to reabsorb 65% of the filtered load, the majority of amino acids, solutes, and low 
molecular weight (LMW) proteins. It is also involved in the acid-base balance (via the uptake 
of filtered bicarbonate), glucose metabolism (by reabsorbing glucose and regulating 
gluconeogenesis) and in the homeostasis and metabolism of essential vitamins (by reabsorbing 
and processing vitamin-binding proteins) (De Matteis et al. 2017; Eckardt et al. 2013; 
Christensen and Gburek 2004).  
 
Figure 1: Structure of the nephron, functional unit of the kidney. The nephron is composed of a filtering unit 





1.1. Architecture  
The PT is composed of a monolayer of polarized epithelial cells. The apical plasma membrane 
of the PT cells forms a brush border that consists of dense microvilli facing the lumen of the 
tubule. These tightly packed microvilli increase the apical surface area absorption by 
approximately 40 times. The basolateral membrane is also folded, increasing the surface area 
available for solute exchange. The PT cells are connected by tight junctions, located next to the 
tubule lumen, maintaining the continuity and polarity of the epithelium (Christensen, Wagner, 
and Kaissling 2012). The tight junctions are different along the tubular segments and are 
involved in several functions. In fact, these complex and dynamic structures are constituents of 
a barrier against paracellular movement of water and ions and are also expressed in signaling 
platforms regulating epithelial biogenesis and functions (Denker and Sabath 2011). The PT 
cells contain many elongated mitochondria that occupy a substantial part of the cell volume and 
are located on the basolateral side. The mitochondria provide the energy required for the high 
transport activity of these epithelial cells. In fact, production of ATP is necessary for the activity 
of the Na+˗K+-ATPase (sodium pump) and other energy demanding transport systems 
associated with the apical and basolateral plasma membrane. An efficient and well developed 
vesicular system, consisting of endocytic invaginations (coated pits), endocytic vesicles, 
vacuoles (early and late endosomes) and lysosomes, characterizes the PT cells. This 
endolysosomal system facilitates the reabsorption and the degradation of solutes in the PT cells 
(Christensen, Wagner, and Kaissling 2012).  
Based on electron microscopy analysis, the PT segment has been divided into three 
interconnecting segments: S1, S2 and S3 (Figure 3). The structural difference between S1 and 
S2 are subtler, while S2 changes suddenly in S3. Compared to the S3, the cells lining the S1 
and S2 segments are characterized by a bigger brush border, a higher number of mitochondria 
and a more developed endolysosomal system (Christensen, Wagner, and Kaissling 2012; 
Polesel and Hall 2019). The morphological distinction between each segment suggests different 
reabsorptive capacity among the three segments, with higher capacity in S1 and S2 compared 





Figure 2: Ultrastructure of the three segments of the proximal tubule. In the first segment (S1), the brush 
border (BB) is taller than in the second segment (S2). The mitochondria (M) and endocytic vacuoles (E) are 
numerous in S1 and S2. The lysosomes appear smaller in the third segment (S3) compared to S1 and S2 (modified 
from Christensen et al, Comprehensive Physiology, 2012). 
 
1.2. Reabsorptive function 
The reabsorptive capacity of PT cells depend on the expression, trafficking and interaction of 
specific transport systems that are expressed on the apical and basolateral membranes. The 
Na+˗K+-ATPase is expressed at the basolateral side and drives the reabsorption of solutes via 
specific sodium-dependent cotransporters located in the apical membrane (Figure 3). The 
sodium pump creates a low cellular Na+ concentration and a negative membrane potential, 
which provides the energy required to transport a multitude of solutes (including glucose, amino 
acids and ions) across the plasma membrane of the PT cells. The mitochondria provide the 
energy necessary for Na+˗K+-ATPase activity (Curthoys and Moe 2014).  
PT cells reabsorb a significant amount of albumin (66,5 kDa) and are responsible for the 
massive uptake of LMW proteins (molecular weight below that of albumin) that are filtered by 
the glomerulus. These LMW proteins include hormones, vitamin carrier proteins, enzymes, 
lipoproteins, cell surface antigen components, immunoglobulin light chains, drugs and toxins 
(van der Wijst et al. 2019). After internalisation of the proteins via receptor-mediated and 
clathrin-mediated endocytosis (and potentially fluid phase), the substances are processed, 
metabolized in the lysosomes and released into the blood circulation. This process represents 
80% of the clearance of small proteins, therefore, the human urine is virtually devoid of plasma 
proteins (Nielsen, Christensen, and Birn 2016). This massive uptake is essential for hormonal 
homeostasis, the maintenance of essential vitamins such as vitamins D, A and B12, and to 
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conserve a protein-free environment for the cells lining the distal nephron (Christensen and 
Birn 2002; Dusso 2011). 
 
Figure 3: Proximal tubule transport. The transport systems in PT cells is driven by the electrochemical gradient 
generated by the basolateral Na+˗K+-ATPase. These transport processes, that require a high energy level, are 
sustained by the numerous mitochondria present in tubular cells (modified from Curthoys et al, CJASN, 2014). 
 
1.3. Renal Fanconi syndrome: global dysfunction of proximal tubule 
The proximal tubule is essential for the reabsorption of water and electrolytes and processing 
of filtered plasma proteins. Therefore, the PT cells are very sensitive to any defect regarding 
differentiation, membrane trafficking and the endolysosomal system. The loss of apical 
transport function in these cells leads to the urinary loss of LMW proteins and solutes, including 
glucose, phosphate and amino acids, which is referred as renal Fanconi syndrome (Klootwijk 
et al. 2015; van der Wijst et al. 2019). This clinical entity was described in the 1930’s by De 
Toni, Debré and Fanconi, who reported independently several paediatric cases presenting renal 
rickets, glycosuria and albuminuria. Renal Fanconi syndrome (also called De Toni – Debré – 
Fanconi syndrome to acknowledge their pioneering work) is characterised by a generalized PT 
dysfunction, leading to massive loss of amino acids, glucose, phosphate, bicarbonate, uric acid 
and other solutes in the urine (Klootwijk et al. 2015). This defect induces acidosis, dehydration, 
electrolyte imbalances, rickets and osteomalacia and osteoporosis, culminating in the onset and 
progression of chronic kidney disease (CKD) (Devuyst and Igarashi 2018).  
The renal Fanconi syndrome can be a congenital or acquired disorder, and can be either 






Table 1: Causes of proximal tubule dysfunction and renal Fanconi syndrome 
Congenital 
 
• Arthrogryposis, renal dysfunction and cholestasis 1; ARCS1 (VPS33B; MIM #208085) 
• Arthrogryposis, renal dysfunction and cholestasis 2; ARCS2 (VIPAS39; MIM #613404) 
• Cystinosis (CTNS; MIM #219800) 
• Cystinuria (SLC3A1, SLC7A9; MIM #220100) 
• Dent disease 1 (CLCN5; MIM #300009) 
• Dent disease 2 (OCRL; MIM #300555) 
• Donnai–Barrow syndrome (LRP2; MIM #222448) 
• Fanconi renotubular syndrome 1; FRTS1 (GATM, MIM #134600) 
• Fanconi renotubular syndrome 2; FRTS2 (SLC34A1; MIM #613388) 
• Fanconi renotubular syndrome 3; FRTS3 (EHHADH; MIM #615605) 
• Fanconi renotubular syndrome 4; FRTS4 (HNF4A; MIM #616026) 
• Fanconi–Bickel syndrome (SLC2A2; MIM #227810) 
• Galactosemia (GALT; MIM #230400) 
• Glycogen storage disease Ia (G6PC; MIM #232200) 
• Hereditary fructose intolerance (ALDOB; MIM #229600) 
• Imerslund–Grasbeck syndrome 1 (CUBN; MIM #261100) 
• Imerslund–Grasbeck syndrome 2 (AMN; MIM #618882) 
• Iminoglycinuria (SLC6A20, SLC6A19, SLC36A2; MIM #242600) 
• Lowe oculocerebrorenal syndrome (OCRL; MIM #309000) 
• Maturity-onset diabetes of the young type 3 (HNF1A; MIM #600496) 
• Renal tubular acidosis proximal, autosomal recessive (SLC4A4; MIM #604278) 
• Tyrosinaemia type I (FAH; MIM #276700) 






• Sjögren syndrome 
• Renal transplantation 
• Acute tubulointerstitial nephritis with uveitis (TINU) syndrome 
• Autoimmune interstitial nephritis and membranous nephropathy 
• Primary biliary cirrhosis 




• Drugs: aminoglycosides, salicylate, valproic acid, Chinese herbal medicine, ifosfamide, cisplatin, 
imatinib, mesylate, adefovir, cidofovir, tenofovir, zoledronic acid, deferasirox, dinanosine, 
gentamicin, azathioprine, streptozocin, ranitidine 
• Chemical compounds: paraquat, bismus, methyl-3-chromone, 6-mercaptopurine, toluene 
• Heavy metals: lead, cadmium, mercury, chromium, platinum 
• Honeybee stings: melittin 
 






Inherited disorders can be caused by mutations in genes encoding endocytic receptors 
(e.g. Donnai–Barrow MIM #222448 and Imerslund–Grasbeck diseases MIM #261100) 
(Nielsen, Christensen, and Birn 2016), components of the endolysosomal system (e.g. Lowe 
syndrome MIM #309000, Dent diseases (De Matteis et al. 2017) and cystinosis MIM #219800) 
(Cherqui and Courtoy 2017), and components of the mitochondrial network (e.g. mitochondrial 
cytopathies) (Emma et al. 2016). The renal Fanconi syndrome can also be induced either by 
exogenous substances (e.g. toxins, drugs) or is associated with autoimmune disorders (e.g. light 
chain monoclonal gammopathy) (Luciani et al. 2015). 
The primary therapy for this syndrome is to treat the cause and replace the substances lost 
in the urine. For instance, the dehydration resulting from polyuria is prevented by 
administration of fluids and electrolytes. Rickets and ostemalacia can be improved by 
supplementation with phosphate, in combination with vitamin D3 (Foreman 2019). The 
prognosis of the patient depends on the cause and the severity of the manifestation. The genetic 
disorders remain a challenge to manage because of the involvement of organs other than the 
kidney and growth impairment, therefore further research regarding etiology and therapy are 
necessary (Karatzas et al. 2017).  
 
2. Role of endomembrane trafficking in proximal tubule 
The main function of PT cells is to reabsorb water/electrolytes and to process proteins, sustained 
by a well-developed endolysosomal system. Proteins reabsorption occurs predominantly by 
receptor-mediated endocytosis, and potentially by fluid-phase (Eshbach and Weisz 2017). For 
both processes, the cargoes are internalized into clathrin-coated structures and degraded inside 
lysosomes (Dickson et al. 2014). The incapacity to internalize or process cargoes is a feature of 
Renal Fanconi syndrome, demonstrating the crucial role of the endolysosomal compartment to 
maintain kidney function (Devuyst and Luciani 2015).  
 
2.1. Endolysosomal system 
2.1.1. Receptor mediated endocytosis 
The LMW proteins filtered by glomerulus are reabsorbed and metabolized by PT cells, such 
that the urine is almost devoid of plasma proteins in physiological conditions (Figure 4a). The 
endocytic receptors megalin and cubilin, which are located at the apical membrane of PT cells, 
coordinate the uptake of most urinary proteins (De Matteis et al. 2017).  
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Megalin (also known as gp330 or LRP2) is a 600 kDa protein encoded by the LRP2 gene  
gene and a member of low-density lipoprotein (LDL) receptor family (Nielsen, Christensen, 
and Birn 2016). It is expressed at the apical surface of the PT cells, with a higher expression in 
S1 segment, and it is present in the apical endocytic compartments (Schuh et al. 2018). This 
transmembrane glycoprotein possesses a large amino-terminal extracellular domain, a single 
transmembrane domain, and a short carboxyl terminal cytoplasmic tail (Figure 4b). The 
extracellular domain of megalin mediates the interaction with ligands in the brush border. It is 
composed of four clusters of cysteine-rich complement-type repeats, which constitute the 
ligand-binding region. These motifs are separated by 17 epidermal growth factor (EGF)-type 
repeats and eight spacer regions, which contain YWTD motifs, implicated in the dissociation 
of the ligand in acidic environment and recycling of the receptor. The cytoplasmic tail contains 
two NPXY sequences that mediate endocytosis, and one additional ‘NPXY-like’ motif 
(VENQNY) that directs the expression of megalin at the apical membrane (Figure 4b). Megalin 
binds and mediates the internalization of many ligands, including plasma protein peptides, 
enzymes, vitamin-binding proteins, hormones, and hormone-binding proteins, drugs and toxins 
(Christensen and Birn 2002). For some ligands, megalin requires the interaction with another 
receptor, cubilin. Cubilin is a 460-kDa peripheral membrane glycoprotein, also identified as an 
intestinal intrinsic factor receptor with no transmembrane segments. Cubilin is composed of 27 
C-terminal CUB domains which are ligand binding. The N-terminal part is composed by a 
stretch of 110 amino acids and by eight Epidermal Growth Factor (EGF)-type repeats (Figure 
4b) (Christensen et al. 2012). The interaction between both receptors forms a multireceptor 
complex and increases their binding capacity. In addition, cubilin can bind exclusively other 
proteins that do not bind megalin such as transferrin, intrinsic-factor vitamin B12 complex and 
apolipoprotein A1. The membrane localization of cubilin depends on the interaction between 
its EGF domains and the single transmembrane protein amnionless (AMN) (Fyfe et al. 2004). 
Amnionless is responsible for the transport of cubilin to the apical surface; the lack of AMN in 
a mouse model or the mutation of the protein in a dog model causes the retention of cubilin in 
intracellular structures (Christensen et al. 2012).  
The involvement of these apical receptors in the reabsorption of LMW proteins is 
supported by rare diseases associated with genetic defects of megalin (Donnai–Barrow facio-
oculo-acousticorenal syndrome, MIM #222448), cubilin (Imerslund–Gräsbeck syndrome 1 or 
megaloblastic anemia 1, MIM #261100) or amnionless (Imerslund–Grasbeck syndrome 2, 
MIM #618882) and animal models deficient for megalin or cubilin (Nielsen, Christensen, and 
Birn 2016). The loss of megalin expression in mice is associated with emphysematous lung 
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phenotype and forebrain defects. A typical PT dysfunction was observed in this mouse model, 
associated with LMW proteinuria and defective bone formation due to the impaired endocytosis 
of vitamin D-binding proteins (Leheste et al. 1999). These data suggest the key role of the 
endocytic receptors in lung and brain development, as well as for kidney function. In humans, 
LMW proteinuria has been described in all patients who showed loss of megalin, due to 
inherited or acquired conditions (Bedin et al. 2020). Albuminuria has been also observed in 
patients presenting variants in the CUBN gene. The majority of the variants were observed after 
the vitamin B12-binding domains, suggesting the crucial role of the C-terminal domain of 
cubilin in albumin reabsorption (Bedin et al. 2020). Conversely, the excessive uptake of 
proteins due to glomerular leakage has been involved in the progression of chronic kidney 
diseases by activation of several pathways, including apoptosis, endoplasmic reticulum stress, 
interstitial inflammation and fibrosis (Zoja, Abbate, and Remuzzi 2014; Karoui et al. 2016). 
However, the role of the endocytic receptors in protein overload condition is not yet deciphered. 
Megalin has been also described to be involved in the uptake of nephrotoxic agents leading to 
acute kidney injury such as gentamicin, aprotinin and aristolochic acid (Mahadevappa et al. 
2013). 
 
Figure 4: Receptor-mediated endocytosis. (a) Filtered proteins, including albumin, bind to receptors, which 
mediate the internalization of the complex ligand-receptor via clathrin-coated pits and their transport to the 
endosomes and lysosomes for degradation. (b) Structure of megalin, cubilin and amnionless (from (a) Christensen 
and Birn, Nature Review Nephology, 2013 (b) Christensen et al, Physiology, 2012). 
 
2.1.2. Endocytic transport and processing of filtered ligands 
The binding of a ligand with the endocytic receptors induces the uptake of the complex ligand-
receptor into clathrin-coated vesicles (CCV) and their transport toward the endocytic 
compartment for the final degradation into the lysosome (Welling and Weisz 2010).    
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The formation of clathrin-coated vesicles is composed of five steps: initiation, cargo 
selection, coat assembly, scission and uncoating (Figure 5). The first event is the interaction 
between the ligand and the receptor, which induces the recruitment of the adaptor protein-2 
(AP2) to the plasma membrane. AP2 is a highly conserved protein that binds the endocytic 
motifs present in the cytosolic tail of receptors (e.g. NXPY motifs for both megalin and 
cubilin/amnionless complex) or interacts with phosphatidylinositol 4,5-bisphosphate 
(PI(4,5)P2), a plasma membrane-specific lipid (McMahon and Boucrot 2011). This initiation 
stage involves accessory proteins that define the site of the plasma membrane where it will be 
internalized (Kaksonen and Roux 2018). This nucleation module mediates cargo selection and 
the recruitment of clathrin to the plasma membrane. The polymerization of clathrin stabilizes 
the curvature of the membrane and helps for the formation of the invagination neck. After the 
assembly of the clathrin-coat, actin filaments polymerize and form the actin module, composed 
by actin filament network and regulatory components including Wiskott-Aldrich syndrome 
(WAS) proteins, myosin motor proteins and dynamin (Kaksonen and Roux 2018). This actin 
cytoskeleton contributes to the membrane bending. The GTPase dynamin is recruited by BAR 
domain-containing proteins such as sorting nexin 9 (SNX9), amphiphysin and endophilin which 
have an affinity for the curvature of the neck. This mechanochemical enzyme mediates the 
constriction and the scission of the vesicles neck (Doherty and McMahon 2009).The 
polymerisation of dynamin creates a helical polymer around the constricted neck, induces GTP 
hydrolysis and therefore the fission of the vesicle from the plasma membrane. Once the vesicle 
is released into the interior of the cell, the endocytic machinery proteins and the clathrin coat 
are disassembled and can be used for another endocytic event. The breakage of clathrin-clathrin 
interaction is mediated the ATPase heat shock cognate 70 (HSC70) and its co-factor auxilin. 
Changes in the phosphoinositide composition of CCV are necessary for the uncoating step and 
are mediated by the phosphatases synaptojanin or inositol polyphosphate 5-phosphatase OCRL 
(Oculocerebrorenal protein) (McMahon and Boucrot 2011; De Matteis et al. 2017).  
 
Figure 5: The clathrin-dependent endocytosis mechanism. The clathrin coat is the first module assembled. The 
cargo is recruited to this site and the membrane is shaped into invagination. Then, different enzymes mediate the 
constriction and the scission of the vesicles neck. Once the vesicle is released, it loses the clathrin coat that can be 
used for a new cycle (from Kaksonen and Roux, Molecular Cell biology, 2018). 
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Once the vesicles are internalized and uncoated, they converge to the endolysosomal 
pathway (Figure 6a). The small Rab guanosine-triphosphate (GTP)-ases control the 
intracellular trafficking by recruiting specific effector proteins, coordinate proteins sorting, 
motility and tethering of the endocytic vesicles. In the apical endosomal compartment, the 
ligand dissociates from the receptor by the acidification of the vesicle (Zhen and Stenmark 
2015). To sustain a new cycle of ligand binding, the endocytic receptors are recycled to the 
apical membrane by slow or fast retrieval pathway. “Fast” recycling is regulated by Rab4 or 
Rab8 and occurs from early sorting endosomes, while “slow” recycling is mediated from the 
endocytic recycling compartment and involves Rab11 (van der Sluijs et al. 1992; Cullen and 
Steinberg 2018). The dissociated cargoes are transported from the early endosome to the late 
endosome or multivesicular body (MVB) and finally to the lysosome for degradation. This 
traffic depends on the progressive acidification of the vesicles, driven by the vacuolar H+-
ATPase (V-ATPase or proton pump), the 2Cl-/H+ antiport ClC-5 and the sodium hydrogen 
antiporter 3 (NHE3) (Eshbach and Weisz 2017). The MVB is characterised by intraluminal 
vesicles and fuses with the lysosome to form a hybrid organelle where the degradation of 
endocytic proteins occurs via the action of acid hydrolases, active upon acidic lysosomal lumen. 
The lysosome are reformed from the hybrid organelle by membrane retrieval (Luzio et al. 
2009). The resulting breakdown products generated by the endolysosomal degradation are 
eventually exported to the cytoplasm for further use to support energy production and 
metabolism (Verdon et al. 2017). 
The lysosome, an ubiquitous and highly dynamic organelle, is responsible for the final 
degradation of the endocytosed proteins, lipids and nucleic acids (Schröder et al. 2010). This 
function of lysosomes is supported by the very acidic pH, the expression of soluble lysosomal 
hydrolases, also called acid hydrolysis, and by the lysosome-associated membrane proteins 
(LAMPs). About fifty lysosomal hydrolases implicated in the catabolic capacity of the 
lysosome have been described. In addition to the substrate degradation capacity, these enzymes 
are involved in antigen processing, degradation of extracellular matrix and initiation of 
apoptosis. The lysosomal lumen contains enzyme activators and protective effectors that sustain 
the degradation capacity. The intraluminal pH of the lysosome is maintained acid (pH 4.5-5.0) 
by the action of the V-ATPase (Saftig and Klumperman 2009). This acidic lumen is necessary 
for the activation of the hydrolases. The lysosomal limiting membrane expresses highly 
glycosylated proteins named LAMPs to protect the lysosome from degradation. These 
membrane proteins are also involved in diverse functions including protein import from the 
cytosol and transport of products derived from the lysosomal degradation. Other lysosomal 
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membrane proteins mediate crucial functions, such as ion channels and transporters, solute 
carriers that mediate sugar export, cholesterol transporters and soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNAREs), involved in fusion events (Figure 6b). 
The efficacy and specificity of the lysosome fusion with organelles, including late endosomes, 
autophagosomes and the plasma membrane, is dependent on the expression of SNARE-
complexes, the presence of additional factors including small GTPases, tethering factors and 
regulators, and the release of Ca2+ (Ballabio and Bonifacino 2020; Saftig and Klumperman 
2009). Beside their degradative function, lysosomes participate to other cellular processes 
including metabolic signaling, gene regulation, immunity, plasma membrane repair and cell 
adhesion/migration.  
The tight regulation of the various stages of the endolysosomal pathway, including the 
internalization of receptors and ligands, sorting/recycling of the receptors and lysosomal 
degradation is essential in PT cells to sustain the high absorptive activity. Indeed, impaired 
apical endocytosis in PT cells, observed in several acute, chronic and genetic diseases, causes 
epithelial dysfunction, loss of LMW proteins, ions and solutes in the urine, and eventually leads 
to kidney failure.  
 
Figure 6: The endolysosomal network. (a) Following their endocytosis, internalized proteins enter the early 
endosomes, where most sorting is initiated. Selected cargo can be recycled back to the cell surface by “fast 
recycling”, or by “slow recycling”. Other cargoes can be degraded into lysosomes. (b) The lysosome expresses 
specific proteins and associated proteins essential for its different functions. Hydrolases are involved in the 
degradation of substrates and express in the lumen. The lysosomal membrane contains several proteins such as 
LAMPs involved in the membrane protection from degradation, V-ATPase essential for the lumen acidification 
and several transporters. The cytosolic face of lysosome expresses protein complexes involved in different 
signalling pathways (modified from (a) Cullen and Steinberg, Molecular Cell Biology, 2018 (b) Ballabio and 





2.2. Autophagy and mitophagy 
Autophagy, literally meaning “self-eating”, is a lysosomal degradation pathway highly 
conserved in all eukaryotes. This cellular mechanism plays a crucial role in the maintenance of 
cellular homeostasis and other processes including development and differentiation. Autophagy 
is a quality control machinery that eliminates long-lived cytosolic proteins and organelles. The 
degradation products are recycled to the cytoplasm to sustain cell homeostasis (Chen and 
Klionsky 2011). 
Depending on the type of pathway by which cargoes are delivered to the lysosome, 
autophagy can be divided into three main types: macroautophagy, microautophagy and 
chaperone-mediated autophagy (CMA). CMA involves the binding of chaperone proteins with 
unfolded substrate proteins containing a specific sequence signal, which are then transported 
into the lysosome for their degradation. Microautophagy refers to the translocation of 
cytoplasmic materials directly into the lysosomes by invagination or protusion. In the case of 
macroautophagy, the large cytoplasmic material is sequestered within a double-membrane 
organelle called autophagosome, which then fuses with the lysosome for degradation. The latter 
will be detailed in the next section and be referred as autophagy (Mizushima and Levine 2020).  
Basal autophagy is crucial for kidney integrity, homeostasis and function. Dysregulation 
of autophagy is involved in the pathogenesis of acute kidney injury (AKI), CKD and kidney 
aging (Tang et al. 2020). Mouse models lacking autophagy related protein 7 (ATG7), essential 
for autophagosome formation, show autophagy defects leading to tubular dysfunction 
(Kawakami et al. 2015; Suzuki et al. 2019). On the contrary, persistent activation of autophagy 
leads to physiological changes in the PT, promoting the transition from AKI to CKD (Tang et 
al. 2020). This dysregulation of autophagy highlights the importance of this pathway in kidney 
physiology. 
2.2.1. Transport of cellular components to the lysosome 
The process of autophagy involves different steps: initiation, nucleation, expansion, fusion and 
degradation (Levine and Kroemer 2019).  
Autophagy pathway is induced in response to a change in the extracellular environment 
of a cell, for example nutrient/energy deprivation. In this case, a non-selective cytosolic bulk 
degradation occurs to supply cells with energy until nutrients can be obtained (Menzies et al. 
2017). The induction step is under the control of the mammalian target of rapamycin (mTOR) 
and adenosine monophosphate-activated protein kinase (AMPK), which exert an opposite role.  
mTOR, the master regulator of autophagy, inhibits autophagy by phosphorylating unc-51-like 
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kinase 1 (ULK1) and  ATG13, while AMPK activates the ATG13/ULK1 complex that triggers 
the formation of the phosphatidylinositol 3 kinase (PI3K) complex (Boya, Codogno, and 
Rodriguez-Muela 2018). This complex is composed of five different proteins (vacuolar protein 
sorting (Vps) 34, Vps15, Vps30/ATG6, ATG14 and ATG38) and regulates the production of 
phosphatidylinositol 3-phosphate (PI3P) into the phagophore membrane. The presence of PI3P 
at the membrane induces the recruitment of PI3P-binding proteins necessary for the phagophore 
expansion. Two ubiquitin-like systems are involved in this step: the formation of the multi-
protein complexes containing ATG12-ATG5-ATG16L and the conversion of cytosolic 
microtubules-associated protein 1 light chain 3 (LC3-I) into membrane bound-LC3-II. The 
continuously assembly of these complexes allows the autophagosomes membrane elongation 
and hence autophagosomes formation (Boya, Codogno, and Rodriguez-Muela 2018; Tang et 
al. 2020; Levine and Kroemer 2019). The fusion of the completed autophagosomes with 
lysosomes, involving several lysosomal proteins such as LAMPs, SNAREs and RAb7, results 
in the formation of an autolysosome (Luzio, Pryor, and Bright 2007). The cargoes are degraded 
by lysosomal acidic hydrolases and the final products, including amino acids, lipids and 
nucleotides, translocate to the cytoplasm in order to be recycled and used for new anabolic 
reactions to sustain cell homeostasis (Yin, Pascual, and Klionsky 2016).  
 
Figure 7: Autophagy dynamics and core machinery. Autophagy is a multistep pathway including initiation, 




2.2.2. Mitochondrial homeostasis and quality control systems 
In addition to non-selective cytosolic bulk degradation, autophagy can also selectively remove 
specific cargoes such as mitochondria (mitophagy), lysosomes (lysophagy), protein aggregates 
(aggrephagy) and lipid droplets (lipophagy). Mitophagy is the best-described form of selective 
autophagy and is essential for cellular homeostasis and energy metabolism (Menzies et al. 
2017). Knowing the major role of mitochondria in PT cells to support energy production and 
transport function, mitophagy is an essential pathway maintaining the integrity of epithelial 
cells and therefore kidney function (Emma et al. 2016a; Luciani et al. 2020; Palikaras, Lionaki, 
and Tavernarakis 2018).   
Autophagy is induced when cells are under stress conditions, such as nutrient deprivation, 
and acts as survival mechanism to maintain cell integrity by regenerating metabolic precursors 
and removing subcellular debris. While autophagy is a non-selective pathway, mitophagy 
occurs to eliminate selectively mitochondria, either to regulate their numbers, or to remove the 
ones that are damaged. Two pathways degrading specifically the mitochondria have been 
described, and are classified as ubiquitin-dependent or independent (Palikaras, Lionaki, and 
Tavernarakis 2018). The PINK1/Parkin pathway is an ubiquitin-dependent mitophagy that 
ensures the elimination of defective organelles. PINK1, a serine/threonine kinase, acts as a 
molecular sensor for the mitochondrial polarization state. In functional mitochondria, PINK1 
is imported into the inner mitochondrial membrane (IMM), rapidly processed and cleaved by 
the protease presenilin-associated rhomboid-like protein (PARL). The truncated form of PINK1 
is then degraded by the ubiquitin-proteasome system (Figure 8a). During mitochondrial 
membrane depolarization following stress, PINK1 is stabilized on the outer mitochondrial 
membrane (OMM) and activated by auto-phosphorylation. In this stage, PINK1 phosphorylates 
basal OMM ubiquitin (Ub) at serine 65 (S65), which induces the recruitment of Parkin from 
the cytosol to the OMM, due to its high affinity with S65-phosphorylated ubiquitin. The binding 
between Parkin and the phosphorylated OMM protein alters Parkin conformation triggering its 
E3 ligase activity. Once fully activated, Parkin conjugates additional ubiquitin onto OMM 
proteins, forming ubiquitin chains. Autophagy adaptor proteins recognise phosphorylated poly-
Ub chains and initiates autophagosomes formation through the binding with LC3. In addition 
to Parkin, several other ubiquitin E3 ligases generate ubiquitin chains triggering the recruitment 
of autophagy adaptors (Figure 8b) (Nguyen, Padman, and Lazarou 2016; Palikaras, Lionaki, 
and Tavernarakis 2018; Hamacher-Brady and Brady 2016). In contrast to PINK1/Parkin 
system, which is ubiquitin-dependent mitophagy, some mitochondrial proteins expressed at the 
OMM serve as mitophagy receptors and target dysfunctional mitochondrial to autophagosomes 
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for degradation (Figure 8c). These mitophagy receptors are transcriptionally regulated, express 
LC3-interacting region motifs which mediate their direct interaction with autophagosomal 
membrane proteins, such as LC3 and GABARAP, and therefore mitochondria removal 
(Hamacher-Brady and Brady 2016; Palikaras, Lionaki, and Tavernarakis 2018).  
The elimination of damaged mitochondria is necessary to maintain the required number 
of functional mitochondria in the cell, a crucial process in several organs with high aerobic 
metabolism, such as kidneys, muscles and brain. (Emma et al. 2016). In fact, mitophagy 
impairment is associated with several disorders, including neurodegenerative, cardiovascular 
and kidney diseases, myopathies, metabolic disorders, inflammation and cancer. In a mouse 
model depleted for PINK1 in cardiomyocytes, impaired mitophagy is associated with an 
increase in the content of mitochondria, which are morphologically altered, leading to 
cardiomyopathies and ventricular dysfunction. Mutation in the genes encoding PINK1 and 
Parkin have been associated with familial forms of Parkinson’s disease (Palikaras, Lionaki, and 
Tavernarakis 2018). The identification of compounds targeting mitophagy may be a promising 
therapeutic strategy for mitochondrial diseases.  
 
Figure 8: Mechanism of mitophagy, the mitochondrial selective autophagy. (a) In healthy mitochondria, 
PINK1 is imported into IMM and subsequently cleaved by PARL. (b) During mitochondrial membrane 
depolarization following stress, PINK1 is stabilized into IMM and phosphorylates Parkin, which initiates the 
selective targeting of damaged mitochondria. Activated Parkin conjugates ubiquitin into OMM proteins, forming 
ubiquitin chains that are recognised by autophagy adaptor proteins and brings the autophagy machinery towards 
the damaged mitochondria. (c) Mitophagy receptors (e.g. BNIP3, NIX and FUNDC1) are localized to the OMM 
and interact directly with LC3 to mediate mitochondrial elimination (modified from (a) (Nguyen et al, Trend in 
Cell Biology, 2016, (b-c) Palikaras et al, Nature cell biology). 
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3. Phosphoinositide: regulator of endomembrane dynamics  
Endocytosis, one of the major function of PT cells, internalizes segments of plasma membrane, 
endocytic receptors and various soluble molecules and allows the intracellular transport of 
components trough vesicles (Kaksonen and Roux 2018). This process relies on dynamic 
changes in membrane identities, especially in the composition of lipids. Specific combinations 
of Rab GTPases and phosphatidylinositols (PIs) are responsible for maintaining and 
coordinating the identity of the different vesicle membranes, creating an identity code for each 
organelle (Jean and Kiger 2012). Despite their low abundance in the cell, less than 10% of all 
phospholipids, it is now clear that PIs are key regulator components of cell membrane for the 
cellular traffic via the recruitment of several PI-binding proteins that triggers signalling events 
(Di Paolo and De Camilli 2006).   
 
3.1. Phosphoinositide metabolism and spatial distribution 
Phosphorylated phosphatidylinositol also called phosphoinositides are a minor class of short-
lived membrane phospholipids involved in crucial cellular mechanisms including signalling, 
motility, development and membrane dynamic. There are seven species of PIs in mammalian 
organisms, generated by the reversible phosphorylation at position 3, 4 and 5 of the inositol 
ring (Figure 9) (Phan et al. 2019). Each of species has a distinct and unique distribution, with 
an affinity for the cytoplasmic side of the plasma and subcellular organelle membranes (Figure 
9). The precursor PI is synthesized in the ER and delivered to other membranes by vesicular 
transport via cytosolic PI transfer protein. The PI 4-phosphates, such as phosphatidylinositol 4-
phosphate (PI(4)P) and phosphatidylinositol 4, 5-biphosphate (PI(4,5)P2), are expressed along 
the exocytic pathway and the plasma membrane, while phosphatidylinositol 3,4,5-triphosphate 
(PI(3,4,5)P3) is enriched at the basolateral side. PI 3-phosphates are prominent components and 
hallmarks of the endosomal pathways:  phosphatidylinositol 3-phosphate (PI(3)P) is present on 
the membrane of early endosome and autophagosome, phosphatidylinositol 3,4-biphosphate 
(PI(3,4)P2) is enriched in non-clathrin endocytic vesicles, and phosphatidylinositol 3,5-
biphosphate (PI(3,5)P2) is expressed on late endosome and lysosome. The phosphatidylinositol 
5-phosphates (PI(5)P) has different subcellular localizations, including nucleus, plasma 
membrane, Golgi complex and ER, however, its precise localization has not been completely 




Figure 9: The different phosphoinositide species and their subcellular distribution. The prominent 
localisation of PIs on plasma and organelle membranes is represented (modified from Phan et al, Cell Death & 
Differentiation, 2019). 
 
The PIs are mediators of signalling events in the entire cellular compartment by recruiting 
proteins to the membrane via their phosphorylated head group or by regulating the function of 
membrane proteins. The interaction between PIs and cytosolic proteins is low affinity; however, 
it can become more stable when PIs cooperate with one or additional binding sites within the 
membrane. The cytosolic proteins are recruited and bind specific PIs via the expression of PI-
binding domains, including FYVE, PHOX homology (PX), pleckstrin homology (PH), ENTH 
and ANTH domains (Matteis and Godi 2004). The conversion of these lipids and their specific 
interactions with adaptor proteins are essential for major cell signalling pathways, such as 
endocytosis and autophagy. In fact, a carrier vesicle must express the lipids necessary to 
promote the factors needed for its function (Di Paolo and De Camilli 2006).  
The spatiotemporally control of the PIs is involved in the regulation of endocytosis 
(Figure 10). The conversion of PI(4,5)P2 to PI(3,4,5)P3 controls the maturation of endocytic 
coated pits. PI(4,5)P2 is enriched in the plasma membrane and participates in nearly all events 
that occur or involve the cell surface (e.g. clathrin-mediated endocytosis) through its role of co-
receptor for the recruitment of endocytic proteins to the plasma membrane. PI(4,5)P2 induces 
the recruitment of clathrin adaptors and the AP-2 complex which activate kinases after their 
binding with the PI and therefore create a pool of PI(4,5)P2 required for clathrin coated pit 
initiation. Following this step, the assembly of clathrin relocates the kinases and therefore 
reduces PI(4,5)P2 synthesis. The maturation of the CCV is followed by the recruitment of 
PI(3,4,5)P3 and  several phosphatases (e.g. OCRL, synaptojanin and SHIP2) involved in the 
removal of PI(4,5)P2 from the membrane. The synthesis of PI(3,4)P2 on the CCV together with 
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AP-2 trigger the recruitment of SNX9. Activated SNX9 and the concomitant presence of PI(3)P 
and PI(4,5)P2 promote the polymerization of actin filament at the base of the vesicle, while 
SNX9 and PI(3,4)P2 mediate membrane constriction and the released of the vesicle in the 
cytosol. PI(3)P is the major lipid expressed on early endosome and it is mostly produced by 
class III PI3 kinase (PI3K) Vps34, and a small pool is derived from the action of class II PI3Ks. 
The conversion of PI(3)P into PI(4)P is required for endosomal exocytosis. The maturation of 
early endosome to late endosome is accompanied by the conversion of PI(3)P into PI(3,5)P2 
(Wallroth and Haucke 2018; Wang, Lo, and Haucke 2019; Zoncu et al. 2009).  
 
Figure 10: Subcellular distribution of PIs during endocytosis in healthy proximal tubule cells. The plasma 
membrane expresses PI(4,5)P2 and PI(4)P at the apical surface, whereas PI(3,4,5)P3 is enriched at the basolateral 
side. The early and late endosomes are enriched in PI(3)P while late endosomes and lysosomes are enriched in 
PI(3,5)P2. Autophagosomes are enriched in PI(3)P and autolysosomes in PI(3)P and PI(3,5)P2 (from De Matteis et 
al. Nature Reviews Nephrology, 2017). 
 
The PI switch plays also a major role in the regulation of the lysosome function and 
autophagy initiation (Figure 11). The membrane of lysosome contains several pools of lipids, 
including PI(3)P, PI(4)P, PI(4,5)P2, PI(3,5)P2, PI(3,4)P2. The regulation of these PIs is essential 
for lysosome function and homeostasis: PI(3)P is involved in the full activation of mTORC1 
while PI(3,4)P2 plays the opposite role (Figure 11a), PI(3,4)P2 regulates lysosomal sterol 
transport, PI(4,5)P2 controls lysosome tabulation and proto-lysosome formation (Figure 11b) 
and PI(3)P facilitates the fusion process between the lysosome and the autophagosome (Figure 
11c) (Ebner, Koch, and Haucke 2019). PI(3)P is also involved in the regulation of autophagy 
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(Figure 11d), by recruiting different proteins involved in the formation of the phagophore. The 
interaction between the protein WIPI and PI(3)P mediates the recruitment of ATG12-AT5-
ATG16L1 E3 ligase complex to the phagophore membrane and therefore promotes 
autophagosome formation (Menzies et al. 2017). 
 
 
Figure 11: PIs switch in the regulation of lysosome homeostasis and autophagy initiation. PIs (a) regulate the 
lysosome positioning and dynamics, (b) control lysosome homeostasis and reformation, (c) regulate the fusion 
between autophagosome and lysosome, and (d) control the initiation of autophagy (modified from (a-c) Ebner et 
al, Biochemical Society Transactions, 2019 and (d) Carlsson and Simonsen, Journal of Cell Science, 2015).   
 
Phosphoinositides act as second messenger and are essential in cells signalling and in 
the regulation of membrane traffic. However, it is still necessary to elucidate the mechanism 
behind the conversion of PI in the different pathways. Monogenic diseases involving PI 
enzymes (both phosphatase and kinases) represent a heterogeneous group of diseases, 
including the nervous system (Joubert syndrome, MIM #213300 caused by mutation in 
INPP5E), affecting muscles (myotubular myopathy, MIM #300219 caused by mutation in 
MTM1), eyes (fleck corneal dystrophy, MIM #121850 caused by mutation in PIP5K1C) and 
kidneys (Lowe syndrome, MIM #309000 caused by mutation in OCRL). These human 
diseases underline the importance of the enzymes involved in lipids conversion and the 
crucial tight regulation of PI homeostasis (Volpatti et al. 2019). 
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3.2. Phosphoinositide kinases and phosphatases  
The spatiotemporal distribution of PIs is dynamically and tightly regulated by specific enzymes 
that add (kinase) or remove (phosphatase) a phosphate group from the inositol ring. Due to the 
fundamental role of these lipids, these enzymes are also subject to regulation through the 
interaction with regulatory proteins. The activity of the kinases and phosphatases are essential 
to coordinate the regulation of PIs. In mammals, the PIs conversion is regulated by 19 kinases 
and 28 phosphatases. The specific local accumulation of the PIs pools is influenced by the 
unique expression of PI kinases and phosphatases (Nakada-Tsukui et al. 2019). 
  
3.2.1. Phosphoinositide kinases 
Studies in PI kinases (PIKs) based on sequences conservation reveal 3 groups: the PI3Ks (class 
I, II and III), the PI4Ks (type II and III) and PIPKs (type I and II) (Figure12) (Burke 2018). 
 
Figure 12: The PI kinases, their domain organisation and associated human diseases (modified from 
Vicinanza et al, EMBO Journal, 2008). 
 
 All PI3Ks phosphorylate in position 3 the hydroxyl group of the PI and possess a ‘PI3K 
signature motif’ composed by a C2 domain, which binds membranes, a helical domain and the 
catalytic kinase domain (Bilanges, Posor, and Vanhaesebroeck 2019). PI3Ks are divided into 
three distinct classes, based mainly on the expression of regulatory binding proteins and their 
specificity for lipid substrates. The class I PI3Ks, generating PIP3 from PIP2, is the most well-
studied PI kinases. It is a heterodimer consisting of one of four catalytic p110 subunits (p110a, 
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b, d or c) and a regulatory subunit (p85a, p85b, p55c, p101 or p84). The production of PIP3 at 
the plasma membrane triggers the recruitment of several PIP3 effectors including protein 
kinases (e.g. PDK1, Akt, BTK) and GTPases. These effectors play an essential role in growth, 
metabolism and survival. Mutations in the gene encoding PI3K class I are associated with 
several human diseases: an inactivating/deletion mutation is frequent in cancer, while an 
activating mutation is linked to congenital lipomatous overgrowth or CLOVES syndrome 
(Venot et al. 2018; Juric et al. 2018). The class II PI3Ks are monomeric enzymes and generate 
PI(3)P and PI(3,4)P2 from PI and PI(4)P respectively. They have additional domains in both N 
and C-terminal extensions, such as a N-terminal clathrin-binding region, suggesting a key role 
in clathrin-mediated endocytosis. These kinases do not have a regulatory subunit but are 
regulated by interacting with proteins such as Rab5 or clathrin. No human diseases have been 
related to PI3K class II mutation (Bilanges, Posor, and Vanhaesebroeck 2019). The class III of 
PI3K, also named vacuolar protein sorting 34 (Vps34), is conserved in all eukaryotes and 
converts PI into PI3. Vps34 forms two different proteins complexes: the complex I (p150, 
Vps30, ATG14 and ATG18) is involved in autophagosome formation, while the complex II 
(p150, Beclin and UVRAG) is involved in the endosomal transport. No human disease has been 
associated with mutations in Vps34 (Burke 2018; Bilanges, Posor, and Vanhaesebroeck 2019; 
Fruman et al. 2017; Jean and Kiger 2012).  
The PI4Ks generate PI(4)P and are subdivided in two subgroups: PI4Ks type II and type 
III. PI4Ks type II exist as two isoforms: PI4KIIα and PI4KIIβ and acts as monomers. They are 
expressed mostly at the membrane of the endosome or trans-Golgi network and are involved in 
endosomal exocytosis. PI4Ks type III are composed of two proteins PI4KIIIα and PI4KIIIβ. 
PI4KIIIα is expressed at the plasma membrane and generates PI(4)P pool which is concerted 
into PI(4,5)P2 and PI(3,4,5)P3, while PI4KIIIβ is expressed on the Golgi and is involved in the 
lipid transport, membrane trafficking and lysosome biogenesis (Burke 2018).  
 PIPKs generate the PI(4,5)P2 by phosphorylating PI4P (the type I PIP4K) or by 
phosphorylating PI5P (PIP5K type II). These kinases are involved in several pathways 
including migration, adhesion, cell division and polarity (Burke 2018).  Dysregulation of PIKs, 
due to mutations, leads to an increase or decrease of their enzymatic activity and has been 
observed in cancer, developmental disorders and primary immune deficiencies. In particular, 
PI3K has been the most studied among the kinases because of its involvement in cancer, making 
it a potential target for drug development. In fact, several drugs targeting PI3K signalling have 
been developed: PI3K/mTOR inhibitors, pan-PI3K inhibitors, and isoform-selective PI3K 
inhibitors. These small molecules are currently employed in several clinical trials 
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demonstrating the effect of PI3K inhibition on tumor progression (Shah et al. 2018; J. Yang et 
al. 2019).  
 
3.2.2. Phosphoinositide phosphatases 
Based on catalytic mechanisms, PI phosphatases are divided into 3 major classes:  PI 3-
phosphatases, PI 4-phosphatases and PI 5-phosphatases (Figure 13).  
 
Figure 13: The PI phosphatases, their domain organisation and asscoiated human diseases (modified from 
Vicinanza et al, EMBO Journal, 2008). 
 
PI 3-phosphatases include PTEN, TPTE and PTEN homologs inositol lipid phosphatase 
(TPIP) and myotubularin (MTM). PTEN is a tumor suppressor which dephosphorylates the D3 
phosphate of PI(3,4,5)P3. By its phosphatase function, it controls negatively the PI3K signalling 
pathway and prevents Akt activation. PTEN is therefore involved in several cellular processes 
such as cell polarity, adhesion, migration, metabolism and DNA repair. The function of PTEN 
is tightly controlled by post-transcriptional and pots-translational mechanisms. This 
phosphatase is found mutated in several human cancers, including breast, prostate and brain. 
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The TPIP, the PTEN homologue, is poorly characterized; however it does not affect the Akt 
pathway. MTM is only found in eukaryotes and is a highly conserved phosphatase that 
hydrolyses PI3P and PI(3,5)P2. Mutated MTM leads to a congenital muscle disorder called X-
linked myotubular myopathy tyrosine phosphatase (Majerus and York 2009). 
PI 4-phophatases are composed of only four proteins, all expressing the CX5R motif in 
the catalytic domain. They are divided in two groups: inositol polyphosphate-4-phosphatase 
(INPP4) and transmembrane protein 55 (TMEM55) which dephosphorylate PI(3,4)P2 and 
PI(4,5)P2 respectively. INPP4 is expressed in endosomal compartments and is involved in the 
recruitment of SNX9 and actin via the generation of PI3P during CCV initiation. TMEM55 is 
implicated in the endocytic and recycling pathway. Loss of the PI 4-phospahatse activity in a 
mouse model leads to neurodegeneration, suggesting its role in neuronal function (Hsu and Mao 
2015). 
The PI 5-phosphatases are a large family of Mg2+-dependent phosphatase. They are 
characterized by a central catalytic domain sharing homology to the apurinic/apyrimidic family 
of endonucleases. This phosphatase dephosphorylate the D-5 phosphoester linkage of PI (3,5)P2 
and PI (4,5)P2 and PI(3,4,5)P3, generating PI(3), PI(4)P and PI(3,4)P2 respectively. This group 
of phosphatases is divided in 4 classes: type I inositol polyphosphate-5-phosphatase (INPP5) 
A, type II includes OCRL, INPP5B, synaptojanin, INPP5J and SKIP, type III consists of 2 
enzymes named SHIP1 and SHIP2s, and finally the type IV is composed of only INPP5E. 
OCRL and INPP5B share amino acid homology, and both are multiple-domain proteins. OCRL, 
which has a clathrin binding domain, regulates the vesicular traffic between endosomes and 
Trans-Golgi network, while INPP5B is involved in the early secretory pathway. Mutations in 
OCRL, observed in Lowe syndrome/Dent disease 2, leads to an increase of PI(4,5)P2 levels at 
the early endosome with the concomitant polymerization of actin on these intracellular 
membranes. Therefore, the abnormal actin reorganisation impairs the vesicular trafficking 
involved in several pathways, such as the endo-lysosomal autophagy system (De Matteis et al. 
2017). Synaptojanin is involved in endocytosis, synaptic vesicles trafficking and recycling. 
INPP5J and SKIP regulate Akt activation by negatively regulating PI(3,4,5)P3. SHIP1 and 2 
which converts PI(3,4,5)P3 to PI(3,4)P2, are involved in insulin and cytokine signalling (De 
Matteis et al. 2017; Majerus and York 2009). 
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4. Genetic disorders targeting the endo-lysosomal and autophagy pathways 
4.1. Endosomal disorders: Dent disease and Lowe syndrome 
Dent disease is a X-linked disorder characterized by PT dysfunction and progression to CKD 
and kidney failure (Blanchard et al. 2016). The clinical manifestations of the disease are LMW 
proteinuria associated with hypercalciuria leading to nephrocalcinosis/nephrolithiasis and 
progressive kidney failure.  Dent disease is characterized by a genetic heterogeneity: 50-60% 
of the patients present a CLCN5 mutation (Dent disease 1), ~15% with OCRL mutation (Lowe 
syndrome or Dent disease 2) and the remaining 25-35% have no identified mutations (Devuyst 
and Luciani 2015; De Matteis et al. 2017). 
Dent disease 1 is caused by inactivating mutation in CLCN5 (MIN #300009). This gene 
is located on the chromosome Xp11.22 and encodes the 2Cl-/H+ exchanger ClC-5. The majority 
of the reported mutations (e.g. missense and nonsense) results in a truncated or absence of ClC-
5 protein, which would trigger a complete loss of its antiporter function (Lloyd et al. 1996). 
This exchanger is expressed predominately in the early endosomes of PT cells, where it co-
localizes with the V-ATPase to contribute to the endosomal acidification. The development of 
Clcn5 knock-out (KO) and knock-in (KI) animal models have provided critical insights into the 
mechanisms of PT dysfunction in Dent disease 1 (Gailly et al. 2008; Novarino et al. 2010). 
These studies have shown that the loss of ClC-5 function impairs the trafficking of endocytic 
receptors along the endocytic pathway, therefore decreasing their expression at the brush border 
of PT cells (Christensen et al. 2003) (Figure 12). In vitro studies have demonstrated that the 
lack of ClC-5 triggers a defective acidification of vesicles, which could cause the endocytic 
defect observed in vivo. However, the mechanism involved in the PT dysfunction in Dent 
disease 1 is more complex. Indeed, despite normal endosomal acidification, the KI mice show 
the same renal phenotype and similar impairment of endocytosis in PT compared to the KO 
mice, suggesting that defective acidification is only partially responsible for the endocytic 
dysfunction (Novarino et al. 2010). The endocytic defect could also be explained by the 
interaction of ClC-5 with megalin and cofilin, involved in LMW protein and albumin 
endocytosis (Hryciw et al. 2003). The loss of ClC-5 is also associated with impaired lysosomal 
function, and per consequence, compromises autophagy pathway (Christensen et al. 2003). The 
accumulation of autophagosomes containing ubiquitinated proteins and dysfunctional 
mitochondria leads to an increase of oxidative stress (Gailly et al. 2008). This change could 
explain the epithelial dysfunction observed in Dent disease 1. In fact, it has been recently shown 
that oxidative stress disrupts the integrity of the junctional complex proteins zonula occludens-
1 (ZO-1) and promotes the release of ZO-1-associated nucleic acid-binding protein (ZONAB). 
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This transcription factor may promote cell proliferation and repress the transcription of megalin 
and cubilin in proximal tubules, leading to PT dysfunction (Devuyst and Luciani 2015; van der 
Wijst et al. 2019). 
 Mutation in OCRL gene, encoding the inositol polyphosphate 5-phosphatase OCRL, 
causes Dent disease 2 (MIM #300555). Clinically, patients harbouring Dent disease 1 and 2 
present similarities: they both show PT dysfunction characterized with the loss of LMW 
proteins, hypercalciuria and progressive renal failure. Patients with Dent disease 2 present 
muscular defects, with muscle hypoplasia and increase of muscle enzymes in serum (Park et al. 
2014). Some patients with OCRL mutations may present additional symptoms including 
cognitive disability and congenital glaucoma and therefore are refered to Lowe 
oculocerebrorenal syndrome (MIM #309000). It is interesting to note that OCRL mutations 
causing Dent disease 2 are different and do not overlap with those causing Lowe syndrome 
(Bökenkamp et al. 2009). Mutations associated with Dent disease involve the 5-phophatase 
domain of the proteins wherease for Lowe syndrome the mutation involves three domains of 
the proteins: the 5-phophatase, ASH and RhoGAP domains (De Matteis et al. 2017).  
OCRL is a cytosolic ubiquitous protein, mainly expressed in the brain, liver and kidney. 
This enzyme is able to hydrolyze the phosphate group in position 5 of the inositol rings of 
PI(4,5)P2 and PI(3,4,5)P3 to generate PI4P and PI(3,4)P2 respectively. Beside its role of 
phosphatase, OCRL contains other domains including the pleckstrin homology (PH) domain, 
the ASPM, SPD-2, Hydin (ASH) domain, and the Rho GTP activating protein (Erdmann et al. 
2007). These motifs are necessary for the interaction between OCRL and several proteins and 
promote its targeting to the different cellular compartments (De Matteis et al. 2017). OCRL is 
expressed mainly in the trans-Golgi network, but it is also located on the plasma membrane, 
clathrin-coated vesicles, early endosomes, primary cilium and lysosomes. OCRL controls 
multiple pools of PI(4,5)P2 at these diverse intracellular locations and the fundamental steps of 
clathrin-mediated endocytosis. In vitro studies deciphered the essential role of OCRL during 
endocytosis: it translocates from the plasma membrane to the early endosome via its interaction 
with Rab5, in order to regulate the abundance of PI(4,5)P2, which is essential for the correct 
trafficking of internalized vesicles along the endocytic pathway. The loss of function of OCRL 
induces accumulation of PI(4,5)P2 in early endosomes. This deficient degradation of  PI(4,5)P2 
triggers the failure to uncoat clathrin-coated vesicles and leads to a hyper-polymerization of 
actin impairing vesicular trafficking of receptors, including those that recycle to the apical 
plasma membrane, such as megalin (Vicinanza et al. 2011; Festa et al. 2018). The trapping of 
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megalin in early endosomes might explain the link between OCRL deficiency, PT dysfunction 
and endocytic defect observed in Lowe syndrome/Dent disease 2 patients.  
The development of mouse models has been essential to decipher the role of OCRL in 
kidney. The lack of OCRL in mouse models triggers PT dysfunction, characterized by LMW 
proteinuria, muscular defects with dysfunctional locomotricity and reduced growth, as 
encountered in patients with Lowe syndrome. The loss of LMW proteins in the urine can be 
explained by the reduced expression of the endocytic receptor megalin at the plasma membrane 
in PT cells (Figure 14) (Bothwell et al. 2011; Bernard and Nussbaum 2010; Festa et al. 2018). 
A recent study has demonstrated the role of OCRL in regulating endosomal homeostasis and 
function. The accumulation of PI(4,5)P2 on the autolysosome membrane due to the loss of 
function of OCRL impairs the autophagosome-lysosome fusion and consequently leads to the 
accumulation of autophagosomes in OCRL-depleted cells and in kidneys of Lowe syndrome 
patients. Consequently, the lysosomal alteration and impaired autophagy flux could drive PT 
dysfunction and possibly central nervous system-related symptoms of the patients (De Leo et 
al. 2016). Furthermore, OCRL may regulate the primary cilium formation and composition, 
since it is involved in the production of the ciliary pool of PI(3,4)P2 (Nachury et al. 2007). 
However, the exact role of OCRL in ciliogenesis is not yet clear and needs further studies.  
 
Figure 14: The role of OCRL and ClC-5 in the pathophysiology of Dent disease. ClC-5 facilitates the 
acidification and the trafficking of endosomes. OCRL is required for a proper vesicular trafficking between the 
plasma membrane and intracellular compartments (adapted from Festa et al., Reviews of Physiology, 
Biochemistry and Pharmacology, 2020). 
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4.2. Metabolic disorder: Methylmalonyl‒CoA Mutase Deficiency 
Methylmalonic academia (MMA; MIM #251000), the most common form of organic aciduria, 
is a rare autosomal recessive disorder caused by inactivating mutations in the MMUT gene 
encoding a mitochondrial enzyme (Oberholzer et al. 1967; Chace et al. 2001). The consequence 
of the mutation is the complete (MMUT0) or partial (MMUT-) loss of the methylmalonyl-
coenzyme A mutase (MMUT) function that mediates the terminal step of branched-chain amino 
acid metabolism and the degradation of certain amino acids and lipids (Barness, 1996) (Figure 
15). This metabolic disorder is characterized by an accumulation of toxic metabolites, including 
methylmalonic acid, propionic acid and 2-methylcitric acid, in plasma, urine and other body 
fluids, leading to abnormal mitochondria network. Therefore, the mitochondria distress triggers 
severe organ dysfunction, affecting primarily the brain, the liver and the kidney. Patients with 
a complete enzyme deficiency develop within their first day of life metabolic acidosis and 
hyperammonemia, progressing to coma and death if untreated (Hörster et al. 2007). There are 
few rational treatments for MMA, including a protein-restricted diet supplemented with 
vitamins and trace elements to decrease the formation of toxic metabolites. However, even with 
a meticulous medical management, patients can present severe, life-threatening metabolic 
decompensation (Baumgartner et al. 2014).  
MMA patients present frequently renal tubular dysfunction and develop CKD (Haarmann 
et al. 2013). However, the link between MMUT deficiency and kidney dysfunction is not yet 
elucidated. The disruption of the tricarboxylic acid cycle (TCA) and the respiratory chain could 
explain the cellular damages (Morath, 2008). The mitochondrial dysfunction, increased 
oxidative stress and mitochondrial DNA depletion might be the cause of cellular damages 
observed in MMA patients (Haarmann et al. 2013).  
Several studies using cells and animal models have tried to decipher the link between 
MMUT deficiency and mitochondria defect. The hepatic expression of Mmut in Mmut−/− mice, 
as a stable transgene under the control of the albumin promoter, rescued the neonatal lethality 
observed in Mmut−/− mice. This mouse model shows a kidney phenotype, including decreased 
glomerular filtration rate, tubulointerstitial nephritis and ultrastructural changes in PT cells. 
Lipocalin 2 (LCN2), a biomarker of oxidative stress and renal mitochondrial dysfunction, was 
decreased after treatment with the antioxidant compounds CoQ10 and VitE, offering a potential 
therapeutic approach for the disease (Manoli et al. 2013). A MmutKO/KI mouse model carrying 
a mutant Mmut allele (p.Met698Lys, corresponding to the patient mutation p.Met700Lys) and 
a KO Mmut allele has been developed and recapitulates some biochemical and clinical 
hallmarks of MMA, including accumulation of MMA and aberrant mitochondria in kidney 
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tubular cells. This mouse model allows the discovery of new biomarkers in MMA, including 
lipocalin 2 (Lcn2), an early marker for chronic kidney damage that could be involved in 
dysfunctional cells (Forny et al. 2016).  
 
Figure 15: Metabolic pathways of methylmalonic acid. Mitochondrial MMUT deficiency leads to accumulation 
of organic acids, including methylmalonic acid and energy depletion of the citric acid cycle (AdoCbl, 
Adenosylcobalamin; cbl, cobalamin; MMUT, methylmalonyl-CoA mutase) (modified from Fowler, 2008). 
 
5. Drug discovery and development in rare genetic diseases 
A rare disease is defined when its prevalence is <1 in 2000 individuals in Europe or affecting 
<200,000 individuals in the USA. Approximatively 7,000 rare diseases are described, each 
affecting a variable number of individuals (Devuyst et al. 2014; Tambuyzer et al. 2020). 
Altogether, rare diseases are estimated to affect 6-7% of the population in the developed world 
(~350 million patients). In more than 80% of cases, these disorders have a genetic origin, caused 
by mutation in a single gene or due to defect in several genes. The incidence of a rare genetic 
disease can vary substantially between regions or ethnic groups (Tambuyzer et al. 2020). The 
next generation sequencing technologies have improved the diagnostic efficiency and identified 
novel causes of rare diseases. Yet, despite advances in our understanding of rare genetic 
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diseases, approximately 90% of them lack an approved treatment (Kaufmann, Pariser, and 
Austin 2018). 
Rare diseases represent an unattractive group of disorders for the drug development and 
biopharmaceutical industry. In fact, compared to common diseases such as diabetes, obesity or 
hypertension, rare diseases represent a small market opportunity and the drug development 
costs are as high as that of any drug development for common diseases. Consequently, the price 
of approved orphan drug is relatively high, thus causing accessibility issues of the compound 
for patients, and the pharmacological companies take economically a risk to develop the drug. 
(Pierzynowska, Kamińska, and Węgrzyn 2020). Therefore, to encourage pharmaceutical 
companies to promote the development of treatments for rare diseases, the Orphan Drug Act 
(ODA) was voted in 1983 in the USA. This program provide financial benefit for the 
development of new drugs for rare disease, such as market exclusivity, tax credit and grant for 
clinical trials (Sarpatwari and Kesselheim 2019). Since the act passed, the number of orphan 
drugs approved has risen exponentially each year, so that in 25 years, 487 orphan-designated 
drugs entered in the USA market, demonstrating the success of this law (Sarpatwari and 
Kesselheim 2019). Nerveless, even if this regulation has been essential for promoting the 
development of therapies for rare disease, there is still a gap between the scientific results and 
its translation into therapies for rare diseases (Tambuyzer et al. 2020).  
The progress in molecular biology and the understanding in the pathophysiology of rare 
diseases have been essential for the development of new therapeutic compounds. The protein-
based therapy, including proteins, peptides and antibodies, antisense oligonucleotides (ASOs), 
small interfering RNAs (siRNAs) and gene/cell therapies have been emerging in the last 
decades, offering the new therapeutic strategy for rare diseases. Small molecules, which 
represents the majority of the marketed therapeutics for rare diseases, have several advantages, 
including a well-defined structure, multiple routes of administration without an immunological 
profile, controlled dosing and stability. Together, all these therapeutic approaches allow to 
cover a broad range of targets and mechanisms, and can be expanded by combining different 
types of therapy, such as small-molecules conjugated to antibodies (Tambuyzer et al. 2020).  
Despite the technical progress and enhanced knowledge of the diseases, the development 
of a new drug is relatively expensive, from $2 to $3 billion for a single FDA-approved drug, 
and it can take over a decade. The high development costs is particularly an issue for orphan 
diseases, as the market is small, thus limiting the potential for return-on-investment. Another 
issue shows that, often, a new drug performs well in the preclinical phase but fails during human 
tests (Tambuyzer et al. 2020). Facing such limitations, drug repurposing or repositioning is a 
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strategy to identify new uses for already approved or investigational drugs that are outside the 
scope of the original medical indication (Pushpakom et al. 2019). This approach offers several 
advantages compared to the development of a new compound. The risk of failure is lower, the 
development process is shorter and cheaper, as the repurposed compounds have already showed 
safety in human, and some molecules have already been tested in clinical trials. In fact, the cost 
to bring a repurposed drug on the market have been evaluated at approximatively $300 million 
(Pushpakom et al. 2019). The number of patients in clinical development can be reduced as the 
drug has already been tested in prior clinical trials which is an important parameter to take in 
account for rare diseases. Finally, the last advantage of drug repurposing is the identification of 
new targets and pathways that can be further investigated (Fetro and Scherman 2020).  
However, drug repurposing presents also some risks and can fail during the clinical trial phases 
(e.g. Ceftriaxone, originally indicated as an antibiotic, failed to show efficacy in Amyotrophic 
lateral sclerosis during phase III) (Cudkowicz et al. 2014). In fact, clinical trials for new 
indications are still needed and may require further investments: the safety profile of one 
candidate may drastically change in a new context (e.g. comorbidities) or following a new 
indication (e.g. long-term versus short-term treatment) (Tambuyzer et al. 2020).  
Drug repurposing is an attractive technology to identify new compounds for rare diseases. 
The identification of repurposed compounds has been successful for several rare diseases.  In 
fact, Sildenafil, originally developed as a drug for coronary heart disease, was first repurposed 
in 1998 for erectile dysfunction and subsequently repurposed for a rare disease, and finally 
approved in 2005 for its use in pulmonary arterial hypertension (MIM #178600). Adalimumab, 
a monoclonal antibody targeting the cytokine tumor necrosis factor (TNF), was first approved 
in 2002 for rheumatoid arthritis and then gained further approval in 2008 for the rare disease 
polyarticular juvenile idiopathic arthritis (Tambuyzer et al. 2020). Recently, Alpelisib, an 
inhibitor of PI3K subunit p110 was first approved in 2019 for breast cancer (André et al. 
2019) and then has shown clinical benefits in children with PROS and CLOVES syndrome 
(MIM #612918) (Venot et al. 2018). These successes have encouraged the development of 
approaches to identify repurposed drugs. Typically, the development of drug repurposing 
consists in three steps: (i) identification of the compound for a given hypothesis, (ii) assessment 
of the compounds’ effect in preclinical models, and (iii) testing the efficacy of the compounds 
in clinical trials. The first step is critical and can be based on experimental strategies or 




Figure 15: The different approaches possible for drug repurposing (from Pushpakom et al, Nature Review 
Drug Discovery, 2019). 
 
5.1. Experimental approaches 
Experimental approaches can be used to identify repurposing drug candidates. It can be based 
on binding assays that identify target interaction or on phenotypic screening (Pushpakom et al. 
2019).  
Phenotypic screening methods are used to identify compounds that have disease-relevant 
effects on in vivo or in vitro model systems. Advances in cellular and molecular technology 
allowed the screening of many compounds using cells-based assays (high throughput 
screening). The miniaturization of these assays (from 96-well plate to 1,536-well plates) was 
an essential step to reduce reagent costs and made screens more practical. Furthermore, 
automated robotic systems allow to screen a large collection of compounds and improve data 




The high throughput screening assay is composed of several steps leading to the 
identification of one lead compound from a large library of drugs. First, it is necessary to set up 
an assay with a readout related to the pathophysiology of the disease and to optimize the assay 
in order to screen a large number of compounds. The cell-based assays generally involve the 
use of cell lines and include different methods such as cell viability, signalling pathways, cell 
apoptosis and motility. The primary screening tests compounds using a single concentration; 
positive hits are selected based on simple criteria such as “inhibition of proteins accumulation 
by 30 %”. A cytotoxicity assay is performed in parallel to exclude toxic compounds. The 
secondary screening is based on the same assay of the first screening but is testing the selected 
compounds at different concentrations to generate a dose-response curve. Finally, the tertiary 
screening uses different formats, such as another assay (fluorescence instead of luminescence 
assay) or other biological models (primary cells instead of cell lines), to identify and prioritize 
few lead compounds (Dvela-Levitt et al. 2019; Sun, Zheng, and Simeonov 2017). 
Whole-organism phenotypic assays have been also emerging in drug repurposing, such 
as zebrafish or Caenorhabditis elegans (nematode), for testing small molecules in disease 
models. They are good models for evaluating drugs efficiency, studying drug uptake in cells or 
testing the toxicity effect (Tambuyzer et al. 2020). While a full library can be tested on the 
worm, the assays focus more on high-quality drugs candidates for zebrafish (Volpatti et al. 
2020). 
The development of compound libraries has increased in the last years, offering 
opportunities to screen larger number of molecules and more extensive families of compounds. 
However, one major limitation of the high-throughput screening is to translate drug candidates 
from in vitro assay to the clinic. The development of new tools and technologies, such as 
inducible pluripotent stem (iPS) cells, gene editing CRISPR–Cas 9 systems, and organoids, 
offer the opportunity to improve the preclinical disease models and therefore the translational 
relevance of the screening approach (Pushpakom et al. 2019).  
 
5.2. Computational approaches 
Computational drug repurposing, also called in silico analysis of FDA-approved compounds, 
is an alternative to experimental approaches that promises to find new and effective drugs for 
rare diseases and to be tested faster in clinic (Paranjpe, Taubes, and Sirota 2019). It involves 
the analysis of big-data, including gene expression, chemical structure, genotype or proteomic 
data or electronic health records, the use of machine learning and leads to the elaboration of 
repurposing hypothesis (Hurle et al. 2013). Various computational approaches can be used 
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individually or in combination in order to analyse large-scale data and then to elucidate the 
repurposing hypothesis. All these big-data need specific tools to be analysed, as they are very 
large and too complex to study and analyse with the traditional and classical statistical 
approaches (Pushpakom et al. 2019).  
In the last decade, the development of transcriptome-based approaches to computational 
drug discovery was aiming to predict compounds that may reverse genetic signatures by 
comparing the gene expression signature before and after drug treatment with gene expression 
signatures in diseases. This approach involves matching of transcriptomic signatures and relies 
on the accessibility of gene expression data. The Connectivity Map (cMap) is the first large 
public database of gene expression profiles, generated after treatment with more than 1,300 
compounds on several human cell lines (Lamb et al. 2006). The aim of this project was to 
generate a map used to find connections between gene expression profiles associated with 
disease states and following treatment. This map allows to identify drugs inducing a 
transcriptional response opposite to the one induced by a disease, and therefore these drugs may 
exert therapeutic effects (Malcomson et al. 2016). The effectiveness of this in silico method to 
predict potential compounds for a disease has been validated by using in vivo models to validate 
the predicted drugs, such as citalopram for metastatic colon cancer (Noort et al. 2014). This 
technique highlights the potential of gene transcription profiling to link chemistry, biology and 
clinic by inferring gene profile similarities and differences.  
Several resources that support the computational drug repositioning based on 
transcriptional data are available. For instance, the cMap has two extensions: statistically 
significant connections' map (sscMap) (Zhang and Gant 2009) and the mode of action by 
network analysis (MANTRA, https://mantra.tigem.it/) tool (Iorio et al. 2010). MANTRA has 
been developed to predict the drug mode of action and drug repurposing from the analysis of 
the cMAP. This approach, based on the network theory of gene expression data, allows us to 
find unexpected relationships among drugs, genes and diseases. It elucidates genome-wide 
targetable candidates by matching disease gene signatures against a library of 1,309 small 
compounds available for drug repurposing. The prediction for drug-disease pairs is based on 
the hypothesis that if a drug reverses the disease gene signature, it might potentially target 
molecular disease pathways. Moreover, this approach allows us to identify repurposed drug by 
searching the neighbourhood of a “seed” compound with a desired mechanism of action for 
compounds never linked before to that mechanism of action. Once potential compounds have 
been identified, in vitro and in vivo experiments are necessary to validate and to evaluate the 
efficiency of drug repositioning candidates (Carrella et al. 2014). Based on the MANTRA 
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analysis, Fasudil (a Rho-kinase inhibitor) was identified as an inducer of autophagy because of 
its close proximity with a known autophagy inducer (2-deoxyD-glucose). Treatment on cells 
with Fasudil reveals the new mechanism of action of this drug as an enhancer of autophagy and 
may be repurposed for neurodegenerative diseases (Iorio et al. 2010). More recently, this 
approach has been used to identify pathways that could be targeted by chemical blockers in the 
context of cystic fibrosis (Hegde et al. 2015). These findings demonstrate the importance of 





 Aim of the thesis 
Studies of inherited kidney diseases have been key in dissecting interactions in cellular and 
molecular pathways that regulate the homeostasis and function of the endolysosomal system in 
tubular cells. The improvement of knowledge regarding cell biology-disease signatures, novel 
preclinical disease models and drug-based phenotypic screenings has been essential for 
developing targeted therapies that might deliver “first in class” drugs to the clinics. In particular, 
drug repurposing and the advent of compound libraries sscreenings are increasingly attractive, 
as they involve the use of lower risk compounds, with lower overall development costs and 
shorter development timelines.  
The first part of the thesis is devoted to understanding the cellular and molecular 
mechanism of OCRL in the regulation of the endolysosomal pathways in the proximal tubule. 
Patients affected by Lowe syndrome or Dent disease 2, caused by mutations in the inositol 
polyphosphate 5-phosphatase OCRL, manifest PT dysfunction and LMW proteinuria, with 
only supportive care available. We characterized a mouse model lacking Ocrl and derived 
primary cultured PT cells in order to describe the role of OCRL in the reabsorptive 
function of kidney PT cells and its involvement in endocytic trafficking. The defect of 
endocytosis and PT absorption in Lowe syndrome and Dent disease 2 is due to increased 
levels of PI(4,5)P2 and aberrant actin polymerization which block endosomal trafficking. 
Based on recent studies demonstrating that phosphatidylinositol 3-phosphates is involved in 
the actin pathways as co-activator with PI(4,5)P2, we targeted PI3 kinase (PI3K) in vitro 
and in vivo by using different class I PI3K inhibitors for drug repurposing in Lowe 
syndrome and Dent disease 2.  
In the second part of the thesis, we analyzed the mechanism linking MMUT deficiency, 
mitochondrial abnormalities and cell toxicity in kidney tubular cells. MMA patients, caused by 
the inactivating mutation of MMUT, display systemic organs dysfunction due to an 
accumulation of toxic organic acids, with no curative treatment. We used cell and animal-based 
models to investigate the consequence of MMUT deficiency on PINK1/Parkin-mediated 
mitophagy and how these changes affect the mitochondria homeostasis and therefore the 
integrity of tubular cells. Following these findings, we performed a drug-disease network-
based computational modeling approach to identify targetable pathways. The in silico 
analysis indicated that targeting mitochondria function might potentially reverse cellular 
dysfunction associated with MMA. 
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The global aim of these studies is to improve our understanding of alterations of 
endomembrane trafficking and cellular homeostasis in a disease context, in order to find 
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Mutations in OCRL encoding the inositol polyphosphate 5-phosphatase OCRL (Lowe 
oculocerebrorenal syndrome protein) disrupt phosphoinositide homeostasis along the 
endolysosomal pathway causing dysfunction of the cells lining the kidney proximal tubule. The 
dysfunction can be isolated (Dent disease 2) or associated with congenital cataracts, central 
hypotonia and intellectual disability (Lowe syndrome). The mechanistic understanding of Dent 
disease 2/Lowe syndrome remains scarce, due to limitations of animal models of OCRL 
deficiency. 
Here, we investigate the role of OCRL in Dent disease 2/Lowe syndrome by using OcrlY/- 
mice, where the lethal deletion of the paralogue Inpp5b was rescued by human INPP5B 
insertion, and primary culture of proximal tubule cells (mPTCs) derived from OcrlY/- kidneys.  
The OcrlY/- mice show muscular defects with dysfunctional locomotricity and present 
massive urinary losses of low-molecular-weight proteins and albumin, caused by selective 
impairment of receptor-mediated endocytosis in proximal tubule cells. The latter was due to 
accumulation of phosphatidylinositol 4,5–bisphosphate PI(4,5)P2 in endolysosomes, driving 
local hyper-polymerization of F-actin and impairing trafficking of the endocytic LRP2 receptor, 
as evidenced in OcrlY/- mPTCs. The OCRL deficiency was also associated with a disruption of 
the lysosomal dynamic and proteolytic activity. Partial convergence of disease-mechanism and 
renal phenotypes observed in OcrlY/- and Clcn5 Y/- mice suggest shared mechanisms in Dent 
disease 1 and 2. 
These studies substantiate the first mouse model of Lowe syndrome and give insights into 
the role of OCRL in cellular trafficking of multiligand receptors. These insights open new 




The maintenance of body fluid and electrolyte homeostasis critically depends on the appropriate 
handling of solutes and water by the epithelial cells lining the proximal tubule (PT) of the 
kidney(1, 2). These cells are characterized by an efficient endolysosomal pathway involving 
the apical multiligand receptors megalin (LRP2) and cubilin (3). By processing internalized 
cargoes and recycling of receptors and transporters at the apical surface, the endolysosomal 
system of the PT cells recover essential substances that are filtered through the glomerulus, 
including a large variety of low-molecular-weight (LMW) proteins that would otherwise be lost 
in the urine (2). Congenital and acquired disorders of the endolysosomal pathway cause PT 
dysfunction (renal Fanconi syndrome) with massive urinary loss of solutes, dehydration, 
electrolyte imbalance, rickets, growth retardation, and the development of chronic kidney 
disease (CKD). Such PT dysfunctions are typically encountered in Dent disease, a rare, X-
linked disorder characterized by LMW proteinuria, renal Fanconi syndrome, kidney stones, 
nephrocalcinosis and progressive renal failure (4, 5). 
 Dent disease is genetically heterogeneous. The majority of cases (approx. 60%) is due 
to mutations in the CLCN5 gene that encodes the electrogenic Cl-/H+ exchanger ClC-5 (Dent 
disease 1, MIM # 300009) (6). In a subset of patients (~15-20%), the disease is caused by 
mutations in OCRL, the gene encoding the type II phosphatidylinositol (PI) bisphosphate 5-
phosphatase OCRL (Dent disease 2, MIM #300555). Mutations in OCRL are also associated 
with the oculocerebrorenal syndrome of Lowe (MIM # 309000), which includes systemic 
manifestations such as congenital cataracts, cognitive disability and hypotonia (4, 7). OCRL is 
a protein of 110 kDa which, in addition to the 5-phosphatase catalytic domain, comprises: (i) a 
pleckstrin homology (PH) domain containing a clathrin-binding site (8); (ii) an ASPM, SPD-2, 
Hydin (ASH) domain, characteristic of protein that localizes to centrosome and primary cilia 
(9); and (iii) a RhoGAP-like domain, which mediates interactions involved in cytoskeleton 
dynamics and progression of cell cycle (10). Almost all the mutations associated with Lowe 
syndrome occur in exons 8-23 which include the 5-phosphatase catalytic domain, the ASH 
domain and the RhoGAP-like domain. Conversely, the majority of mutations that cause Dent 
disease 2 are positioned in exons 1-7 which comprise the PH domain (11). Although mutations 
in the catalytic domain of OCRL have been described in both clinical profiles, the mutations in 
Dent disease 2 are always missense - compatible with a residual biological activity that could 
explain a less severe cellular phenotype (7). 
 The convergence of clinical phenotypes among patients with mutations in OCRL and 
CLCN5 raises the questions whether these genes products are part of the same pathways and 
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how they cause dysfunction of endolysosomes in PT cells. ClC-5 is predominantly expressed 
in the early endosomes of PT cells of the kidney, potentially involved in their maturation 
towards the degradative compartments or the recycling route (6). Studies in mouse models 
showed that the functional loss of ClC-5 generates a trafficking defect involving megalin and 
cubilin, reflected by defective endocytosis and manifestations of PT dysfunction (6, 12). OCRL 
is located at different stations of the endo-lysosomal pathway where it maintains the cellular 
metabolism of phosphatidylinositol 4, 5-bisphosphate PI(4,5)P2 , an essential regulator of 
membrane trafficking. Increased PI(4,5)P2 levels and marked vesicular trafficking defects 
affecting the endocytic network have been observed in cells lacking OCRL, resulting in 
defective receptor-mediated endocytosis (13).  
 The direct impact of OCRL on transport events leading to renal Fanconi syndrome 
cannot be reliably assessed on dedifferentiated cell systems including non-kidney or non-
epithelial cell types, or clonal cells isolated from urine (14). Renal biopsy material, usually 
obtained at an advanced disease stage, is of limited value. Furthermore, limitations of animal 
models of OCRL deficiency impede the development of translational studies. The first Ocrl KO 
mouse showed no kidney, eye or brain defects (15), due to a compensation by INPP5B, the 
closest paralogue of OCRL in mice and humans (16). Accordingly, a generalized endocytic 
defect (affecting both receptor-mediated and fluid-phase endocytosis) was detected in a 
conditional tubular deletion of Ocrl and Inpp5b mouse model (17). However, studies performed 
in this strain do not allow to discriminate the individual role of OCRL and INPP5B in the 
pathophysiology of Dent disease. 
  Recently a mouse model expressing human INPP5B in OcrlY/-; Inpp5b−/− background 
was generated (18). The replacement of mouse Inpp5b with human INPP5B in the whole body 
of OcrlY/- mouse provides a humanized background, which therefore allows to investigate the 
consequences related to the specific loss of OCRL activity. Preliminary studies revealed PT 
dysfunction in this line (18), with no investigation of the time-course, multi-systemic aspect, 
and cellular basis of this defect. Here, we analyzed in detail the multi-systemic phenotype of 
these OcrlY/-; Inpp5b-/-; BAC-INPP5B mouse model; compared the kidney dysfunction to that 





OcrlY/- mice show early manifestations of proximal tubule dysfunction 
A humanized mouse model for Lowe syndrome/Dent disease 2 was generated by targeted disruption 
of both Ocrl and Inpp5b and oocyte injection of a bacterial artificial chromosome (BAC) containing 
the human gene INPP5B to avoid embryonic lethality (18). The mouse littermates lacking Inpp5b 
while harbouring BAC-INPP5B expression with Ocrl are referred to as OcrlY/+ (OcrlY/+; Inpp5b-/-; 
BAC-INPP5B) whereas those lacking Ocrl are OcrlY/ - (OcrlY/-; Inpp5b-/-; BAC-INPP5B) mice, 
respectively. All mice were born at mendelian ratio and were viable and fertile. The genotype of Ocrl 
mice was demonstrated by genomic DNA analyses of Ocrl, Inpp5b and BAC-INPP5B (Suppl. Fig. 
1A) and immunoblotting for OCRL (Suppl. Fig. 1B) in kidney samples derived from OcrlY/- and 
OcrlY/+ mice.  
We first used the Ocrl mice to characterize the kidney phenotype over time. Growth 
retardation was observed in OcrlY/- mice starting from 16 weeks of age onwards (Fig. 1A), whereas 
manifestations of PT dysfunction appeared in OcrlY/- mice from 8 weeks of age, with albuminuria 
(Figs. 1B and 1C) and LMW proteinuria (Figs. 1D and 1E). The inappropriate loss of the LMW clara 
cell secretory protein 16 (CC16) in the urine of OcrlY/- mice was observed at all time points analyzed 
(Fig. 1D). Western blotting of the urine confirmed the major loss of transferrin (TFR) and vitamin D 
binding protein (VDBP) along CC16 in the urine of OcrlY/- mice (Fig. 1E). The OcrlY/- mice did not 
show manifestations of renal failure, and no polyuria, calciuria, glycosuria and phosphaturia during 
the timeframe of investigation, suggesting a partial renal Fanconi syndrome (Table 1). The expression 
levels of BAC-INPP5B were not associated with variable levels of PT dysfunction in OcrlY/- mice 
(Suppl. Figs. 1C-F). Since mutations in CLCN5 and OCRL produce similar kidney defects in human 
patients, we compared the severity of PT dysfunction in the Clcn5Y/- and OcrlY/- mouse models. The 
OcrlY/- mice display a milder LMW proteinuria (CC16) than that observed in Clcn5Y/- mice (Fig. 1F). 
This difference is most likely reflecting specific roles of ClC-5 and OCRL along the endo-lysosomal 
pathway.  
 
OcrlY/- mice show a specific defect in receptor-mediated endocytosis 
To determine the mechanism of LMW proteinuria, we followed the in vivo uptake of the LMW 
protein Cy5-labelled β-lactoglobulin in the kidneys of OcrlY- mice compared to their control 
littermates. Fifteen minutes after injection, a substantial accumulation of fluorescent vesicles was 
observed in the brush border of PT cells of the OcrlY/+ mice, contrasting with a considerable 
reduction of the signal in PT cells from OcrlY/- mice (Fig. 2A). A similar defective uptake in Cy5-
labelled β-lactoglobulin was observed in Clcn5Y/- tubules (Fig. 2B). By contrast, the internalization 
of Alexa 647-dextran, a marker of fluid phase endocytosis, was unaltered in OcrlY/- mice (Fig. 2C), 
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suggesting that loss of OCRL function impacts specifically on receptor-mediated endocytosis. To 
substantiate this observation, we investigated the LRP2 receptor and found its expression 
dramatically decreased in PT cells of the OcrlY/- kidneys whereas its mRNA level was unchanged 
(Figs. 2D-F). In line with absent phosphaturia and glycosuria, no modifications in the sodium- 
phosphate cotransporter IIa (NaPi-IIa), the sodium-glucose cotransporter 2 (SGLT2) or other PT 
components were observed in OcrlY/- kidneys (Figs. 2E and 2F).  
These data reveal that a defective receptor-mediated endocytosis, caused by a decreased 
protein level of LRP2, characterizes OcrlY/- mice, similar to Clcn5Y/- mice. The renal Fanconi 
syndrome is restricted to LMW proteinuria in OcrlY/- mice, contrasting with a more severe PT 
dysfunction in Clcn5Y/- mice. At age 8 weeks, the latter showed a decreased expression of SGLT2 
and NaPi-IIa (Suppl. Fig. 2A), explaining glycosuria and phosphaturia along polyuria and calciuria 
(Table 1; Suppl. Figs. 2C-D), and a defective uptake of fluid-phase endocytosis (dextran) markers 
(Suppl. Fig. 2B).  
 
Loss of OCRL increases PI(4,5)P2 and disrupts receptor-mediated endocytosis in vitro 
In order to further analyse the endocytic defect observed in vivo, we developed primary cultures of 
PT cells (mPTC) from micro-dissected PT segments of OcrlY/- mice aged 8 weeks. This cell culture 
system preserves the differentiation and polarized transport processes and therefore represents a 
relevant in vitro model to investigate mechanisms underlying PT disorders (19). To validate the Ocrl 
cellular system, we evaluated whether the loss of OCRL in mPTC reproduced the typical endosomal 
accumulation of PI(4,5)P2 observed in Lowe syndrome/Dent disease2 (20). Compared to control, 
OcrlY/- mPTCs exhibited a remarkable increase of PI(4,5)P2  in early endosomal structures, as shown 
by colocalization with the early endosome marker EEA1 (Figs. 3A-B). The unchanged PI3P levels, 
the PI hallmark of the endosomal system, demonstrated that OCRL disruption in mPTCs exclusively 
targets the homeostasis of PI(4,5)P2 (Suppl. Fig. 3A). These results, which are consistent with 
PI(4,5)P2 accumulation observed in a transgenic zebrafish model of Lowe syndrome or in OCRL-
depleted immortalized cells, substantiate the reliability of Ocrl mPTCs system (13, 21). 
Given that the tight regulation of PI(4,5)P2 homeostasis is fundamental for a proper endocytic 
trafficking, we asked whether its increase at the early endosomes might impair the endocytic function 
of mPTCs. Functional studies demonstrated that albumin uptake was markedly reduced in OcrlY/- (-
84%) when compared to control mPTCs (Fig. 3C). A similar disruption of the endocytic capacity was 
observed in Clc5Y/- mPTCs (Fig. 3D). Confirming the observations made in vivo, fluid phase 
endocytosis was unaltered in OcrlY/- mPTCs (Fig. 3E), highlighting the specificity of the defect in 




OCRL deficiency perturbs expression of LRP2 through aberrant F-actin polymerization  
We next examined whether the defective uptake capacity of OcrlY/- mPTCs was reflected by 
alterations of the endogenous LRP2 expression. LRP2 protein level was reduced in the total lysates 
of mPTCs lacking OCRL (Fig. 4A), similarly to Clcn5Y/- mPTCs (Suppl. Fig. 4A). This reduction 
was confirmed by the analysis of the confocal Z-stack images, evidencing a decreased LRP2 
fluorescent signal in each focal plane throughout the entire volume of OcrlY/- mPTCs (Fig. 4B and 
Suppl. Fig. 4B). The latter analysis showed a shift of LRP2 signal from the apical plasma membrane 
towards a more intracellular compartment in OcrlY/- mPTCs, whose polarization is defined by the 
typical apical (wheat germ agglutinin, WGA) and basolateral (Na+, K+-ATPase) markers (Fig. 4C and 
Suppl. Fig. 4C). This result was corroborated by a striking decrease of LRP2 level in the plasma 
membrane fraction of OcrlY/- mPTCs (Fig. 4D). These changes were not associated with LRP2 
transcriptional modifications or alterations of other PT receptors or transporters (Suppl. Fig. 3B).  
The intracellular localization of LRP2 in OcrlY/- mPTCs prompted us to examine its organelles 
compartmentalization. OCRL is known to modulate the trafficking of endocytic receptors by 
orchestrating the recycling of endosomal vesicles to the surface (13). Thus, lack of OCRL function 
might disrupt the return of the endocytic receptors to the apical membrane, leading to their 
accumulation in endosomal structures. Imaging studies confirmed LRP2 increase within EEA1+ early 
endosomes in OcrlY/- mPTCs, suggesting that loss of OCRL function impacts on both expression and 
distribution of this endocytic scavenger (Fig. 4E).  
As PI(4,5)P2 promote the recruitment of the actin nucleating machinery, we asked whether 
their endosomal accumulation, observed in OcrlY/- mPTCs, might locally induce an aberrant actin 
polymerization and, in turn, affect the trafficking of endocytic receptors (22).We observed that, in 
OcrlY/- mPTCs, the levels of actin stress fibres decreased and foci of filamentous actin (F-actin) 
accumulated on internal membranes ruffles (Suppl. Fig. 4D). Compared to controls, an increase of F-
actin structures, colocalizing with EEA1, was observed in OcrlY/- mPTCs (Suppl. Fig. 4E). This 
uncontrolled actin dynamics might impede the entrance of the endosomes in the recycling route and 
coerce LRP2 to stick inside them. Supporting this hypothesis, a considerable amount of LRP2 vesicles 
were coalescent with F-actin membranes (Fig. 4F). Furthermore, by high magnification confocal 
microscopy, it was possible to visualize the formation of F-actin basket-like structure surrounding 
LRP2 (Suppl. Fig. 4F). These data indicate that the increased association of F-actin with early 
endosomes may affect the endocytic trafficking and prevent the recycling of LRP2 to the apical 
surface. In order to substantiate the role of OCRL in maintaining the recycling activity, we 
investigated the localization of the canonical recycling marker transferrin receptor (TfR), which 
crosses the same endocytic stations traveled by LRP2 (plasma membrane - early endosomes/recycling 
endosomes) (23). Our data showing the redistribution of TfR from the plasma membrane to enlarged 
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cytoplasmic structures, which also trap LRP2, provide another evidence of defective endocytic 
recycling in OcrlY/- mPTCs (Suppl. Fig. 5A and Fig. 4G).  
We also tested whether the lack of OCRL might affect the trafficking of the cation-
independent mannose 6-phosphate receptor (CI-MPR), which is required for the transport of 
lysosomal enzymes and travels through intracellular itineraries diverging from those exploited by 
LRP2 (trans golgi network-late endosomes- plasma membrane) (24). An increase in the CI-MPR 
associated with peripheral structures and a decrease in the perinuclear pool was observed in the 
kidneys and mPTCs from OcrlY/– mice compared to controls (Suppl. Figs. 5B-C), indicating a 
defective retrograde transport of CI-MPR from the endosomes to the Golgi. All together, these data 
suggest that the actin-trapping mechanism impairing the recycling of LRP2 extends to other receptors 
traveling through the endosomal structures of OcrlY/- mice, highly relevant for the molecular basis of 
Lowe syndrome.  
 
OCRL depletion alters lysosomal dynamics and function 
It has been recently shown that, under lysosomal overload conditions, OCRL translocates on the 
lysosomal membrane, where it ensures adequate levels of PI(4,5)P2 necessary for fusion and 
subsequent degradation of  cargo vesicles (25). We thus explored whether loss of OCRL function 
might generate a rearrangement of PI(4,5)P2 at the lysosomal membrane and, consequently, affect 
lysosomal morphology. Confocal microscopy analysis showed that Ocrl deletion increased the 
number of PI(4,5)P2 positive structures colocalized with LAMP1-labeled lysosomes (Fig. 5A). These 
changes were associated with dramatic modifications in the dynamics of lysosomes as evidenced by 
their abnormal increase in number and size (Fig. 5B). As changes in lysosomal dynamics could affect 
their proteolytic activity, we examined whether OCRL disruption impairs the lysosomal cargo 
degradation in OcrlY/- mPTCs. To this end we used dequenched BSA (BSA-DQ) reagent, which is 
readily incorporated by cells via fluid-phase endocytosis. Upon fusion with endo-lysosomes, BSA-
DQ is digested into smaller fragments, thereby relieving its self-quenching properties and causing a 
fluorescent signal that reflects lysosomal degradative capacity (26). OcrlY/- mPTCs showed a 
remarkable decrease in BSA-DQ fluorescent puncta colocalized with LAMP1 (Fig. 5C), indicating a 
specific impairment of lysosomal proteolysis as fluid phase endocytosis was not affected by the loss 
of OCRL. To substantiate the defective lysosomal activity, we tested the processing of the epidermal 
growth factor receptor (EGFR), an endogenous protein which, upon EGF induced internalisation, is 
normally sorted to endo-lysosomal proteolytic pathway for degradation (27). Control mPTCs, 90 min 
after EGF stimulation, showed an efficient degradation of EGFR. On the contrary, at the same time 
frame, the levels of EGFR remained high in OcrlY/- mPTCs, suggesting a delayed lysosomal 
processing of the receptor (Fig. 5D). One mechanism by which cargo clearance might be impeded is 
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a defective maturation of lysosomal cathepsins. Western blot analyses of Cathepsin D (Cts-D) showed 
a decreased generation of the 32kDa mature Cts-D in OcrlY/- mPTCs compared to control (Fig. 5E). 
We next tested the lysosomal Cts-D activity by incubating the cell with Bodipy-FL-PepstatinA 
(PepA), a fluorescence-tagged PepA that binds to the active site of Cts-D in acidic lysosomes. 
Although the majority of lysosomes were co-stained with PepA in control mPTCs, the number of 
PepA-labeled vesicles colocalizing with LAMP1 were substantially lower in OcrlY/- mPTCs (Fig. 5F). 
Similarly, the lysosome-based processing of the LMW -lactoglobulin, which is normally 
internalized and degraded by endolysosomes, was dramatically reduced in OcrlY/- proximal tubules 
compared to wild-type (Fig. 5G).  
To investigate whether mis-sorting of lysosomal hydrolases in the extracellular space might 
contribute to the aberrant lysosomal proteolysis observed in OcrlY /– mice, we tested for and detected 
significantly increased levels of the lysosomal protease Cts-D (immature form) in the plasma of these 
mice (Suppl. Fig. 6A). This result was in line with the mis-trafficking of CI-MPR at the cell periphery 
and with previous studies performed in patients with Lowe syndrome (13). Collectively these data 
indicate that OCRL is important to maintain lysosome homeostasis, itself crucial for PT function. Of 
note, impaired lysosomal proteolysis and insufficient degradation of β-lactoglobulin was also 
observed in Clcn5Y/- proximal tubules (Suppl. Figs. 6B-D) indicating that OCRL and ClC-5 are part 
of the same cellular pathways. 
 
The OcrlY/- mice show dysfunctional locomotricity associated with muscular defects 
In order to test whether the deletion of OCRL in this model was reflected by extra-renal 
manifestations, we performed comprehensive behavioral tests of Ocrl mice to examine basic motor 
activity, learning and memory skills, social behaviour and vision. To identify disturbances in 
locomotor activity, we evaluated the general mobility of the mice by challenging them with the open 
field large arena test, which has been extensively used for analyzing the locomotor defects exhibited 
by Parkinson and Huntington mouse models (28, 29). While velocity was comparable between 
genotypes (data not shown), OcrlY/- mice exhibited an overall decreased locomotor activity, as scored 
by the measurement of their trajectories (Figs. 6A and 6B). The OcrlY/- mice presented more resting 
episodes than controls, as well as fewer lingering and walking events during the test (Fig. 6C). Of 
note, center-field avoidance was robust and equal in both genotypes (data not shown), suggesting that 
the impaired motor activity in OcrlY/- mice was more likely driven by a muscular defect rather than 
an abnormal anxiety-related response.  
To test the latter hypothesis, we pursued mice analyses in IntelliCage, an automated system, 
which allowed the evaluation of the spontaneous behaviour of the animals (30). During free 
adaptation phase, OcrlY/- mice made fewer corner visits compared to controls, confirming the reduced 
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locomotor and exploratory activity shown in the test above (data not shown). However, OcrlY/- mice 
showed an incompetent licking pattern, which became more evident during the drinking restriction 
protocol and was associated with slower progress of water intake during drinking sessions (Fig. 
6D).We excluded an influence of the kidney defect on the licking pattern as similar water intake was 
detected between genotypes (Suppl. Fig. 7A). Thus, the impaired licking of OcrlY/- mice was most 
likely caused by a global muscular dysfunction, which affected also the oro-lingual motor apparatus.  
To explore whether the defective locomotricity evidenced in OcrlY/- mice was driven by 
muscular defects, we performed whole body composition analysis (EchoMRI), which evidenced a 
striking decrease in lean mass/body weight ratio in OcrlY/- mice compared to controls (Fig. 6E), with 
a global reduction of the mass of several hind limb (gastrocnemius, triceps surae, plantaris, tibialis 
posterior/anterior and quadriceps) muscles relative to body weight (Fig. 6F) demonstrating skeletal 
muscle atrophy. These changes were paralleled by a strong increase in plasma creatine kinase (CK) 
activity, suggesting membrane fragility of striated muscles. (Fig. 6G). These events, which are in line 
with the muscle hypotonia observed in Lowe Syndrome patients (7), support the motor defect detected 
in OcrlY/- mice. 
To assess the cognitive function of Ocrl mice we applied IntelliCage standard protocol which 
investigated the hippocampus-dependent spatial learning ability of the animals. No sign of 
dysfunctional learning was observed in OCRL deficient mice, even during the most challenging 
chaining task (data not shown). Aggressive behavior reported in patients with Lowe syndrome was 
also not reflected in OcrlY/- mice, which showed intact sociability (Suppl. Fig. 7B). Given that 
congenital cataract and glaucoma are hallmarks of Lowe syndrome, we also examined the 
visuospatial and visuoperceptual ability of Ocrl mice. During water maze cue navigation, OcrlY/- mice 
exhibited a robust learning without evidences for an inadequate vision (Suppl. Fig. 7C). In addition 
no noticeable differences were observed in lens epithelium and in retinal morphology between control 
and OcrlY/- mice. Irrespective of the Ocrl genotype, an impairment of retinal photoreceptor layer was 
observed in mice harboring rd8 (retinal degeneration 8) mutation in Crb1 gene, a spontaneous 
mutation associated with C57BL/6N genetic background, leading to photoreceptor rosette-like 




In these studies, we present the first OCRL-deficient mouse model that associates renal and extra-
renal manifestations encountered in patients with Lowe syndrome. The absence of OCRL in kidney 
proximal tubule triggers endolysosomal defects and epithelial dysfunction, with a consistent LMW 
proteinuria reflecting defective receptor-mediated endocytosis due to decreased expression of LRP2 
endocytic receptor, in absence of renal failure. We also evidence a partial convergence of disease-
mechanism and kidney tubular phenotype between mouse models deficient in ClC-5 (Dent disease 1) 
and OCRL (Lowe syndrome/Dent disease 2). These results provide insights into the mechanisms of 
endocytosis and the pathophysiology of Dent disease/Lowe syndrome. 
 In contrast with a previous kidney tubular conditional Ocrl and Inpp5b KO mouse model, 
where the phenotype reflects the combined loss of OCRL and INPP5B (17), the genetic architecture 
of the mouse line investigated here allows to directly address dysfunctions related to the single loss 
of OCRL activity (18). The reinsertion of human INPP5B in the Ocrl−/−; Inpp5b−/− background, 
irrespective of its level of expression, was fundamental for survival but it was not compensating for 
the renal defect. This observation is in line with studies on cells derived from patients with Lowe 
syndrome, which exhibit INPP5B-independent phenotypic variability (32). Although the renal defect 
was observed in all the OcrlY/- mice analysed, a noticeable spread was observed comparing individual 
animals. This individual variability was not due to different levels of INPP5B expression. The 
possibility that compensatory changes in kinases or phosphatases crossing the same metabolic 
pathway than OCRL may contribute to such variability should be further investigated. 
The differences between the conditional double Ocrl and Inpp5b KO and the humanized 
transgenic OcrlY/- mice studied here are evident when comparing the defective tubular endocytic 
phenotypes. The conditional deletion of OCRL and INPP5B resulted in an unspecific impairment of 
the clathrin-dependent and clathrin-independent endocytosis. By contrast, the single lack of OCRL 
in OcrlY/- transgenic mice resulted in a selective dysfunction of the clathrin receptor-mediated 
endocytosis, as evidenced by the defective uptake of β-lactoglobulin and the unaffected 
internalization of the fluid-phase marker dextran. These differences are in line with the function of 
OCRL in regulating the membrane trafficking of clathrin-coated vesicles (33). 
Defective receptor-mediated endocytosis was reflected in OcrlY/- mice by a consistent LMW 
proteinuria, occurring early, in absence of renal failure. In contrast, the OcrlY/- mice did not show 
glycosuria, phosphaturia and calciuria, even at old age, mimicking the partial renal Fanconi syndrome 
typically present in the majority of patients carrying mutations in OCRL (7, 34) . The Clcn5Y/- mice 
showed a similar defect in receptor-mediated endocytosis, causing a severe LMW proteinuria. The 
Clcn5Y/- mice also showed a defective uptake of fluid phase endocytosis markers, in line with previous 
data from mouse models and patient-derived cells (35-37) but not with others (12). The presence of 
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a more complete form of renal Fanconi syndrome in the Clcn5Y/- mouse model was evidenced by the 
hypercalciuria, phosphaturia and glucosuria detected at 8 weeks, paralleled by a decreased expression 
of SGLT2 and NaPi-IIa in addition to LRP2.  
Filtered LMW proteins are reabsorbed through megalin /LRP2 and cubilin endocytic receptors 
expressed at the apical membrane of PT cells. This reabsorptive function is maintained by the 
degradative and recycling activity of the endolysosomal system, as evidenced by severe defects in 
tubular homeostasis associated with endolysosomal disorders (1, 2). Our investigations characterize 
the involvement of LRP2 in the pathogenesis of Lowe syndrome, and demonstrate analogies with the 
endocytic defect associated with the loss of ClC-5 in Dent disease1/Clcn5Y/- mouse model (12). 
Previous studies, relying on OCRL-deficient immortalized cells expressing LRP2 mini‐receptor, 
showed a redistribution of LRP2 from the apical membrane to the intracellular compartments rather 
than a defective expression (13). Here, analyses on kidney tissues reveal a remarkable decrease of 
LRP2 protein in the proximal tubule from OcrlY/- mice, similar to that observed in Clcn5Y/- mice. 
These findings are in line with observations made in zebrafish pronephros, demonstrating the 
evolutionary conservation of the role of OCRL in endocytosis (21). The identification of converging 
kidney phenotypes in mouse models for Lowe syndrome and Dent disease supports the view that the 
endosomal exchanger ClC-5 and the 5-phosphatase OCRL impact on common pathways operating in 
kidney tubular cells. In absence of transcriptional changes, the mechanism by which the loss of ClC-
5 or OCRL might affect LRP2 protein levels remains to be clarified. First, the decrease of apical 
LRP2 may reflect an increased shedding of the receptor in the urine in response to the endolysosomal 
engorgement observed in OcrlY/- mice. Previous studies showed that LRP2 is a substrate for 
metalloproteases and is constitutively subjected to ectodomain shedding (38). This event produces 
LRP2 membrane-associated fragments, which in turn form the substrate for - secretase, the main 
player of regulated intramembrane proteolysis. Preliminary data showing a higher abundance of 
LRP2 fragments in OcrlY/- urine, together with a transcriptional increase of all subunits composing 
the -secretase (39) are in line with this hypothesis (data not shown). Alternatively, the loss of LRP2 
could be explained by an increased urinary excretion of (full length) LRP2-containing exosomes. A 
third mechanism might be an aberrant degradation of LRP2, mediated by the proteasome in response 
to altered lysosomal proteolysis (see below). Further studies of post-translational modifications 
potentially triggering LRP2 to the proteasome are necessary to test this hypothesis (40). 
By establishing differentiated and polarized proximal tubular cell cultures (mPTCs) directly 
derived from OcrlY/- mouse kidneys (19), we were able to reconstitute critical aspects of the disease 
in vitro. The OcrlY/- mPTCs recapitulate the selective impairment of receptor-mediated endocytosis 
and the ectopic accumulation of PI(4,5)P2 in early endosomes (20). The latter is due to the loss of 5-
phospatase activity of OCRL that regulates the transition from high (plasma membrane) to low (early 
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endosomes) levels of PI(4,5)P2  in clathrin coated vesicles, enabling progression of the cargo/receptor 
along the endocytic pathway (33, 41). The PI(4,5)P2 dynamic is critical for actin assembly at the 
plasma membrane ruffles and early endosomes, hence, for the regulation of membrane trafficking 
(42, 43). Accordingly, the endosomal accumulation of PI(4,5)P2  in OcrlY/- mPTCs triggers an 
aberrant F-actin polymerization, which impairs the recycling of residual LRP2, thus impeding the 
endocytic uptake. The actin-trapping mechanism impairing LRP2 recycling might be extended to 
other receptors, as evidenced by the redistribution of the canonical recycling marker TfR in OcrlY/- 
mPTCs. These defects in receptor recycling represent an appealing druggable target for rescuing the 
epithelial dysfunction associated with the disease. 
It has been shown recently that OCRL can translocate to the lysosome under cargo overload 
conditions, where its fine regulation of PI(4,5)P2 balance is instrumental for maintaining lysosomal 
function (25). Here, we demonstrate that lack of OCRL induces an abnormal lysosomal accumulation 
of PI(4,5)P2 leading to altered lysosomal dynamics and defective lysosomal function, as scored by 
decreased expression and activity of lysosomal cathepsin D and impaired processing of lysosomal 
substrates in OcrlY/- kidney and mPTCs. These results, which are consistent with previous 
observations on biopsies derived from Lowe patients (25), raise the issue of the mechanisms 
responsible for lysosomal dysfunction associated with loss of OCRL. The peripheral mislocalization 
of the CI-MPR, a protein regulating the transport of lysosomal hydrolases from the Golgi to 
lysosomes, along with increased levels of lysosomal protease Cathepsin D (immature form) in the 
plasma, indicates that misrouting of lysosomal enzymes could be involved. This finding is in line 
with previous studies performed in Lowe syndrome patients (13). Alternatively, the lysosomal 
engulfment of PI(4,5)P2 driven by the loss of OCRL may somehow alter the vacuolar-type H+-
ATPase (V-ATPase) complex, thereby impairing lysosome acidification and activation of cathepsins. 
It should be noted that similar defects in receptor-mediated endocytosis and lysosomal dynamic and 
activity are observed in mouse and cellular models deficient for the endosomal ClC-5 or lysosomal 
cystinosin (CTNS) transporters, highlighting the role of the endolysosome network as crucial 
signaling hub to ensure epithelial homeostasis (44). 
Studies on the locomotor, neurological and vision abnormalities detected in patients with 
Lowe syndrome have been hindered by the limitations of available mouse models. Deep phenotyping 
analyses unveiled a defective locomotricity in OcrlY/-mice, which reflects a global impairment of the 
muscular apparatus, as indicated by the increased plasma activity of protein creatine kinase and 
atrophy of several hind limb muscles. This phenotype was reminiscent of the muscle hypotonia 
associated with Lowe syndrome and therefore highly relevant (45). Whether this defective 
muscular/motor pattern originates from a primary myopathy or is rather a consequence of 
neurological alterations and how OCRL contributes in maintaining muscular tone remains to be 
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further investigated. Behavior, learning-memory function and vision were not altered in OcrlY/-mice. 
The discrepant clinical manifestations in mice and humans could be partly explained by differences 
in tissue-specific expression of enzymes with overlapping functions or by specific roles of OCRL in 
the tissues affected by the disease (46, 47).  
Collectively, these studies validate the first mouse model of Lowe syndrome and give 
insights into the role of OCRL in cellular trafficking of multiligand receptors. Partial convergence 
of disease-mechanism and renal phenotypes observed in OcrlY/- and Clcn5 Y/- mice suggest shared 
mechanisms in Dent disease 1 and 2. These insights open new avenues for therapeutic interventions 
in Lowe syndrome and Dent disease.  
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MATERIALS AND METHODS  
Antibodies and reagents. The following antibodies were used: rabbit anti-human transferrin (A0061, Dako); rabbit anti-
human Gc-globulin (also known as VDBP, A0021, Dako); rabbit anti-uteroglobin (also known as CC16, ab40873, 
Abcam); rabbit anti-SLC1A5 (also known as SGLT2, ab84903, Abcam); rabbit NaPi-IIa (gift from C.A.Wagner, 
University of Zurich, Zurich, Switzerland); rabbit anti-human AQP1 (ab2219, Millipore); mouse anti--actin (A2228, 
Sigma-Aldrich); mouse conjugated to Fluorescein (FITC) anti-PI(4,5)P2 (Z-G045, Echelon Biosciences Inc.); mouse anti-
EEA1 (610456, BD Bioscience); rabbit anti-RFP (600-401-379, ROCKLAND); sheep anti-LRP2 (gift from P. Verroust 
and R. Kozyraki, INSERM, Paris, France); mouse anti Flotillin-1(610821, BD Bioscience); mouse anti-α-tubulin (T5168, 
Sigma-Aldrich); rabbit anti-GAPDH (2118, Cell Signaling Technology); rat anti-LAMP1 (sc-19992, Santa Cruz 
Biotechnology); goat anti-Cathepsin-D (Cts-D; sc-6486, Santa Cruz Biotechnology); rabbit anti -EGFR (1005 
sc-03, Santa Cruz Biotechnology); Alexa-488 Phalloidin (F-actin , A12379, Thermofisher Scientific); mouse 
anti-Transferrin Receptor Antibody (H68,4, ThermoFisher Scientific), wheat germ agglutinin (WGA) 
FITC Conjugate (L 4895, Sigma-Aldrich), mouse anti -Na+/K+-ATPase subunit 1 (C464.6 EMD 
Millipore), rabbit anti -MPR and rabbit anti -OCRL (gift from A. De Matteis, Telethon Institute of 
Genetics and Medicine (TIGEM), Pozzuoli,  Italy).  
 
Mouse models. Experiments were conducted on age- and gender-matched OcrlY/+; Inpp5b-/-; and OcrlY/-; Inpp5b-/- mouse 
littermates harboring BAC-INPP5B expression in equal copies (BAC1) (129S/SvEv * 129S6/SvEvTac * FVB/N* 
C57BL/6 background), (18) and Clcn5Y/+and Clcn5Y/- mice littermates (C57BL/6 background) (48). All the mice used in 
this study were expressing similar levels of INPP5B as analyzed by RT-qPCR (see below). Mice were maintained under 
temperature-and humidity-controlled conditions with 12 h light/12 h dark cycles with free access to appropriate standard 
diet in accordance with the institutional guidelines of National Institutes of Health Guide for the Care and Use of 
Laboratory Animals.  
 
Renal function parameters. Mice were placed overnight in metabolic cages with ad libitum access to food and drinking 
water. Urines were collected over ice and body weight, water intake and diuresis were measured at the indicated time 
point (49). Blood (from sublingual vein) was obtained after anesthesia with ketamine/xylazine or isoflurane. Urine and 
blood parameters were measured using a UniCel DxC 800 pro Synchron (Beckman Coulter, Fullerton, CA, USA), 
whereas urinary Clara cell protein (CC16) concentration was measured in duplicate by enzyme-linked immunosorbent 
assay (ELISA; BIOMATIK EKU03200) (44). Albuminuria was measured by Coomassie Blue staining by using 
ProtoBlue Safe (EC-722, national diagnostics) according to manufacturer instructions.   
 
Kidney isolation and primary cultures of proximal tubule cells. The kidneys were harvested from OcrlY/+ and OcrlY/- 
mice and Clcn5Y/+and Clcn5Y/- mice as previously described (44). Briefly, one half of the kidney was fixed in 4% PFA 
and processed for immunostaining while the other half was used for protein isolation or RT-qPCR analysis. The 
contralateral kidney was taken to generate primary cultures of mouse proximal tubule cells (mPTCs) according to a 
previously established protocol (14). Confluent monolayers of mPTCs, characterized by a high endocytic uptake capacity, 
were expanded from tubular segments after 6–7 days. 
 
Genotyping. Genomic DNA was isolated from ear biopsies from OcrlY/+; Inpp5b -/-; BAC-INPP5B and OcrlY/-; Inpp5b -/-
; BAC-INPP5B mice by using E.Z.N.A Forensic DNA Kit (OMEGA bio-tek) according to the manufacturer instruction. 
PCR was performed by using the following primers: Ocrl wild-type: the forward primer 5’-CCC TTT 
TCATCTGTTAGGAGAAATC-3’is located at the junction of intron 18 and the 5’end of exon 19. The reverse primer 5’- 
GCATGG TTAAACGCACTATGTGG-3’ is located in intron 19, which is deleted in the OcrlY/- line. Ocrl knock-out: the 
forward primer 5’GCCCTTTGATTCTAATCCCTTTTC ATC-3’ is located in the intron positioned just before the exon 
19. The reverse primer 5’-TCT GAGCCCAGAAAGCGAAG-3’ is located in the PGK promoter, which is part of the neo-
cassette gene targeting vector. Inpp5b knock-out: the forward primer 5’-TAAAGTCTGAAA ATCCAAGGC-3’ is located 
in exon 25. The reverse primer 5’-CTCATTTCTCCTTGATTC CAAT-3’ is located in exon 34. BAC-INPP5B: the 
forward primer 5’-CCACCCCACGATTGACTC-3’ is localized in exon 1. The reverse primer 5’-
GGTGTCCCAGCCCTCAG-3’ is localized also in exon 1. PCR conditions were: 32 cycles of 94°C for 30 sec, 55°C for 
30 sec and 72°C for 1min. 
 
Quantitative real-time PCR. Total RNA was extracted from mouse kidney tissues using Aurum Total RNA Fatty and 
Fibrous Tissue Kit according to manufacturer’s protocol (Bio-Rad, Hercules, CA). DNAse I treatment was performed to 
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eliminate genomic DNA contamination. Total RNA was extracted from primary cell cultures with RNAqueous kit 
(Applied Biosystems, Life Technologies). 1 μg of RNA was used to perform the reverse transcriptase reaction with 
iScript™ cDNA Synthesis Kit (Bio-Rad). Changes in target gene mRNA levels were determined by relative RT-qPCR 
with a CFX96™ Real-Time PCR Detection System (BioRad) by using iQ™ SYBR Green Supermix (Bio-Rad). RT-
qPCR analyses were performed in duplicate. Specific primers were designed by using Primer3 (Supplementary Table 1). 
PCR conditions were 95°C for 3 min followed by 40 cycles of 15 sec at 95°C, 30 sec at 60°C. The PCR products were 
sequenced with the BigDye terminator kit (Perkin Elmer Applied Biosystems, Thermo Fischer Scientific). The efficiency 
of each set of primers was determined by dilution curves (Supplementary Table 1). The relative changes in targeted genes 
over Gapdh, Actb, Hprt1, Ppiase, 18S, 36B4 mRNAs were calculated using the 2−ΔΔCt formula (50).  
 
Immunofluorescence and confocal microscopy. Mouse kidneys were fixed by perfusion with 50–60 ml of 4% PFA in 
PBS before being snap-frozen in cryogenic Tissue-Tek OCT compound (Electron Microscopy Sciences, Hatfield, USA). 
The embedded tissues were sectioned at 5 µm and processed for immunofluorescent staining as previously described (44). 
The slides were acquired on Leica SP5 confocal laser scanning microscope (Center for Microscopy and Image Analysis, 
University of Zurich) equipped with a Leica APO 63x NA 1.4 oil immersion objective at a definition of 1024 x 1024 
pixels, adjusting the pinhole diameter to 1 Airy unit for each emission channel. Quantitative image analysis was performed 
by selecting random visual fields containing at least 3-5 proximal tubules (LTL-positive) each one and acquired with the 
same setting parameters. For quantification of -lactoglobulin and dextran internalization, the integrated density signal 
detected within each LTL-positive tubule was calculated. Internalization was then expressed as a ratio between the internal 
fluorescence and tubule area. Tubules at the border of the picture were excluded. ImageJ software was used for the 
analysis (17). 
The mPTCs were fixed in 4% PFA and processed for immunofluorescent staining as previously described (44).  
Briefly, after incubation with blocking/permeabilization solution (0.1% Saponin ,0.5% BSA and 50mM NH4Cl in PBS), 
mPTCs were stained overnight with the appropriate primary antibodies and 45 minutes with the suitable fluorophore-
conjugated Alexa secondary antibodies (Invitrogen) or with Alexa-488 Phalloidin (F-actin) or 10 minutes with wheat 
germ agglutinin (WGA) FITC Conjugate . Immunostained mPTCs were analyzed by a Leica SP5 confocal laser 
scanning microscope using the settings described above. The quantitative cell image analyses were performed by using 
ImageJ software and the open-source cell image analysis software CellProfilerTM (51).  More details regarding the 
quantifications are described in Supplementary Materials. 
 
Endocytosis assays. Proximal tubules endocytic capacity of Ocrl and Clcn5 mice was examined by measuring β-
lactoglobulin and dextran uptake. β-lactoglobulin was tagged with Cy5 using TM2 Ab labeling kit (Amersham) in 
accordance with the manufacturer’s instructions. 15 minutes after tail-vein injection of Cy5 β-lactoglobulin (1mg/kg 
B.W., L3908, Sigma) or 30 minutes after injection of 10 kDa Alexa 647-dextran (6 mg/kg B.W.; D22914, Thermo Fisher 
Scientific), mice were anesthetized and their kidneys were harvested and processed for confocal microscopy.  The 
endocytic capacity of Ocrl and Clcn5 mPTCs was examined by measuring albumin and dextran uptake as described 
previously (44). Briefly mPTCs were incubated at 37°C with 100g/mL Alexa488-BSA (A13100, Thermo Fisher 
Scientific) or 250g/mL Alexa 647-dextran diluted in medium without FBS supplementation, for 15 and 30 min 
respectively. After washing, the cells were fixed in 4% PFA and processed for confocal microscopy  
  
PI(4,5)P2 and PI3P staining. mPTCs were grown on 35mm dishes and PI(4,5)P2 or PI3P staining were performed 
according to previously established protocols (25). Briefly, mPTCs were fixed for 15 min in 2% PFA and permeabilized 
for 5 min with 20µM digitonin in buffer A (20mM PIPES pH 6.8, 137mM NaCl, 2.7mM KCl) for PI(4,5)P2 or buffer A1 
(150 mM NaCl, 20 mM Hepes, pH 7.4, and 2 mM EDTA) for PI3P. Next, mPTCs were incubated  for 45 minutes with 
buffer A containing 10% fetal bovine serum and anti-PI(4,5)P2 antibody or in buffer A1 supplemented with 5% goat 
serum and mCherry-2×FYVE  PI3P-binding domain (gift from J.Gallop, Gurdon Institute, University of Cambridge). 
Anti –RFP was used for amplifying m-cherry staining. Studies of colocalization with early endosomes or lysosomes were 
performed by 1h incubation at room temperature with anti-EEA1 or anti-LAMP1 antibodies respectively. After washing 
and subsequent incubation with appropriate secondary antibodies, mPTCs were post-fixed for 5 min in 2% PFA and 
analyzed by confocal microscopy. 
 
Lysosomal activity and degradation assays. The detection of lysosomal activity and degradative capacity in mPTCs was 
performed by using Bodipy-FL-PepstatinA (P12271, Thermo Fischer Scientific) and DQ-RED BSA (D12051, Thermo 
Fischer Scientific), respectively. Briefly, mPTCs were pulsed with 1μM Bodipy-FL-Pepstatin A or with 10μg/mL DQ-
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RED BSA in pre-warmed media at 37°C for 1h. After washing, cells were fixed, immunostained with anti-LAMP1 and 
suitable secondary antibody and subsequently analyzed by confocal microscopy (14, 26).  Lysosomal processing in Ocrl 
and Clcn5 mice was measured by confocal analysis of kidney proximal tubules after 120 minutes from tail-vein injection 
of Cy5 β-lactoglobulin.  
 
Western blotting. Proteins were extracted from mouse kidney tissues or primary cultured cells and lysed as previously 
described (44). Samples were normalized for protein or urinary creatinine levels before loading (20 μg/lane or 4μg/lane, 
respectively), diluted in Laemmli buffer and separated by SDS–PAGE in reducing conditions. Briefly, gels were blotted 
onto PVDF membranes, blocked in 5% non-fat milk and probed with appropriate primary and peroxidase-labeled 
secondary antibody. Protein bands were visualized by chemiluminescence (WBKLS0050, Millipore, Life technologies). 
Image intensity was measured by ImageJ.  
 
Plasma membrane isolation. mPTCs were lysed in a fractionation buffer (250mM sucrose, 20mM HEPES, 10mM KCL, 
1.5mM MgCl2, 1mM EDTA, 1mM EGTA) containing protease and phosphatase inhibitors and passed through a 25G 
needle. Cell lysates were kept on ice for 20 minutes and centrifuged at 720 g (5 minutes at 4°C). The resultant postnuclear 
supernatants were centrifuged at 10,000 g (5 minutes at 4°C) to eliminate mitochondria. The postmitochondria supernatant 
were centrifuged at 100,000 g (1h at 4°C) to separate cytosolic (supernatant) and membrane fractions (pellet). The 
membrane pellets were washed in fractionation buffer by centrifugation (100,000 g for 45min at 4°C) and suspended in 
lysis buffer (10% glycerol and 0.1% SDS supplemented with protease and phosphatase inhibitors). The cytosolic and 
membrane fractions were analyzed by SDS-PAGE and western blotting. 
 
Behavioral tests. Open field large arena test, water maze cue navigation and  three chambers sociability test were 
performed on a cohort of  32 male mice aged 32 weeks (16 OcrlY/+;Inpp5b -/-;BAC-INPP5B and 16 OcrlY/-; Inpp5b -/-;BAC-
INPP5B)  in order to investigate motor coordination, vision and  spatial learning and the social attitude of the mice 
respectively. Behavior testing procedures will be described briefly here and in more detail in the Supplementary Materials. 
Open field large arena test. Each subject was released near the wall of the arena and observed for 10 min on two 
subsequent days. Movements were tracked using Noldus EthoVision. Water-maze cue navigation. Animals were trained 
for 2 days to reach the goal platform hidden under milky-water and marked by a salient cue. The localization of the 
platform in the pool changed for every trial. All subjects were trained on the same sequence of goal positions and released 
from the same start points (52). Three-chambers sociability test. The test consisted of a 10-minutes trial where a test 
mouse was given the choice to spend time in the chamber with the novel object (the cylinder) plus the unfamiliar mouse 
(social stimulus) and the chamber containing only the empty cylinder. The time spent by the test mouse in the lateral 
chambers was noted (53). 
 
IntelliCages experiments. Intellicages experiments were performed on a cohort of 28 male mice aged 24 weeks (13 
OcrlY/+; Inpp5b -/-, BAC-INPP5B and 15 OcrlY/-; Inpp5b -/-; BAC-INPP5B). More details regarding the description of 
IntelliCage apparatus and mice preparation for IntelliCage experiments are provided in the Supplementary Materials.  
Exploration and free adaptation. During the first 4-7 days in IntelliCage all doors were open providing free access to 
all 8 drinking bottles (free adaptation). Data of the first 24h of free adaptation were analyzed separately to monitor 
exploration and habituation of the mice in the new environment (IntelliCage exploration). Nosepoke adaptation. During 
3-7 days, all doors were closed but can be opened at any time with a nosepoke for 5s once per visit. Drinking session 
adaptation. During 3-7 days the mice were adapted to a fixed drinking schedule with doors opening in response to nose 
pokes only in the following time spots: 04:00-05:00, 11:00-12:00, 16:00-17:00 and 23:00-00:00. (30). 
 
Epon embedding and retinal morphology. 36 weeks old mice were euthanized and perfused with PFA 4%. Eyes were 
enucleated and post-fixed in 4% PFA or 2.5% glutaraldehyde before being embedded in paraffin or epon plastic, 
respectively. For light microscopy, paraffin sections (including the lens, 5 µm) were stained with hematoxylin-eosin (HE), 
while plastic-embedded semi-thin cross-sections (0.5 μm) were counterstained with toluidine blue as described previously 
(54, 55) . Retinal morphology was analyzed by light microscopy (Zeiss, Axioplan, Jena, Germany).  
 
Muscle analyses.  Muscles analyses were performed on OcrlY/+vs. OcrlY/- male mice aged 24 weeks. Lean mass/body 
weight ratio was determined in 6 pairs of live mice by using the whole body composition analyzer EchoMRI™ (Zinsser 
Analytic, Frankfurt, Germany) (56) . Five pairs of mice were used for muscle and blood sampling. The mice were slightly 
sedated using isoflurane before being anesthetized with an i.p. injection of a mixture containing urethane (1.5 g/kg) and 
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diazepam (5 mg/kg) and killed by exsanguination. Blood and muscle tissues were collected as previously described (57). 
Selected leg muscles (triceps surae, soleus, plantaris, gastrocnemius, tibialis anterior, tibialis posterior, quadriceps) were 
carefully dissected bilaterally and weighed. Muscle mass was expressed relative to body weight. Creatine kinase (CK) 
activity in plasma was determined by spectrophotometry using a kit (C184-0B ; Catachem, Nuuchem, Oxford, CT, USA) 
according to the manufacturer’s instructions (57). 
 
Data analysis and Statistics. The quantitative data were expressed as means ± standard error of the mean (s.e.m.). 
Differences between experimental groups were evaluated using analysis of variance followed by post hoc test, when 
appropriate. When only two groups were compared, unpaired or paired two tailed Student’s t-tests were used as 
appropriate. No statistical methods were used to predetermine the sample size. The sample size (n of biological replicates 
derived from distinct mice) of each experimental group is described in figure legends. GraphPad Prism software was used 
for all statistical analyses. Statistical significance was set at a P<0.05. 
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Figure 1. Growth retardation and renal phenotype in a whole body OcrlY/- mouse model. (A) Dot plot representing the measurement of body weight, (B) albumin and (D) clara cell protein 16 (CC16) urinary 
excretion in Ocrl male mice at 8, 16, 24 and 48 weeks after birth (8 weeks n= 7 mice per group, 16 weeks n= 7 mice per group, 24 weeks n=7 mice per group, 48 weeks n=5 mice per group). (C) Coomassie blue-
stained SDS-PAGE analysis of urine derived from 8 weeks old Ocrl mice and densitometry quantification of Albumin (n=3 mice per group).10 μg of bovine serum albumin (BSA) were loaded as posit ive control 
(first lane; molecular weight (MW) 66.5 kDa). (E) Representative western blotting and densitometry quantification of transferrin (TFR), vitamin D binding protein (VDBP) and CC16 in urine derived from 8 
weeks old Ocrl mice. (TFR, VDBP and CC16 n= 5 mice per group). (F) Quantification of CC16 urinary excretion in 8 weeks old Clcn5 and Ocrl mice (n=5 mice per group). All the urine parameters were 
normalized to urinary creatinine concentration. Plotted data represent mean ± SEM. Each dot of the graphs represents one mouse. Two-tailed unpaired Student’s t-test, *P < 0.05, **P < 0.01 and ***P < 0.001 






Figure 2. Defective receptor-mediated endocytosis in OcrlY/- mice. (A-B) Representative confocal micrographs showing Cy5 labeled β-lactoglobulin (red, 1mg/kg B.W.) or (C) Alexa 647–labeled dextran uptake 
(red, 6 mg/kg B.W.) after 15 and 30 minutes from tail vein injections respectively and quantifications of the corresponding f luorescent signal in LTL+ (Lotus Tetragonolobus Lectin, green) proximal tubules from 
Ocrl and Clcn5 mouse kidneys (n=90 Ocrl and n=70 Clcn5 proximal tubules for Cy5 labeled β-lactoglobulin uptake;  n = 40 Ocrl proximal tubules for Alexa 647 dextran uptake); n=2 per group, each dot 
representing fluorescence intensity in one proximal tubule; fluorescence intensity was normalized on tubule area; two-tailed unpaired Student’s t-test, ***P < 0.001 relative to OcrlY/+or Clcn5Y/+ kidneys. ns: not 
significant). Insets: high magnification of Cy5 labeled β-lactoglobulin+ or Alexa 647 dextran+ structures in LTL+ proximal tubules. (D) Representative confocal micrographs showing LRP2 (red) expression in 
LTL+ (green) proximal tubules of Ocrl mouse kidneys. Insets: high magnification of LRP2+ structures in LTL+ proximal tubules. (E) Western blotting and densitometry analyses of LRP2, SGLT2, NaPi-IIa and 
AQP1 protein levels in whole kidney lysates from Ocrl mice. β-actin was used as loading control. Protein levels normalized on β-actin and relative to OcrlY/+ mice (black dotted line), (LRP2 n = 6 mice per group; 
SGLT2, NaPiIIa and AQP1 n=3 mice per group. Mann-Whitney U test, **P < 0.01 relative to OcrlY/+ kidneys). (F) The mRNA kidney levels of Lrp2, Sglt2, Slc34a1 and Aqp1 were analyzed by real-time qPCR. 
Gene target expression normalized to Gapdh and relative to OcrlY/+ mice (black dotted line), (n = 3 mice per group). Nuclei counterstained with DAPI (blue) in A, B, C and D. Scale bars 25µm. Plotted data 






Figure 3. Altered PI(4, 5) P2  subcellular distribution and receptor-mediated endocytosis in OcrlY/- mPTCs. (A) Representative confocal micrographs and quantification of PI(4,5)P2+ structures (green) in Ocrl 
mPTCs (n  80 cells pooled from three mouse kidneys per condition; each dot representing the number of PI(4,5) P2+ structures in a cell). (B) Representative confocal micrographs of Ocrl mPTCs immunostained 
with anti- PI(4,5)P2 (green) and anti-EEA1 (red, early endosomes) and quantification (adjacent panel) of the number of PI(4,5)P2/EEA1+ structures by confocal microscopy (percentage of total EEA1+ vesicles; n= 
3 OcrlY/+; n=4 OcrlY/-  randomly selected fields per condition, each containing  15-20 cells). Insets: high magnification of PI(4,5)P2/EEA1+ structures. (C-D) Ocrl and Clcn5 mPTCs were loaded with Alexa 488-
BSA (green, 100 μg ml−1 for 15 min at 37 °C), fixed, and analyzed by confocal microscopy. Quantification of the number of Alexa 488-BSA+ structures (n 150-250 cells pooled from three mouse kidneys per 
condition; each point representing the number of BSA+ structures in a cell). (E) Ocrl mPTCs were loaded with Alexa 647-dextran 10kDa (red, 250 μg ml−1 for 30 min at 37 °C), fixed, and analyzed by confocal 
microscopy. Quantification of the number of Al647-dextran+ structures (n 200-250 cells pooled from three mouse kidneys per condition; each dot representing the number of dextran+ structures in a cell). Nuclei 
counterstained with DAPI (blue). Scale bars in A and B 15μm, in C, D and E 10 μm. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test, **P < 0.01, ***P < 0.001 relative to OcrlY/+ or 






Figure 4. OcrlY/- mPTCs exhibit decreased expression of LRP2 and defective endocytic recycling. (A) Representative western blotting and quantification of LRP2 in whole Ocrl mPTCs lysates. α- tubulin was 
used as loading control (n=4 mice per group). (B) Dot plot representing distribution and average fluorescence intensity of LRP2 along Z-stacks projections in Ocrl mPTCs. Yellow rhombus represents the maximum 
peak of fluorescence intensity. Quantifications of Z-stacks were obtained from 3 randomly selected fields per condition, with each containing  15-20 cells. (C) Representative confocal micrographs and 
quantification of LRP2/WGA+ structures by confocal microscopy (in percentage of total LRP2+ vesicles, n=7 OcrlY/+; n=8 OcrlY/- randomly selected fields per condition, each containing 10-15 cells). (D) 
Representative western blotting and quantification of LRP2 protein levels in plasma membrane fraction derived from Ocrl mPTCs. Flotillin A1 and GAPDH were used as purity marker and loading control of the 
plasma membrane and cytosolic fractions respectively (n=3 independent experiment). (E) Representative confocal micrographs of Ocrl mPTCs immunostained with anti-LRP2 (red) and anti-EEA1 (green, early 
endosomes) and quantification (adjacent panel) of the number of LRP2/EEA1+ structures by confocal microscopy (percentage of total LRP2+ vesicles; n=5 OcrlY/+; n=6 OcrlY/- randomly selected fields per condition, 
each containing  15-20 cells). Insets: high magnification of LRP2/EEA1+ structures. (F) Representative confocal micrographs of Ocrl mPTCs immunostained with anti-LRP2 (red) and Alexa-Fluor-488-phalloidin 
(green, F-actin). Quantification (adjacent panel) of the number of F-Actin/LRP2+ structures (in percentage of total LRP2+ vesicles, n= 4 OcrlY/+; n=6 OcrlY/- randomly selected fields per condition, each containing 
10-15 cells). Insets: high magnification of F-actin/LRP2+ structures. (G) Representative confocal micrographs of Ocrl mPTCs stained with anti-TfR (green) and anti-LRP2 (red) and quantification of the number 
of TfR/LRP2+ structures by confocal microscopy (in percentage of total LRP2+ vesicles, n=8 randomly selected fields per condition, each containing 20-25 cells). Insets: high magnification of TfR/LRP2+ 
structures. Nuclei counterstained with DAPI (blue) in C, E, F and G. Scale bars in E, F and G 15μm and in C 20μm. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test, *P < 0.05, **P < 






Figure 5.  Altered lysosomal dynamics and degradative capacity in OcrlY/- mPTCs. (A) Ocrl mPTCs were immunostained with anti-PI(4,5)P2 (green) and anti-LAMP1 (red, lysosomes) and the number of 
PI(4,5)P2 /LAMP1+ structures were quantified by confocal microscopy (in percentage of total PI(4,5)P2+ vesicles; n=3  randomly selected fields per condition, each containing  40-50 cells). (B) Representative 
confocal micrographs of Ocrl mPTCs immunostained with anti-LAMP1 (green). Quantification of the average LAMP1+ vesicles diameter (top, n= 4 OcrlY/+ ; and n=6 OcrlY/- randomly selected fields per condition, 
each containing  50-60 cells) and number of structures (bottom, n 200-220 cells pooled from 3 Ocrl kidneys per group, each point representing the number of LAMP1+ structure in a cell ). (C) Ocrl mPTCs were 
loaded with DQ (dequenched) Red BSA (red, 10 μg ml−1 for 1h at 37 °C), immunostained with anti- LAMP1 (green, lysosomes) fixed and analyzed by confocal microscopy. Quantification of number of DQ Red 
BSA /LAMP1+ structures (in percentage of total LAMP1+ structures, n = 8 randomly selected fields per condition, with each containing  10–15 cells). Insets: high magnification of DQ Red BSA / LAMP1+ 
vesicles. (D) Ocrl mPTCs were serum starved for 24 h and then stimulated with EGF (100 ng/ml) for the indicated times. EGFR protein levels were evaluated by western blotting and quantified relative to time 0 
(starved cells). (n=3mice per group; two-tailed unpaired Student’s t-test, *P < 0.05, **P < 0.01 relative to OcrlY/+ or OcrlY/- starved mPTCs. ns: not significant). (E) Western blotting and densitometry analyses of 
Cathepsin D (Cts-D) protein levels in Ocrl mPTCs (n= 4mice per group). (F) Ocrl mPTCs were loaded with Bodipy-FL-PepA (1 μM, for 1 h at 37 °C, green), immunostained with anti- LAMP1 antibody (red) and 
analysed by confocal microscopy. Quantification of numbers of PepA/LAMP1+ structures (in percentage of total LAMP1+ structures; n = 4 randomly selected fields per condition, with each containing ~ 20–25 
cells). (G) Representative confocal micrographs showing Cy5 labeled β-lactoglobulin (red) after 120 minutes from tail vein injections and quantifications of the corresponding fluorescent signal in LTL+ proximal 
tubules from Ocrl mouse kidneys (n=50 Ocrl proximal tubules; each dot representing fluorescence intensity in one proximal tubule; fluorescence intensity was normalized on tubule area). Nuclei counterstained 
with DAPI (blue) in A, B, C, F and G. Scale bars in A, B and C 15 μm; in F 10 μm and in G 50 μm. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test.  **P < 0.01, ***P < 0.001 relative to 






Figure 6. Impaired locomotor activity and muscular defects in OcrlY/- mice. (A-C) Open field large arena test was performed during 10 minutes of two subsequent days in a circular arena with a diameter of 
150 cm on a cohort of 16 OcrlY/+and 16 OcrlY/- age matched male mice. (A) Illustrative pictures representing the trajectories traveled by Ocrl mice during the open field large arena test. (B) Dot plot representing 
the distance covered by Ocrl mice during the large open field arena test. The distance traveled by each mouse is normalized to 1 minute observation time and plotted as function of time for each bin (bin=5 minutes) 
(split ANOVA effects followed by post-hoc tests between genotype for each bin: Bin1 ’P < 0.1, Bin2 *P < 0.05, Bin3 *P < 0.05). (C) Dotted bar graph representing the frequency of resting, lingering and walking 
episodes exhibited by Ocrl mice during the open field large arena test (split ANOVA effects followed by post-hoc tests between genotype for each state: rest *P < 0.05, linger, *P < 0.05, walk *P < 0.05). (D) 
IntelliCage experiments were performed on a cohort of age matched male Ocrl mice (13 OcrlY/+and 13 OcrlY/-). Dot plot representing the median licking frequency during drinking restriction protocol. Base 
indicates the licking frequency during the last 24h of nose poke adaptation phase (split ANOVA effects followed by post-hoc tests between genotype for each time point: Day1 **P < 0.01, Day 2-2last *P < 0.05, 
Last day **P < 0.001). (E) Lean mass/body weight ratio determined by whole body composition analysis in Ocrl mice (n=6 mice per group). (F) Muscle mass, relative to body weight, of selected hind limb muscles 
obtained by bilateral dissection of 5 pairs of Ocrl mice (n=10 values for symmetrical leg muscles). (G) Plasma creatine kinase activity (CK) in the corresponding 5 pairs of Ocrl mice (as in B). Plotted data represent 







Table 1. Body weight, urine and blood parameters in Ocrl and Clcn5 mice. 
       
 
U, Urine; CC16, Clara cell protein 16; BUN, Blood urea nitrogen. All the measurements were performed on OcrlY/+ and OcrlY/- male mice matched per age. 
Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test was applied between genotypes for the indicated time point. 
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MATERIALS AND METHODS 
Cell profiler quantifications. The pipeline “Speckle counting” derived from the open source Cell Profiler image 
analysis software was used to identify dots (PI(4,5)P2 or PI3P or BSA or Dextran or LAMP1 or MPR-positive 
structures) surrounding nuclei and to perform per-nuclei aggregate measurements (eg. the number of 
dots/nucleus), as described by Carpenter et al. (2006) and De Leo et al. (2016). Briefly, the images were converted 
to greyscale using the module “ColorToGray”. The “IdentifyPrimaryObjects” module was used to identify nuclei 
and dots while cells were identified by using the module “IdentifySecondaryObjects”. “MaskObject” and 
“RelateObject” modules were used to establish a parent-child relationship between the cells and the dots, identified 
as masked objects, and to calculate the average of dots per cell. The module “MeasureObjectIntensityDistribution” 
was used to score the fluorescence intensity of MPR and TfR positive structures contained into perinuclear region 
(area defined by the first 10 bin) and peripheral region (area defined by the last 10 bin) of the cells. Briefly, the 
software generates 20 concentrically bin around the nucleus of each cell and calculates the intensity distribution 
for each bin. The module “MeasureObjectSizeShape” was used to score the vesicle size of LAMP1. The pipeline 
“Cell/particle counting, and scoring the percentage of stained objects” was used to score the percentage of EEA1+ 
structures colocalizing with PI(4,5)P2 or F-actin, the percentage of LRP2+ structures colocalizing with F-actin, 
EEA1 or TfR and the percentage of LAMP1+ structures colocalizing with PI(4,5)P2, DQ-BSA or PepA. Briefly, 
the images were converted to greyscale using the module “ColorToGray”. Then the “ObjectIdentification” module 
was used to identify the nuclei and the aforementioned stained structures/vesicles. The “RelateObject” module 
was used to establish a parent-child relationship between the stained objects. In this case, a “parent” object is one 
that touches, overlaps or encloses a “child” object. Objects1 that touch or overlap with an Object2 are considered 
to be colocalized and will be assigned as a parent to a corresponding child. The “ClassifyObjects” and 
“FilterObjects” modules were used to categorize structures that were either colocalizing or not-colocalizing, and 
to calculate the percentage of colocalizing structures on the total amount per image. Fluorescence intensity of 
LRP2 was measured from a Z stack of 55 serial images acquired, according to Nyquist theorem, every 0.13 µm to 
maximize the spatial information. The average fluorescence intensity of LRP2 was calculated every 0.5 µm of the 
Z-stacks projection by using ImageJ software. Qualitative analysis of F-actin dynamics was performed by maximal 
projection of Z-stack images acquired throughout the entire volume of the cells. 
 
Behavioral tests. Open field large arena test. The large open-field arena is circular with a diameter of 150 cm, a 
slightly roughened white plastic floor, and 35cm high smooth sidewalls made of white polypropylene. Illumination 
is performed by indirect diffuse room light (4 40W bulbs, 12 lux). Each subject is released near the wall and 
observed for 10 min on two subsequent days. Movements are tracked using Noldus EthoVision. Between subjects, 
the arena is thoroughly cleaned with water and dried. Water-maze cue navigation. The water maze is constituted 
by a round white poly-propylene pool with a diameter of 150 cm with 68 cm high walls. It is filled with water (24-
26° C, depth 15 cm) which is rendered opaque by addition of 1l of milk (UHT whole milk 3.5% fat, Coop, 
Switzerland). The white quadratic goal platform (14x14 cm) is made of metallic wire mesh and painted white. It 
is hidden 0.5 cm below the water surface in the center of one of the 4 quadrants, approximately 30 cm from the 
side wall. Salient extra-maze cues made of black cardboard are placed on the walls of the testing room. Computer 
and experimenter are hidden behind a curtain. Illumination is performed by indirect diffuse room light (4 40W 
bulbs, 12 lux at the center of the pool). During the test animals are trained for 2 days with the goal platform marked 
by a salient cue and placed in a different quadrant for every trial. All subjects are trained on the same sequence of 
goal positions and released from the same start points. Three-chambers sociability test. The 3-chamber cage is a 
polycarbonate type III cage (20.5 cm high, 58 × 40 cm top, 55 × 37.5 cm bottom, Techniplast, 2000P, Buguggiate, 
Italy). Two dividers provided with gates regulate the access of the test mouse from the middle to the lateral 
chambers. One unfamiliar stimulus mouse is placed inside a metallic cylinder in one of the two lateral chambers. 
The cylinder allows visual and olfactory contact between the test mouse and the stimulus mouse, reducing the 
possibility of physical contact. In the other lateral empty chamber, an empty cylinder is placed giving then the test 




(social stimulus) and the chamber containing only the empty cylinder. This test runs for 10 minutes after which 
the stimulus mouse is considered to be familiar to the test mouse. The time spent by the test mouse in the lateral 
chambers is noted. 
IntelliCage apparatus and mice preparation. The IntelliCage apparatus (TSE Systems, Bad Homburg, 
Germany) is placed in a polycarbonate cage (20.5 cm high, 58 × 40 cm top, 55 × 37.5 cm bottom, Techniplast, 
2000P, Buguggiate, Italy) and accommodates up to 16 mice. Its aluminum top contains a freely accessible food 
rack filled with standard mouse chow (Standard 3430, Kliba Nafag, Kaiseraugst, Switzerland). The floor is 
covered with woodchip bedding and provides 4 central red shelters (Techniplast, Buguggiate, Italy). Four 
triangular conditioning chambers (15×15×21 cm) are fitted in the cage corners and provide room for one mouse 
at a time. Each chamber contains two drinking bottles, accessible via two round openings that can be opened and 
closed with motorized doors. Mice were tagged with RFID-transponders, subcutaneously implanted under 
isoflurane anesthesia, which can be read by a circular RIFD antenna located at the entrance of each chamber. The 
duration of their visit is determined by both the antenna reading and a temperature sensor that detects the presence 
of the animal inside the corner. During a visit, number and duration of individual nosepokes at each door are 
recorded using IR-beam sensors. Licking episodes at each bottle are monitored using lickometers (duration of the 
episode, number of licks, total contact time). IntelliCages have individual controllers and are connected to a central 
PC running the software that permits to design and control experiments remotely, as well as to analyze the recorded 
data (IntelliCage Plus, TSE Systems, Bad Homburg, Germany). After RIFD implantation, mice are allowed to 
recover for one week in groups of 8-16 mice in standard Type III cages with water and food ad libitum. The same 
grouping is maintained when the mice are later transferred to IntelliCages. During all adaptation phases and tasks 
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Supplementary Figure 1 
 
 
Supplementary Figure 1. Genotype confirmation and analyses of the kidney phenotype in OcrlY/- mice harboring different levels of human BAC-INPP5B expression. (A) Ocrl, Inpp5b and BAC-INPP5B 
genomic DNA analyses by PCR and agarose gel electrophoresis isolated from kidney biopsies derived from Ocrl mice. (B) Western blotting of OCRL protein level in whole kidney lysates from Ocrl mice. GAPDH 
was blotted as loading control. (C) BAC-INPP5B mRNA expression in kidneys derived from Ocrl mice was analyzed by quantitative RT-PCR. Gene target expression was normalized on 6 housekeeping genes 
and expressed as relative to OcrlY/+ BACI-INPP5B (n=5 mice per condition). (D) Dot plot representing the measurement of the body weight, (E) Clara cell secretory protein (CC16) and (F) albumin urinary excretion 
in Ocrl mice harboring different level of BAC-INPP5B expression as shown in C. Each dot represents one mouse (n=6 mice per group). All the analyses in D, E and F were performed on mice matched for age (24 
weeks) and gender (male). All the urine parameters were normalized to urinary creatinine concentration. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test, **P < 0.01 relative to OcrlY/+ or 




Supplementary Figure 2 
 
Supplementary Figure 2. Proximal tubule dysfunction in Clcn5Y/ - mice. (A) Western blotting and densitometry analysis of LRP2, NaPi-IIa and SGLT2 protein levels in whole kidney lysates from Clcn5 mice. 
β-actin was used as loading control. (n= 3 mice per group). (B) Representative confocal micrographs showing Alexa 647–labeled dextran uptake (red, 6 mg/kg B.W.) in LTL+ (Lotus Tetragonolobus Lectin, green) 
proximal tubules of Clcn5 mouse model after 30 minutes from tail vein injections. Nuclei counterstained with DAPI (blue). Scale bar 25μm. (C) Dot plot representing the measurement of glucose and (D) phosphate 
urinary excretion in 8 weeks old Clcn5 mice. Each dot represents one mouse (n=4 mice per group). All the urine parameters were normalized to urinary creatinine concentration. Plotted data represent mean ± 






Supplementary Figure 3 
 
 
Supplementary Figure 3. OcrlY/- mPTCs exhibit no changes in PI3P (Phosphatidylinositol 3 phosphate) levels and no transcriptional alterations of proximal tubule receptors and channels. (A) 
Representative confocal micrographs and quantification of the number of PI3P+ structures stained by 2XFYVE-mcherry domain (red) in Ocrl mPTCs (n  200-250 cells pooled from three Ocrl kidneys per group; 
each point representing the number of PI3P+ vesicles in a cell). Nuclei counterstained with DAPI (blue). Scale bar 15μm. (B) The mRNA mPTCs levels of Lrp2, Sglt2, Slc34a1 and Aqp1 were analyzed by real-
















Supplementary Figure 4 
 
Supplementary Figure 4. LRP2 dynamics in Dent disease. (A) Western blot and densitometry analysis of LRP2 in whole Clcn5 mPTCs lysates. β-actin was used as loading control (n= 4 mice per group). (B) 
Representative confocal micrographs and X–Z side view of Ocrl mPTCs immunostained with anti-LRP2 (red). (C) Representative confocal micrographs of X–Z side view of a z-stack performed on Ocrl mPTCs 
immunostained with WGA (green) and Na,K-ATPase (cyan) in the upper panels, WGA (green) and LRP2 (red) in the middle panels and Na,K-ATPase (cyan) and LRP2 (red) in the lower panels. (D) Maximum 
intensity projection of a confocal Z-stacks series representing Ocrl mPTCs immunostained with Alexa-Fluor-488-phalloidin (green, F-actin). (E) Representative confocal micrographs of Ocrl mPTCs 
immunostained with anti-EEA1 (red, early endosomes) and Alexa-Fluor-488-phalloidin (green, F-actin). Quantification of F-actin/EEA1+ structures (in percentage of total EEA1+ vesicles, n=5 OcrlY/+; n=4 OcrlY/- 
randomly selected fields per condition, each containing   10-15 cells). Insets: high magnification of F-actin/EEA1+ structures. (F) High magnification confocal micrographs of Ocrl mPTCs immunostained with 
anti-LRP2 (red) and Alexa-Fluor-488-phalloidin (green, F-actin). Nuclei counterstained with DAPI (blue) in B-F. Scale bars in C 10μm, in B, D, E and F 15μm. Plotted data represent mean ± SEM. Two-tailed 




Supplementary Figure 5 
 
 
Supplementary Figure 5. Impaired trafficking of MPR and TfR cellular receptors in OcrlY/- mPTCs. (A) Representative confocal micrographs and quantification of TfR+ structures distribution (green) in 
Ocrl mPTCs (in percentage of the total TfR+ vesicles, n=4 OcrlY/+; n=6 OcrlY/- randomly selected fields per condition, each containing  20 cells). Two-tailed unpaired Student’s t-test, ***P < 0.001 relative to 
OcrlY/+ mPTCs. (B) Representative confocal micrographs and quantification of distribution of MPR+ structures (green) in Ocrl mPTCs (perinuclear vs peripheral in percentage of the total MPR+ vesicles, n=3 
randomly selected fields per condition, each containing  40-50 cells). Two-tailed unpaired Student’s t-test, Peripheral/perinuclear MPR+ vesicles ***P < 0.001 relative to OcrlY/+ mPTCs. (C) Representative 
confocal micrographs showing MPR+ structures (red) in LTL+ (Lotus Tetragonolobus Lectin, green) proximal tubules of Ocrl mouse kidneys. Plotted data represent mean ± SEM. Nuclei counterstained with DAPI 












Supplementary Figure 6 
 
 
Supplementary Figure 6. Altered lysosomal activity in Dent disease. (A-B)Western blotting and densitometry analysis of Cathepsin D (Cts-D) protein levels in (A) plasma samples from Ocrl mice (n= 4 OcrlY/+ 
and  n= 5 OcrlY/- mice) and in (B) Clcn5 mPTCs (n= 3 mice per group). β-actin was used as loading control. Plotted data represent mean ± SEM. Two-tailed unpaired Student’s t-test, *P < 0.05 relative to OcrlY/+ 
plasma or Clcn5Y/+ mPTCs. (C) Confocal micrographs showing Clcn5 mPTCs immunostained with Bodipy-FL-PepA (1 μM, for 1 h at 37 °C, green). (D) Representative confocal micrographs showing Cy5 labeled 
β-lactoglobulin (red, 1mg/kg B.W.) after 120 minutes from tail vein injections in LTL+ proximal tubules from Clcn5 mouse kidneys. Nuclei counterstained with DAPI (blue) in C and D. Scale bars 15μm in C and 




Supplementary Figure 7 
 
Supplementary Figure 7. No impairment of social behavior neither defective ocular morphology is observed in OcrlY/- mice. (A) Dot plot representing the measurement of water intake, over 12 hours, in 24 
weeks old Ocrl male mice. Each dot represents one mouse. (B) Dotted bar graph representing the number of nose contact time with the social (cage with mouse) and object (empty cage) stimulus during the 3 
chambers sociability test. Plotted data represent mean ± SEM. Each dot of the graphs represents one mouse. (C)  Schematic representation of the water maze cue navigation test (left panel): animals are trained in 
the water maze to reach a platform marked by a salient cue and placed in a different quadrant for every trial. Dot plot (righ t panel) representing the swim path as function of 3 trial blocks. Each dot of the graphs 
represents one mouse. (D) Light microscopy representative pictures of high magnification hematoxylin-eosin stained lens (left panels, scale bars 50μm) and midsagittal sections of whole eyes (right panels, scale 
bars 500μm) derived from Ocrl mice. LC (lens capsule), LE (lens epithelium), DFL (differentiating lens fiber), MFL (mature lens fiber), L (lens) and R (retina). (E) Toluidine blue stained retina derived from Ocrl 
mice in presence or absence of the spontaneous rd8 (retinal degeneration 8) mutation in Crb1 gene (right panel, rd8/rd8). RPE (retinal pigment epithelium), PS (photoreceptor segments), OLM (outer limiting 
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Loss-of-function mutations in the OCRL gene, which encodes the phosphatidylinositol [PI] 4,5-
bisphosphate [PI(4,5)P2] 5-phosphatase OCRL, cause defective endocytosis and proximal 
tubule dysfunction in Lowe syndrome and Dent disease 2. The defect is due to increased levels 
of PI(4,5)P2 and aberrant actin polymerization, blocking endosomal trafficking. PI 3-phosphate 
[PI(3)P] has been recently identified as a coactivator with PI(4,5)P2 in the actin pathway. Here, 
we tested the hypothesis that phosphoinositide 3-kinase (PI3K) inhibitors may rescue the 
endocytic defect imparted by OCRL loss, by rebalancing phosphoinositide signals to the actin 
machinery. The broad-range PI3K inhibitor copanlisib and class IA p110α PI3K inhibitor 
alpelisib reduced aberrant actin polymerization in OCRL-deficient human kidney cells in vitro. 
Levels of PI 3,4,5-trisphosphate, PI(4,5)P2 and PI(3)P were all reduced with alpelisib treatment, 
and siRNA knockdown of the PI3K catalytic subunit p110α phenocopied the actin phenotype. 
In a humanized OcrlY/- mouse model, alpelisib reduced endosomal actin staining while restoring 
stress fiber architecture and levels of megalin at the plasma membrane of proximal tubule cells, 
reflected by improved endocytic uptake of low molecular weight proteins in vivo. Thus, our 
findings support the link between phosphoinositide lipids, actin polymerization and endocytic 
trafficking in the proximal tubule and represent a proof-of-concept for repurposing alpelisib in 




Epithelial cells lining the proximal tubules (PTs) of the kidney possess an efficient receptor-
mediated endolysosomal pathway that recovers and processes essential substances that are 
filtered through the glomerulus. Congenital disorders affecting endolysosomes cause PT 
dysfunction (renal Fanconi syndrome) with urinary loss of solutes and low-molecular-weight 
(LMW) proteins, often complicated by metabolic and growth complications and development 
of chronic kidney disease (1). Inactivating mutations in OCRL have been associated with Dent 
disease 2 (MIM #300555), a disorder characterized by PT dysfunction, kidney stones, and 
progressive kidney failure, and with the oculocerebrorenal syndrome of Lowe (MIM #309000), 
which displays, in addition to the PT dysfunction and kidney failure, systemic manifestations 
such as congenital cataracts, cognitive disability, and hypotonia (2-4).Current treatments for 
Dent disease 2 and Lowe syndrome are only supportive.  
LMW proteinuria is a consistent feature observed in Lowe syndrome/Dent disease 2, 
revealing that OCRL affects receptor-mediated endocytosis (5). OCRL encodes the 
phosphatidylinositol (PI) 4,5-bisphosphate [PI(4,5)P2] 5-phosphatase OCRL (6), which 
controls lipid identity in the endolysosomal pathway by degrading PI(4,5)P2 (Figure 1a). 
Deficient degradation of PI(4,5)P2 through OCRL is implicated in the failure to uncoat clathrin-
coated vesicles in fibroblasts, accompanied by the formation of “comet” structures of 
polymerized, filamentous actin from the resulting aberrant early endosome-like organelles (7-
9). In other cell types, most notably the PT cells of the kidney, OCRL deficiency results in F-
actin “basket” structures surrounding aberrant endolysosomal organelles (10). The excess F-
actin blocks membrane trafficking through the endocytic and endolysosomal pathway, and is 
suggested to decrease recycling of the multiligand receptor megalin to the apical membrane, 
aggravating the defect within the endolysosomal pathway (11). In agreement with a prime role 
of aberrant F-actin, defective endocytic uptake caused by OCRL mutations is alleviated by 
targeting the actin machinery with latrunculin B, or by depleting actin regulatory proteins as 
well as by small, interfering RNA (siRNA)-mediated depletion of PI(4)P 5-kinase to adjust the 
synthesis of PI(4,5)P2 (7,10) (Figure 1a). 
Actin polymerization is increasingly understood as arising not only from PI(4,5)P2 but also 
from other phosphoinositide lipids. For example, PI(3,4,5)P3 activates Rho-type GTPase Rac 
and PI(3)P acts in conjunction with PI(4,5)P2 to stimulate actin polymerization downstream of 
another Rho-type GTPase, Cdc42 (12-14). The interconversion of these phosphoinositides is 
coupled to the movement of lipids through the endocytic and endosomal pathway. PI(4,5)P2 is 
phosphorylated by class I phosphatidylinositol-3′-kinase (PI3K) to PI(3,4,5)P3 at the plasma 
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membrane and becomes progressively dephosphorylated to PI(3,4)P2 and PI(3)P or PI(4,5)P2 
(14,15). PI(3)P is enriched at endosomes, where it is essential for their function and 
predominantly made by direct by phosphorylation of PI by class III PI3K, Vps34 (16) 
(Figure 1a). In an OCRL-deficient retinal pigmented epithelial (RPE) cell line, actin comets 
generated are reduced by treatment with PI3K inhibitors wortmannin and Vps34-IN1, in 
agreement with biochemical studies showing a coregulation of actin via the coincidence of both 
PI(3)P and PI(4,5)P2 (14).  
The rescue of endocytosis observed when targeting the actin machinery in OCRL patient 
and knockout (KO) cells (7,10),together with upstream regulation of actin by PI3K activity (14) 
and the highly interconnected nature of PI conversion, provides an intriguing possibility that 
class I PI3K inhibitors may be of utility in Lowe syndrome. Such inhibitors, developed for 
cancer therapy, are approved for clinical use (17) and are thus potentially amenable for drug 
repurposing. Although compounds such as copanlisib (18) have a broad specificity and side 
effects, recent success has been demonstrated for more specific inhibitors. Idelalisib (19), which 
targets PI3K subunit p110δ, is approved for chronic lymphocytic lymphoma, and alpelisib, 
which targets p110α, is approved for use in breast cancer (20,21). Moreover, alpelisib has 
shown clinical benefit in children with PROS/CLOVES syndrome (22), a rare overgrowth 
syndrome resulting from activation of PIK3A. 
Here, we tested the hypothesis that class I PI3K inhibitors may rescue the endocytic 
defect due to the loss of OCRL, using established cellular and mouse models (10,11,23). 
We show that the inhibition of PI3K activity via copanlisib or alpelisib, or siRNA-mediated 
depletion of the alpelisib-target catalytic subunit p110α reduces the excess actin polymerization 
in human kidney (HK2) cells deficient in OCRL. Focusing on alpelisib as the most specific 
compound for clinical use, we show that it reduces actin polymerization and improves uptake 
through the endolysosomal pathway in PT cells from humanized OcrlY/− mice in vitro. 
Furthermore, alpelisib treatment in vivo alleviates proteinuria, reduces PT dysfunction, and 
rescues the cellular levels of megalin in humanized OcrlY/− mice. These results support alpelisib 




Class I PI3K inhibitors reduce actin aggregation in OCRL-KO HK2 cells 
We used CRISPR-Cas9 gene editing to knockout (KO) OCRL in the HK2 cell line to allow 
testing of class I PI3K inhibitors on the characteristic actin aggregation at endolysosomal 
compartments (7,810,14). Western blotting verified a 98.0 ± 0.7% reduction in OCRL 
expression in lysates from the KO HK2 cells (Figure 1b). The OCRL KO recapitulated the actin 
basket phenotype in the HK2 cells, as indicated by an increased overlap between F-actin and 
early endosome antigen 1 (EEA1), quantified on Airyscan confocal microscopy z-stacks 
(Figure 1c–e). This increased overlap observed in OCRL KO cells was reversed by treatment 
with copanlisib (C), a broad-range PI3K inhibitor that targets p110α and δ and to a lesser extent 
the p110β and γ isoforms (Figure 1c). By western blotting of HK2 whole cell extracts, we found 
that the PI3K p110 regulatory subunits α, β, and δ were all well expressed in both wild-type 
(WT) and KO cells, with only trace levels of the p110γ isoform present (Supplementary 
Figure S1A). 
We distinguished the PI3K specificity of the inhibition of F-actin using alpelisib (A), a 
selective inhibitor of p110α, and GSK2636771 (G) and idelalisib (I), selective inhibitors of 
p110β and p110δ, respectively (Supplementary Figure S1A). Although alpelisib treatment gave 
a similar reduction in endosomal actin polymerization compared with copanlisib (Figure 1d), 
GSK2636771 and idelalisib had a little effect on actin accumulation (Figure 1e). The class I 
PI3K inhibitors had no increased toxicity on OCRL KO relative to unmodified cells, based on 
the MTT assay (Supplementary Figure S1B). 
 
Alpelisib and p110α knockdown rescue the actin phenotype in HK2 cells 
For our ensuing studies, we focused on alpelisib as it is the most selective and least toxic PI3K 
inhibitor developed so far, and is currently used to treat a mosaic overactivation of PI3K class 
Iα in children with PROS/CLOVES syndrome (22). Alpelisib reduced the actin baskets in 
OCRL KO HK2 cells in a dose-responsive fashion (Figure 2a). The effects were observed at 10 
μM dosage as soon as 4 hours after treatment, without apparent toxicity (Supplementary 
Figure S2). To test whether PI3K inhibition by alpelisib was the source of the decreased actin 
staining, we specifically reduced its target, the p110α subunit, using siRNA (Figure 2b). 
Compared with treatment with a control (sequence-scrambled) siRNA, siRNA against p110α 
yielded a 78.3 ± 4.8% and 68.9 ± 7.7% depletion of p110α protein in WT and OCRL KO HK2 




Reduced levels of PI(3,4,5)P3, PI(4,5)P2, and PI(3)P in alpelisib-treated HK2 cells 
To examine how phosphoinositide lipids are affected by OCRL KO and alpelisib treatment, we 
stained HK2 cells with antibodies or protein domains against PI(3,4,5)P3, PI(3)P, and PI(4,5)P2, 
using optimized fixation conditions for the plasma membrane or intracellular staining (24,25). 
PI(3,4,5)P3 has a diffuse localization to the plasma membrane, and alpelisib treatment (10 μM) 
induced a robust decrease in staining for PI(3,4,5)P3 in both WT and OCRL KO cells, as 
expected from its mechanism of action and specificity for class IA PI3K p110α (Figure 3a). 
PI(3,4,5)P3 is expected to be dephosphorylated progressively as membranes are endocytosed 
and trafficked into endosomes (14,26,27). By fixing cells such that intracellular PI(3)P is 
preserved (25), we found that PI(3)P punctae were also reduced by alpelisib treatment (in a 
dose-responsive fashion apparent from concentrations as low as 10 μM for the 16-hour 
treatment) in both WT and OCRL KO cells (Figure 3b and Supplementary Figure S2C). As 
expected, the KO of OCRL in HK2 cells induced a marked increase in the levels of PI(4,5)P2 
both at the plasma membrane (Figure 3c) and intracellularly (Figure 3d), compared with WT 
cells (10,28). Treatment with alpelisib markedly reduced the elevation of PI(4,5)P2 generated 
by OCRL KO in both compartments, whereas it had no effect in WT cells (Figure 3c and d). 
Alpelisib is reported to inhibit PI 4-kinase β with a 50% inhibitory concentration of 0.5 μM 
(19), which is a possible source of the reduction in PI(4,5)P2. Collectively, our data suggested 
that alpelisib inhibits actin assembly on OCRL KO endosomes via a bispecific effect on the 
PI(4,5)P2 and PI(3)P levels. 
 
Alpelisib reduces intracellular phosphoinositides and alleviates cytoskeletal defects in 
OcrlY/− mPTCs 
We next tested whether alpelisib had the same effects in primary cells of PT cells derived from 
the humanized Ocrl-deficient mouse model (OcrlY/−), which recapitulates the abnormal actin 
polymerization and endocytic defect observed in patient-derived cells (10,11). The mouse PTCs 
(mPTCs) expressed similar class I PI3K regulatory subunits to HK2 cells in both WT and 
OcrlY/− mice, and displayed a similar toxicity profile toward alpelisib when assessed by MTT 
assays (Supplementary Figure S3). Imaging by confocal microscopy revealed a striking 
disruption of the normal F-actin stress fiber architecture in mPTCs from OcrlY/− compared with 
OcrlY/+ mice, likely due to the relocation of actin regulatory proteins from their normal cellular 
locations to endosomes, as large assemblies of actin surround these organelles and are thought 
to be the origin of the trafficking defect (10,29). Treatment of OcrlY/− mPTCs with alpelisib (10 
μM) restored the stress fiber architecture (Figure 4a). 
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As the main problem in Lowe syndrome and Dent disease 2 is reduced endosomal 
trafficking and consequent megalin degradation, we sought to distinguish endosomal actin from 
the stress fibers. We collected laser-scanning confocal z-stacks throughout the cells, 
reconstructed the staining pattern in 3D surface renderings, and used size shape/parameters to 
identify punctate actin structures and the degree to which they overlapped with endosomal 
structures (Supplementary Figure S4 and Movies S1–S3). This analysis revealed that treatment 
with alpelisib decreased aberrant polymerization of F-actin at endosomes stained with EEA1, 
distinct from the stress fiber architecture (Figure 4b). The mPTCs derived from OcrlY/− mice 
showed significant changes in intracellular staining for PI(3)P (decreased) and PI(4,5)P2 
(increased), compared with mPTCs from WT OcrlY/+ mice (Figure 4c and d). Treatment of 
mPTCs from OcrlY/− mice with alpelisib resulted in a significant reduction in intracellular 
PI(3)P and PI(4,5)P2 staining (Figure 4c and d). 
 
Alpelisib improves endocytic uptake in OcrlY/− mPTCs 
We next assessed whether the effect of alpelisib on the cytoskeletal and vesicular defects 
observed in mPTCs resulted in changes in the endocytic uptake capacity. To differentiate the 
effect of alpelisib on binding and/or internalization of the ligand, mPTCs were first incubated 
with labeled bovine serum albumin (BSA), to induce binding of the probe with the endocytic 
receptors, and then incubated with growth medium, to follow the internalization of albumin 
(Figure 5a). The OcrlY/− cells showed a lower plasma membrane binding of Alexa 488-bovine 
serum albumin along with impaired internalization of albumin compared with OcrlY/+ cells. 
Treatment with alpelisib rescued both the binding and the uptake of albumin in the OcrlY/− cells, 
with a 50% overall rescue of endocytic uptake (Figure 5b and c). These data were supported by 
the measurement of total albumin uptake (Supplementary Figure S5a and b). We noted that the 
internalized/bound Alexa 488-bovine serum albumin ratio remained similar between the 
different conditions (Figure 5d), implying that the reduced uptake of albumin is mainly due to 
impaired binding rather than a defective internalization process per se. 
 
Alpelisib improves PT dysfunction and receptor-mediated endocytosis in OcrlY/− mice 
We tested the potential therapeutic effect of alpelisib on PT dysfunction in vivo. Ocrl mice were 
administered with either vehicle or alpelisib (50 mg/kg body weight per day) by oral gavage for 
6 weeks (Figure 6a). This regimen was chosen according to previous in vivo studies 
demonstrating efficacy and safety (22,30). In line with alpelisib administration being known to 
cause insulin resistance and hyperglycemia (22), alpelisib treatment led to a significant increase 
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in glycosuria in both OcrlY/+ and OcrlY/− mice, which could be considered as a biomarker for 
drug dosing (Supplementary Table S1). After 6 weeks of alpelisib treatment, the OcrlY/− mice 
displayed a significant reduction in the urinary excretion of the LMW proteins CC16 (−34%) 
and albumin (−38%), compared with vehicle-treated controls (Figure 6b and c), whereas 
volume of urine and other parameters were unaffected (Supplementary Table S1). Alpelisib-
treated mice of both genotypes showed a similar reduction in growth rate relative to control 
mice, as previously described (22). Nevertheless, both vehicle and treated mice gained body 
weight, indicating that the drug does not severely affect postnatal development (Figure 6d and 
Supplementary Table S1). 
To test whether the effect of alpelisib on LMW proteinuria reflected recovery of 
receptor-mediated endocytosis in PT cells, we followed the in vivo uptake of Cy5-labeled β-
lactoglobulin in a mouse kidney. Alpelisib-treated OcrlY/− mice displayed a significant rescue 
of Cy5-labeled β-lactoglobulin uptake, close to the extent of internalization observed in vehicle-
treated OcrlY/+ mice (Figure 6e). This was mirrored by a significant rescue in expression of the 
endocytic receptor megalin in PT cells, as observed by immunolabeling and western blotting of 
the kidney lysates of alpelisib-treated OcrlY/− mice; note that there was no change in expression 
of the PT marker AQP1 (Figure 6f and g and Supplementary Figure S5C and D). These data 
show that the PI3K inhibitor alpelisib induces a substantial improvement of the PT endocytic 




There is currently no treatment to alleviate the defective endocytosis causing PT dysfunction in 
Lowe syndrome and Dent disease 2. Our findings reveal that alpelisib alleviates the aberrant 
actin phenotype by reducing levels of PI(4,5)P2 and PI(3)P, causing a substantial improvement 
of the endocytic machinery and absorptive capacity in cellular systems and a humanized mouse 
model for Lowe syndrome/Dent disease 2. These results support the link between 
phosphoinositide lipids, actin polymerization, and endocytic trafficking, with immediate 
relevance for highly active epithelial cells involved in crucial homeostatic processes (Figure 7). 
Given the lack of effective therapies and the apparent safety of this class of PI3K inhibitors, 
alpelisib is a promising candidate for drug repurposing in Lowe syndrome and Dent disease. 
LMW proteinuria is the most consistent feature encountered in patients with Lowe syndrome 
and Dent disease 2 due to inactivating mutations in OCRL (4). These LMW proteins can readily 
be detected and quantified, offering a faithful biomarker of defective receptor-mediated 
endocytosis in PT cells (1). LMW proteinuria is particularly relevant, as it is detected more 
consistently and often earlier than other solutes (e.g., glucose, phosphate, amino acids) being 
part of the classical “renal Fanconi syndrome”—at least in congenital disorders of the 
endolysosomal pathway (1). 
Here, we show that alpelisib rescues the apical endocytic uptake capacity of PT cells 
in vitro and in vivo, due to restored levels of megalin receptor at the plasma membrane. This 
effect is reflected by significant reductions in the urinary loss of LMW proteins (CC16 and 
albumin) in OcrlY/− mice treated with alpelisib for 6 weeks. These effects of alpelisib have been 
observed in mPTCs, which keep their apical differentiation and are particularly well suited to 
investigate receptor-mediated endocytosis in physiology and disease (9). In particular, we 
obtained mPTCs from a humanized mouse model expressing human INPP5B in 
OcrlY/−;Inpp5b−/− background, which allows us to investigate the specific consequences of the 
loss of OCRL activity (11,23).  
The rescue of endocytosis by alpelisib is explained by its effect on actin machinery, clearly 
evidenced in OCRL KO HK2 cells and mPTCs. Our observations thus confirm and extend 
previous studies showing the link between control of the phosphoinositide balance and F-actin 
in the early endosomal pathway in OCRL patient and KO cells (7,10). The functional loss of 
OCRL activity impairs the degradation of PI(4,5)P2, which, in turn, leads to a failure to uncoat 
clathrin-coated vesicles resulting in aberrant endosomal organelles in various cell types 
including the PT cells (7-10). 
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We recently showed that the excess F-actin decreases the recycling of the multiligand receptor 
megalin to the apical membrane of PT cells, causing defective endocytosis and LMW 
proteinuria (11). 
Our data indicate that the mechanism of action of alpelisib on endosomal actin arises 
from a bispecific effect of alpelisib inhibition: first on production of PI(3,4,5)P3 and its 
conversion to PI(3)P, and second on production of PI(4,5)P2. The decrease in PI(4,5)P2 levels 
directly counteracts the OCRL deficiency and is in agreement with previous work alleviating 
excess actin and increasing endocytic flux by reduction in the levels of phosphatidylinositol 4-
phosphate 5-kinase, an enzyme that generates PI(4,5)P2 (10). 
Alpelisib has a 0.5 μM 50% inhibitory concentration on the PI(4,5)P2 generating kinase PI4Kβ, 
which may be responsible, or it could result from more general effects on phosphoinositide 
balance resulting from the combination of OCRL KO and alpelisib treatment. We have 
identified that class IA PI3K inhibition by alpelisib is relevant to actin inhibition as siRNA-
mediated depletion of p110α inhibits actin accumulation similarly to alpelisib treatment and 
copanlisib (which is not reported to inhibit PI4Ks). In RPE cells we have previously observed 
that siRNA of INPP4A, which converts PI(3,4)P2 to PI(3)P, inhibits actin assembly in OCRL 
KO cells, providing a pathway from inhibition of PI(3,4,5)P3 production to a decrease in 
endosomal PI(3)P. We showed that some PI(3)P remains, presumably the pool produced at the 
early endosome by class III PI3K, Vps34, because we found that endosomal trafficking is 
enhanced rather than suppressed by alpelisib treatment. The complex coregulation of PI 
metabolism and its relevance for OCRL inactivation has also been highlighted in a recent study 
where noncatalytic functions of phosphoinositide 3-phosphatase PTEN activates PI(4,5)P2 
degradation via PLCXD, alleviating cellular phenotypes and absorption of ligands in a zebrafish 
model (31).  
The alleviation of the actin phenotype by reduced levels of PI(4,5)P2 and PI(3)P by 
alpelisib treatment agrees with the synergistic action of PI(4,5)P2 and PI(3)P in recruiting SNX9 
to activate the actin machinery at Ocrl endosomes (14), suggesting a very effective match of 
alpelisib specificity to manipulate the molecular regulation of actin activation at endosomes. In 
turn, as previously demonstrated, reduced endosomal actin assembly in turn leads to an 
improvement in PT endocytosis in OCRL-deficient cells (10). Further characterization will be 
needed to better understand whether regulation of actin through phosphoinositide metabolism 
is the true source of the therapeutic effect that we observe with alpelisib in the OcrlY/− mouse 
model. Because class I PI3K regulate pathways control cell growth, proliferation, survival, 
metabolism, and autophagy (32), we cannot exclude that the endocytic rescue is due to effects 
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on PI(3,4,5)P3 directly and the combined effect on other pathways modulated by class I PI3K. 
More work is also needed to test whether PI3K inhibitors might also alleviate the neurologic 
and other clinical manifestations of patients harboring OCRL mutations (4). 
The recent experience of alpelisib in pediatric patients with PROS/CLOVES syndrome 
suggests that the drug has the potential to be well tolerated. Alpelisib is taken orally, selectively 
targets the α isoform of PI3K class I, and shows a minor toxicity profile compared with pan-
PI3K inhibitors. As alpelisib does not completely block PI3K activity, thus maintaining 
functions of the signaling pathway, it may be particularly suitable for long-term use. Of interest, 
the hyperglycemia arising from alpelisib use may be manageable by dietary changes (22). 
Because PT dysfunction is the first manifestation of kidney disease observed in young infants 
with Dent disease 2 and Lowe syndrome, an early treatment of such PT dysfunction, leading to 
improvements in the metabolic profile and growth, might therefore slow progression to chronic 
kidney disease and therefore have a significant impact on lifespan and quality of life (33). 
Although the disease manifestations of OCRL mutation are particularly wide, recent studies 
based on large cohorts of genotyped patients with Lowe syndrome of Dent disease 2 did not 
evidence significant effects of the type of mutation or the location of the mutation on renal 
survival (34). Collectively, our data highlight the potential for repurposing alpelisib for treating 
PT dysfunction in Lowe syndrome/Dent disease 2, thus providing a basis for rapid and cost-




Full details can be found in the Supplementary Methods. 
HK2 cells were treated with copanlisib, alpelisib, GSK2636771, or idelalisib at indicated concentrations for 16 
hours unless otherwise stated. Proteins were extracted using standard methods from cells or kidney tissues and 
western blotting performed using published or commercially available antibodies. siRNA knockdown was 
performed using 2 transfections 72 and 24 hours before analysis. We used age- and gender-matched 
OcrlY/+;Inpp5b−/−; and OcrlY/−;Inpp5b−/− mouse littermates harboring BAC-INPP5B expression. Primary cultures 
of mPTCs were generated from the kidneys harvested from 8 week-old Ocrl mice and the endocytic capacity of 
Ocrl mPTCs assessed by measuring albumin uptake. Alpelisib treatments were 10 μM for 16 hours, unless 
otherwise stated. Albumin uptake in mPTCs was assessed using a “pulse-chase” protocol to assess apical binding 
and resultant uptake. mPTCs were stained overnight with the appropriate primary antibody and for 45 minutes 
with suitable fluorophore-conjugated secondary antibodies and/or Alexa-488 Phalloidin. PI(3)P staining on 
mPTCs was performed using the FYVE domain probe. Image analysis was performed with CellProfiler, using 
custom pipelines to measure actin/EEA1 overlap and number of puncta, and with ImageJ to measure 
immunofluorescence intensity and detected edges to calculate stress fiber score. Quantitative data were expressed 
as means ± standard error of the mean. For the in vivo experiments, mice aged 6 weeks were treated with vehicle 
or alpelisib 50 mg/kg body weight. Urine was collected every 14 days and animals were sacrificed after 42 days 
of treatment, with blood and kidneys harvested. The PT endocytic capacity of Ocrl mice was examined by 
measuring β-lactoglobulin uptake. 
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Figure 1. PI3K inhibitors relieve aberrant actin assembly at endosomes in an OCRL-deficient human kidney (HK2) cell model. (a) Steps of phosphoinositide 
lipid conversion relevant for this study indicating the conversions between PI(4,5)P2, PI(3,4,5)P2, and PI(3)P with the most relevant enzymes in bold, most relevant 
conversions in solid lines, and others in dashed lines. PI(4,5)P2 is elevated in Lowe syndrome due to the lack of 5-phosphatase activity from OCRL and is made 
from the phosphorylation of PI by phosphatidylinositol 4-kinases (PI4Ks) and PI(4)P 5-kinase (PIP5K). PI(4,5)P2 is phosphorylated by class I PI3Ks to produce 
PI(3,4,5)P3. PI(3,4,5)P3 can be dephosphorylated to PI(4,5)P2 by PTEN or to PI(3,4)P2 by SH-2–containing inositol 50 polyphosphatase (SHIP) 1 and 2, 
synaptojanin 1 and 2, and also OCRL, although this is thought to be minor. PI(3,4)P2 is dephosphorylated to PI(3)P by inositol polyphosphate-4-phosphatase type 
I A (INPP4A) and B. PI(3)P is also made at endosomes via the phosphorylation of PI by class III PI3K, vacuolar sorting protein Vps34. (b) Western blots illustrating 
OCRL expression loss in the HK2 OCRL CRISPR knockout (KO) cell line compared with wild-type (WT) HK2 control cells with atubulin as loading control. (c–
e) Representative Airyscan confocal micrographs and quantification of early endosome antigen 1 (EEA1)/actin overlap (expressed  as a percentage of total detected 
EEA1þ vesicles) for HK2 WT or OCRL KO cells treated with either dimethylsulfoxide (DMSO) (d) or the indicated inhibitor and fixed using the 4% formaldehyde 
fix. In all cases, the images illustrate a single z-slice from an Airyscan-processed confocal stack of cells immunolabeled for EEA1 (yellow), phalloidin (actin, 
magenta), and 40,6-diamidino-2-phenylindole (DAPI) (cyan). Bars=5 mm. In the quantifications, the lines indicate the mean ± SEM and each data point is an 
individual cell. In all experiments, treatments were applied 16 hours before fixation. In all quantifications, statistical significance was assessed by a Kruskal-Wallis 
(KW) analysis of variance with Dunn’s multiple comparisons test. (c) WT or KO cells treated with either DMSO or 100 nM of copanlisib, demonstrating rescue 
of the actin-endosomal overlap. K-W test: ***P < 0.001, multiple comparisons; WT DMSO versus KO DMSO, KO DMSO versus KO copanlisib both ***P < 
0.001, WT copanlisib versus KO copanlisib P=0.44 (not significant [ns]). N=52, 85, 67, and 63 cells for WT DMSO, WT copanlisib, KO DMSO, and KO copanlisib, 
respectively. (d) WT or KO cells treated with either DMSO or 10 mM of alpelisib, demonstrating rescue of the actin-endosomal overlap. K-W test: ***P < 0.001, 
multiple comparisons; WT DMSO versus KO DMSO, KO DMSO versus KO alpelisib both ***P < 0.001, WT alpelisib versus KO alpelisib. P > 0.99 (ns). N=31, 
30, 43, and 41 cells for WT DMSO, WT alpelisib, KO DMSO, and KO alpelisib, respectively. (e) WT or KO cells treated with either DMSO, 10 mM of 
GSK2636771, or 10 mM of idelalisib, demonstrating that neither compound is able to significantly reduce the actin-endosomal overlap. K-W test: ***P < 0.001, 
multiple comparisons; WT DMSO versus KO DMSO, ***P < 0.001, KO DMSO versus KO GSK, *P=0.04, KO DMSO versus KO idelalisib, P > 0.99 (ns). N=159, 





 Figure 2. Alpelisib effects on actin are dose-responsive and recapitulated by siRNA of PI3K p110a. (a) Representative Airyscan confocal micrographs (fixed 
using the 4% formaldehyde fix and immunolabeled for early endosome antigen 1 [EEA1], yellow; actin [phalloidin], magenta; and 40,6-diamidino-2-phenylindole 
[DAPI], cyan; bars=5 mm) and quantification of wild-type (WT) or knockout (KO) human kidney (HK2) cells treated with dimethylsulfoxide (DMSO) or the 
indicated doses of alpelisib for 16 hours, demonstrating dose-responsive rescue of the actin-endosomal overlap. In all cases, the lines indicate mean ± SEM and the 
points indicate individual cells. N=31, 30, 71, 42, 90, 89, 41, 69, 66, and 67 cells for WT control, WT 10 mM, WT 50 mM, KO DMSO, and KO 2.5, 5, 10, 15, 25, 
and 50 mM alpelisib, respectively. Statistical significance assessed by the Kruskal-Wallis (K-W) test with Dunn’s multiple comparisons test: overall ***P < 0.001, 
multiple comparisons; WT DMSO versus KO DMSO, KO DMSO versus KO 5, 15, 25, and 50 mM alpelisib all ***P < 0.001, KO DMSO versus KO 2.5 mM 
alpelisib *P ¼ 0.0131, KO DMSO versus KO 10 mM alpelisib **P=0.0043, WT DMSO versus both WT 10 and 50 mM alpelisib P > 0.9999 (not significant [ns]). 
(b) Western blot for p110a and the loading control a-tubulin of WT or KO cells treated with either scramble (Scram.) or p110a siRNA. (c) Representative Airyscan 
confocal micrographs (fixed using the 4% formaldehyde fix and immunolabeled for EEA1, yellow; actin [phalloidin], magenta; and DAPI, cyan; bars=5 mm) and 
quantification of WT or KO cells treated with either scramble (S) or p110a siRNA, demonstrating reduction of EEA1-actin overlap on p110a depletion. K-W test 
with Dunn’s multiple comparisons test: ***P < 0.001, multiple comparisons; WT scramble versus KO scramble, KO scramble versus KO p110a siRNA both ***P 

















Figure 3. Levels of phosphatidylinositol (PI) 4,5-bisphosphate [PI(4,5)P2] are elevated with OCRL knockout (KO), and PI(3,4,5)P3, 
PI(4,5)P2, and PI(3)P are suppressed by alpelisib treatment. In all experiments, the indicated treatments were applied 16 hours before fixation. In the 
quantifications, the lines indicate the mean ± SEM and each data point results from an individual cell. In all quantifications, statistical significance was assessed 
by a Kruskal-Wallis (K-W) analysis of variance with Dunn’s multiple comparisons test. Bars=20 mm in all images. (a) Representative widefield micrographs of 
wild-type (WT) or KO human kidney (HK2) cells treated with dimethylsulfoxide (DMSO) or 10 mM of alpelisib and then fixed with the plasma membrane fix and 
immunolabeled for PI(3,4,5)P3 (red) and 40,6-diamidino-2-phenylindole (DAPI) (cyan), with quantification of the mean cellular PI(3,4,5)P3 labeling intensity, 
showing the effectiveness of alpelisib treatment on PI(3,4,5)P3 synthesis. N=96, 128, and 109 cells for WT DMSO, WT alpelisib, KO DMSO, and KO alpelisib, 
respectively. K-W (test: overall ***P < 0.001, multiple comparisons; WT DMSO versus KO DMSO, WT DMSO versus WT alpelisib, and KO DMSO versus KO 
alpelisib all ***P < 0.001. (b) Representative confocal micrographs of WT or KO HK2 cells treated with either DMSO, 10 mM-,or 50-mM alpelisib for 16 hours 
and then fixed with the Golgi fix and labeled using the mCh-2xFYVE PI(3)P probe (magenta) and DAPI (cyan), with quantification of the number of PI(3)P-
positive puncta detected in cells treated with a range of alpelisib concentrations, as indicated, showing PI(3)P-positive punctae are reduced in a dose-responsive 
fashion. N=280, 254, 210, 287, 324, 239, 340, 250, 240, and 215 cells for WT control, WT 10 mM, WT 50 mM, KO DMSO, and KO 2.5, 5, 10, 25, and 50 mM 
alpelisib, respectively. K-W test: overall ***P < 0.001, multiplecomparisons; WT DMSO versus KO DMSO, WT DMSO versus WT 10 and 50 mM alpelisib, KO 
DMSO versus KO 50 mM alpelisib all ***P < 0.001; KO DMSO versus KO 2.5 and 5 mM alpelisib both P > 0.9999 (not significant [ns]); KO DMSO versus KO 
10 mM alpelisib **P=0.0049; KO DMSO versus KO 25 mM alpelisib ***P=0.0002. (c) Representative widefield micrographs of WT or KO HK2 cells treated 
with DMSO or 10 mM of alpelisib and then fixed with the plasma membrane fix and immunolabeled for PI(4,5)P2 (yellow) and DAPI  (cyan), with quantification 
of the mean cellular PI(4,5)P2 labeling intensity, showing increased plasma membrane PI(4,5)P2 in KO cells, which is reduced by alpelisib treatment, specifically 
in KO cells. N=126, 112, 85, and 116 cells for WT DMSO, WT alpelisib, KO DMSO, and KO alpelisib, respectively. K-W test: overall ***P < 0.001, multiple 
comparisons; WT DMSO versus KO DMSO and KO DMSO versus KO alpelisib both ***P < 0.001; WT DMSO versus WT alpelisib P=0.4752 (ns). (d) 
Representative widefield micrographs of WT or KO HK2 cells treated with DMSO or 10 mM of alpelisib and then fixed with the 4% formaldehyde fix and 
immunolabeled for PI(4,5)P2 (yellow) and DAPI (cyan), with quantification of the number of PI(4,5)P2-positive puncta, showing increased PI(4,5)P2 puncta in 
KO cells, which is reduced by alpelisib treatment, specifically in KO cells. N=75, 65, 52, and 69 cells for WT DMSO, WT alpelisib, KO DMSO, and KO alpelisib, 
respectively. K-W test: overall ***P < 0.001, multiple comparisons; WT DMSO versus KO DMSO and KO DMSO versus KO alpelisib both ***P < 0.001; WT 




Figure 4  
 
Figure 4. Alpelisib alleviates actin defects of Ocrl in cultured humanized OcrlY/_ mouse PTCs (mPTCs). (a) Representative maximum intensity Z-projection 
confocal micrographs of OcrlY/+ or OcrlY/- mPTCs treated with DMSO or 10 µM of alpelisib for 16 hours then fixed with the 4% formaldehyde fix and 
immunolabelled for actin [phallodin] (white) and DAPI (blue), with quantification of the degree to which stress fibres are present in each condition, showing that 
stress fibres lost in OcrlY/- mPTCs are rescued by alpelisib treatment. Lines indicate means ± SEM, data points indicate each imaging region: N=5 imaging regions 
per condition (each containing ≈15-20 cells). Significance was assessed by ordinary one-way ANOVA with Holm-Sidak’s multiple comparison test, **P=0.001, 
multiple comparisons; OcrlY/+ DMSO vs OcrlY/- DMSO **P=0.002, OcrlY/- DMSO vs OcrlY/- alpelisib **P=0.004, OcrlY/+ DMSO vs OcrlY/- alpelisib P=0.50 (ns). 
Scale bars=20m. (b) Representative 3D surface rendering of Ocrl mPTCs treated with DMSO or 10 µM of alpelisib for 16 hours then fixed with the 4% 
formaldehyde fix and immunolabelled for EEA1(purple), actin [phalloidin] (yellow) and DAPI (blue) and quantification illustra ting rescue of the rescue of the 
actin-endosomal overlap by alpelisib. Lines indicate mean ± SEM. N=42, 47 and 45 randomly selected fields for OcrlY/+ + DMSO, OcrlY/- + DMSO and OcrlY/- + 
alpelisib conditions respectively, in each case pooled from four mouse kidneys per condition. Significance was tested by Kruskal Wallis ANOVA with Dunn’s 
multiple comparisons test: overall ***P < 0.001; multiple comparisons; OcrlY/+ DMSO vs OcrlY/- DMSO and OcrlY/- DMSO vs OcrlY/- alpelisib ***P < 0.001, 
OcrlY/+ DMSO vs OcrlY/- alpelisib P > 0.99 (ns). Scale bars = 5μm in the upper panels and 1μm in the lower panels. (c) Representative confocal micrographs of 
OcrlY/+ or OcrlY/- mPTCs treated with DMSO or 10 µM of alpelisib then fixed with the golgi fix and labelled using the mCh-2xFYVE PI(3)P probe (magenta) and 
DAPI (cyan), with quantification of the number of PI(3)P positive puncta detected in cells. N = 188, 177, 246, 206 cells from OcrlY/+ + DMSO, OcrlY/+ + alpelisib, 
OcrlY- + DMSO, and OcrlY/- + alpelisib respectively; cells were pooled from three Ocrl kidneys per group. K-W test: overall ***P < 0.001; multiple comparisons; 
OcrlY/+ DMSO vs OcrlY/- DMSO, OcrlY/+ DMSO vs OcrlY/+ alpelisib and OcrlY/- DMSO vs OcrlY/- alpelisib, all ***P < 0.001. (d) Representative confocal 
micrographs of OcrlY/+ or OcrlY/- mPTCs treated with DMSO or 10 µM of alpelisib then fixed with the 4% formaldehyde fix and immunolabelled for PI(4,5)P 2 
(yellow) and DAPI (cyan), with quantification of the number of PI(4,5)P2 positive puncta, showing increased plasma membrane PI(4,5)P2 cells in OcrlY/- cells, and 
reduction of PI(4,5)P2 by alpelisib treatment. N=477, 444, 423 and 494 from OcrlY/+ + DMSO, OcrlY/+ + alpelisib, OcrlY/- + DMSO, and OcrlY/- + alpelisib 
respectively; cells were pooled from three Ocrl kidneys per group. K-W test: overall ***P < 0.001; multiple comparisons; OcrlY/+ DMSO vs OcrlY/- DMSO, OcrlY/+ 






Figure 5. Alpelisib improves endocytic uptake of humanized OcrlY/-  mPTCs. (a) Schematic illustrating the pulse-chase experiment used to examine the binding 
and internalization of Alexa 488-BSA into mPTCs. Cells were exposed to Alexa 488-BSA (0.2 mg ml−1) for 1h at 4°C to allow BSA to bind to cell surface receptors 
(pulse) and then warmed to 37°C in cell medium for 20min before fixation to allow ligand internalization (chase). (b) Representative confocal micrographs of 
OcrlY/+ or OcrlY/- mPTCs treated with DMSO or 10 µM of alpelisib and subjected to the Alexa 488-BSA (green) pulse-chase experiment, before being fixed and 
labelled for DAPI (blue). The pulse phase of the experiment is shown in the top panel for each condition, with the chase belo w. Scale bars = 20μm. (c) Quantification 
of cell surface Alexa 488-BSA (i) and internalized Alexa 488-BSA (ii), evaluated as mean fluorescence intensities per cell. Alpelisib rescues the rescued BSA 
binding and internalization observed in OcrlY/- cells. N=209, 228, 186 , 196 cells for OcrlY/+ DMSO, OcrlY/+ alpelisib, OcrlY/- DMSO and OcrlY/- alpelisib conditions 
respectively in (i) and n=203, 183, 199, 233 cells for OcrlY/+ DMSO, OcrlY/+ alpelisib, OcrlY/- DMSO and OcrlY/- alpelisib conditions respectively in (ii), in each 
case pooled from two mouse kidneys per condition; each data point represents the mean fluorescence intensity in an individual  cell. Significance was tested by 
Kruskal Wallis ANOVA with Dunn’s multiple comparisons test: for (i) cell surface BSA, overall ***P < 0.001, multiple comparisons: OcrlY/+ DMSO vs OcrlY/- 
DMSO and OcrlY/- DMSO vs OcrlY/- alpelisib ***P < 0.001, OcrlY/+ DMSO vs OcrlY/+ alpelisib P=0.60 (ns), for (ii) internalized BSA, overall ***P < 0.001, multiple 
comparisons: OcrlY/+ DMSO vs OcrlY/- DMSO and OcrlY/- DMSO vs OcrlY/- alpelisib ***P < 0.001, OcrlY/+ DMSO vs OcrlY/+ alpelisib P=0.66 (ns). (d) Quantification 
of the ratio between the cell surface Alexa 488-BSA and the internalized Alexa 488-BSA fluorescence intensities, showing no significant differences in ratios 
between each condition. Each point representing the average of the ratio in a field containing ≈15-20 cells, (n=13, 13, 10 and 11 randomly selected fields for OcrlY/+ 
DMSO, OcrlY/+ alpelisib, OcrlY/- DMSO and OcrlY/- alpelisib conditions respectively, in each case pooled from two mouse kidneys per condition). Significance was 
tested by Kruskal Wallis ANOVA with Dunn’s multiple comparisons test: overall P=0.46 (ns), multiple comparisons: OcrlY/+ DMSO vs OcrlY/- DMSO and OcrlY/- 




Figure 6  
 
Figure 6. Alpelisib improves the PT function of OcrlY/- mice. (a) Experimental setup of the study. Ocrl mice were treated for 6 weeks with a daily oral dose of 
either carboxymethylcellulose 1% (vehicle) or alpelisib (50 mg kg -1 body weight). On the last day of the treatment, mice were injected with Cy5-labelled β-
lactoglobulin (N=6 OcrlY/-, or 8 OcrlY/- mice per group). (b-d) the  values shown indicate the mean change from BL to D42 for the condition ± SEM. (b) Clara 
Cell protein 16 (CC16), (c) albumin urinary output (both within 15 hours), and (d) Body mass was measured in OcrlY/- mice treated with either vehicle or alpelisib 
at the indicated time point. Each dot represents one mouse. Significance was assessed by two-tailed paired Student’s t-test; in (b) CC16 output change relative to 
baseline; + vehicle, P=0.9802 (ns), + alpelisib, *P=0.0334, in (c) albumin output change relative to baseline; + vehicle, P=0.0502 (ns), + alpelisib, P=0.0006 (***), 
in (d) Body mass change relative to baseline; + vehicle, ***P < 0.0001, + alpelisib, **P=0.0083. (e) Representative confocal micrographs showing Cy5-labeled β-
lactoglobulin (magenta) 15 min after tail vein injection and labelled for DAPI (cyan), plus quantification of the corresponding fluorescent signals from Ocrl mouse 
kidneys (n= 412, 500 and 588 tubules respectively for OcrlY/++ vehicle, OcrlY/- + vehicle and OcrlY/- + alpelisib) for 3 mice per treatment group. β-lactoglobulin 
uptake is recued by alpelisib treatment. Scale bars = 20 µm. In the quantifications, each dot represents fluorescence intensi ty normalized by tubule area; plotted 
data indicates the mean ± SEM. Significance was assessed by Kruskal-Wallis followed by Dunn’s multiple comparison test; ***P < 0.001, multiple comparisons, 
OcrlY/++ vehicle vs OcrlY/- + vehicle and OcrlY/- + vehicle vs OcrlY/- + alpelisib, both ***P < 0.001. (f) Western blotting and densitometry analysis of megalin levels 
in whole kidney lysates from Ocrl mice. α-tubulin was used as a loading control. The reduced megalin expression in OcrlY/- is rescued by alpelisib. In the 
quantification of the densitometry analysis, each dot represents 1 mouse (N=4 OcrlY/++ vehicle and OcrlY/- + vehicle and N=3 OcrlY/- + alpelisib mice) lines indicate 
mean ± SEM. Significance was assessed by 2-tailed unpaired Student’s test: OcrlY/++ vehicle vs OcrlY/- + vehicle, **P=0.0057, OcrlY/- + vehicle vs OcrlY/- + alpelisib, 
*P=0.0246. (g) Representative confocal micrographs with high-magnification insets and quantification of megalin (yellow) intensity in Aqp1+ PTs (magenta) from 
Ocrl kidneys also labeled for DAPI (cyan) illustrating rescue of megalin levels after alpelisib treatment. Bars= 20 mm. In the quantifications, each dot represents 
fluorescence intensity normalized by tubule area; plotted data indicate the mean ± SEM; N=142, 191, and 266 tubules, respectively, for OcrlY/++ vehicle, OcrlY/- + 
vehicle, and OcrlY/- + alpelisib for 3 mice per treatment group. Significance was assessed by K-W analysis of variance followed by Dunn’s multiple comparison 








Figure 7. Proposed model depicting the therapeutic effect of alpelisib on proximal tubule cells in Lowe syndrome. Proximal tubule cells reabsorb urinary 
ligands (e.g., albumin and low-molecular-weight proteins) through megalin-mediated endocytosis. The 5-phosphatase activity of OCRL regulates the transition 
from high phosphatidylinositol (PI) 4,5-bisphosphate [PI(4,5)P2] at the plasma membrane to low levels at the early endosome with a transient coincidence of 
PI(4,5)P2 and PI(3)P in the vesicles. Once in the early endocytic compartment, the ligands dissociate from the receptors and are delivered to the lysosome for 
degradation, whereas the receptors recycle back to the plasma membrane for a new cycle of cargo binding. The loss of OCRL leads to an ectopic accumulation of 
PI(4,5)P2 at the endosomal compartment, which results in a persistent coincidence with PI(3)P. We suggest that this event is responsible for aberrant F-actin 
polymerization blocking endocytic recycling and preventing ligand reabsorption (middle panel). Alpelisib rebalances the levels of PI(4,5)P2 and PI(3)P, which 
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Cell culture and CRISPR KO cell line generation. Human Kidney 2 (HK2) cells (ATCC, CRL-2190) were 
maintained in a 37 oC, 5% CO2 humidified incubator in DMEM/F12 media (containing GlutaMAX; Gibco, 
31331) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 100 μg/ml penicillin/100 U/ml 
streptomycin (Gibco), and were sub-cultured twice weekly. HK2 OCRL KO cell lines were generated exactly as 
previously described to generate RPE-1 OCRL KO lines1. Briefly, the all-in-one Cas9D10A vector was used 
alongside the following single-guide RNA (sgRNA) pairs: sense sgRNA; forward (5’-3’)-
ACCGCCTCCTGATATCTACTGCAT, reverse (5’-3’)-AAACATGCAGTAGATATCAGGAGG, antisense 
sgRNA; forward (5’-3’)-ACCGCAAGGTTCTAACCCGCTATC, reverse (5’-3’)-
AAACGATAGCGGGTTAGAACCTTG, and following transfection into HK2 cells were sorted by FACS to 
generate monoclonal cultures, then screened by western blot to confirm OCRL KO. 
 
Drug treatments in HK2 cells. Drugs were dissolved in DMSO at appropriate dilutions such that the maximum 
dosage added to cells was no more concentrated than a final dilution of 1:1000. Drugs were added to cells at the 
indicated concentrations and time points (16 hours prior to analysis, unless otherwise stated). Alpelisib and 
copanlisib were from Selleck chemicals (alpelisib: S2814, copanlisib: S2802). GSK2636771 and idelalisib were 
from Apexbio (supplied via Stratech Scientific; GSK2636771 B2186, idelalisib A3005). 
 
siRNA treatments. Cells were grown in antibiotic free medium. siRNA was transfected into cells using 
Lipofectamine RNAiMAX (Thermo-Fisher) according to manufacturer’s instructions. Briefly, cells were 
subjected to a two-shot protocol, with transfections at 72 and 24 hours prior to analysis. siRNA was added at a 
final concentration of 25 nM. Sequences were from Dharmacon; p110a: ON-TARGETplus Human PIK3CA (J-
003018-15), scramble: siGENOME Non-Targeting siRNA #2 (D-001210-02). 
 
Mouse models. Experiments were conducted on age- and gender-matched OcrlY/+;Inpp5b-/-; and OcrlY/-
;Inpp5b-/- mouse littermates harbouring BAC-INPP5B expression (129S/SvEv * 129S6/SvEvTac * FVB/N* 
C57BL/6 background)2. Mice aged 6 weeks were treated with vehicle (1% carboxymethylcellulose, n=8 mice per 
genotype) or with alpelisib (MedChem Express; 50 mg/kg body weight in 1% carboxymethylcellulose, n=8 mice 
per genotype) daily by oral gavage and sacrificed after 42 days of treatment. Urine samples were collected every 
14 days. Blood and kidneys were harvested at the time of sacrifice. During the treatment, two OcrlY/- mice treated 
with alpelisib were injured by the oral gavage, euthanized and excluded from the analysis. All of the experiments 
were performed in accordance with the ethical guidelines at University of Zurich and the legislation of animal care 
and experimentation of Canton Zurich, Switzerland (ZH039/19). 
 
Renal function parameters and glycaemia. Urine and blood parameters were measured as described2, 3. The 
urinary excretion values were obtained from overnight (15 hours) urine collection. Plasma glucose was analysed 
using GLU-TEST STRIPS (Nova Biomedical, 42214) according to manufacturer’s instructions. 
 
Primary cultures of mouse proximal tubule cells. The kidneys were harvested from Ocrl mice (8 weeks) and used 
to generate primary cultures of mPTCs as previously described (3). Where indicated, the cells were treated with 
alpelisib (10 μM for 16 h, unless otherwise stated). The cells were processed and analysed as described below. 
 
Cell viability assay. The viability of HK2 cells and mPTCs after drug treatments were assessed via MTT assay 
(ab211091, Abcam) in accordance with the manufacturer’sinstructions. Briefly, the cells were washed three times 
with PBS and then incubated with 0.5 mg/ml of MTT diluted in medium. After 4 hours of incubation at 37 °C and 
until appearance of intracellular purple formazan crystals, the remaining crystals were dissolved with dimethyl 
sulfoxide (276855, Sigma-Aldrich) or SDS, and the absorbance measured at 570 nm. 
 
Immunofluorescence. HK2 cells were grown on glass coverslips. The kidneys and mPTCs were harvested and 
processed as previously described2, 3. Samples were fixed using one of the following fixation methods (typically 





1. 4% formaldehyde fix  
Samples were fixed in 4% formaldehyde and permeabilised in permeabilization/blocking buffer for 20 minutes 
(0.1% saponin, 50 mM NH4Cl, 10% goat serum (HK2 cells) or 0.5% BSA (mouse samples) in PBS). Samples 
were stained for either 1 hour (HK2 cells) or overnight (kidneys and mPTCs) with primary antibodies, and for 45 
minutes with secondary antibodies, then with DAPI for 5 minutes prior to mounting. 
 
2. Plasma membrane fix  
This was specifically used to preserve and examine plasma membrane labelling of PI(4,5)P2 and PI(3,4,5)P3 in 
HK2 cells, based on methods of Hammond et al4. Samples were fixed in 4% formaldehyde + 0.2% glutaldehyde 
for 15 minutes. After fixation, samples were transferred to 4 oC (and were kept at this temperature until the post 
fixation step). They were blocked and permeabilized using a buffer containing 10% goat serum and 0.5% saponin 
in buffer A (150 mM NaCl, 20 mM Na-HEPES, pH 7.4, 2 mM EDTA) for 45 minutes. Primary antibodies were 
made up in antibody incubation solution (1% goat serum and 0.1% saponin in buffer A), and incubated with the 
samples for 1 hour. Secondary antibodies were incubated with the sample for 45 minutes, followed by DAPI for 5 
minutes prior to mounting. Cells were then subjected to a post-fixation step in 2% formaldehyde, which was added 
at 4oC for 5 minutes, followed by 10 minutes warming to room temperature before mounting. 
 
3. Golgi fix 
This was specifically used to preserve PI(3)P staining on endosomes, and was modified from previously 
established protocols1, 5 . Solutions were made up in buffer A. Briefly, cells were fixed in 2% formaldehyde for 
15 mins, after which they were permeabilized using 20μM digitonin. Cells were blocked in 10% goat serum 
containing 1 μg/ml purified mCh-2xFYVE, then immunolabelled using an anti-RFP primary antibody and DAPI. 
Cells were post-fixed in 2% formaldehyde for five minutes prior to mounting. The following antibodies and other 
fluorescent reagents were used; mCherry-2xFYVE1, mouse anti-PI(4,5)P2 (abcam ab11039; used in HK2 cells), 
mouse anti-PI(4,5)P2 (Echelon ZA045; used in mPTCs), mouse anti-PI(3,4,5)P3 (Echelon, Z-A345), mouse anti-
EEA1 (BD Bioscience, 610456), sheep anti-megalin (gift from P. Verroust and R. Kozyraki, INSERM, Paris, 
France), rabbit anti-AQP1 (ab2219, Millipore), rabbit anti-RFP (Rockland, 600-401-379), Alexa-Fluor conjugated 
secondary antibodies (Goat anti rabbit AF 568, A11011, Goat anti mouse 647 A21235, Thermo-Fisher), Alexa-
488 Phalloidin (A12379, Thermo-Fisher), and DAPI (62247, Thermo-Fisher). Samples were mounted with either 
hydromount (National Diagnostics, in HK2 cells) or Prolong Gold Anti-fade reagent (mouse samples). 
 
Microscopy. HK2 cell EEA1/actin colocalization images were acquired on a Zeiss LSM 880 equipped with 
Airyscan and Plan-Apochromat 40x NA 1.3 or Plan-Apochromat 63x NA 1.4 objectives using the Airyscan Fast 
imaging mode. Images were processed using Airyscan processing, strength 6. HK2 cell confocal images were 
taken on an inverted microscope (Ti-E; Nikon) equipped with a 250-μm piezo-driven Z stage/controller 
(NanoScanZ) as an 11 x 0.4 μm Zstack using a spinning disk unit (X-light Nipkow; Crest) and LED illumination 
(Lumencor 
Spectra X) through a Plan Apo 60x 1.4 NA oil objective (Nikon). Images were captured on an EMCCD camera 
(Evolve Delta; Photometrics) in 16-bit depth using Metamorph (software version 7.8.2.0). HK2 cell widefield 
images were taken on an inverted microscope (Ti-E; Nikon) through a Plan Apo 60x 1.4 NA oil objective (Nikon). 
Images were captured on an EMCCD camera (iXon Ultra 897; Andor) in 16-bit depth using Nikon NIS-Elements 
AR (software version 4.50). All mPTCs and mouse tissue images were obtained using either a Leica SP5 confocal 
laser scanning microscope, or a Leica SP8 inverse FALCON microscope (Center for Microscopy and Image 
Analysis, University of Zurich), in both cases equipped with a Leica APO 63x NA 1.4 oil immersion objective, 
with images taken at a definition of 1024 x 1024 pixels, and the pinhole diameter adjusted to 1 Airy unit for each 
emission channel. The quantitative cell image analyses were performed by using ImageJ software and the open-
source cell image analysis software CellProfilerTM 6 (Broad Institute, Cambridge, MA). 
 
Immunofluorescent image quantifications. 
Quantification of “mean fluorescence intensity” 
For all measurement of “mean fluorescence intensity”, an outline of each cell was drawn by 
hand using FIJI (Image J), and the mean fluorescence intensity recorded. For measurements of PI(3,4,5)P3 and 
PI(4,5)P2 intensity in HK2 cells, 10 imaging regions were taken for each condition. For measurement of 488-BSA 
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(binding or internalized) and Cy5-β-lactoglobulin uptake in mPTCs, results were taken from 10 separate imaging 
regions for each mouse. 
 
Quantification of “puncta per cell” 
The pipeline “Speckle counting” in CellProfilerTM was used to the number of PI(3)P or PI(4,5)P2 puncta 
surrounding nuclei and to perform per-nuclei aggregate measurements (eg. the number of dots/nucleus), as 
previously described5, 6. Briefly, the images were converted to greyscale using the module “ColorToGray”. The 
“IdentifyPrimaryObjects” module was used to identify nuclei and dots while cells were identified by using the 
module “IdentifySecondaryObjects”. “MaskObject” and “RelateObject” modules were used to establish a parent-
child relationship between the cells and the dots, identified as masked objects, and to calculate the average of dots 
per cell. 
 
Quantification of “EEA1/actin overlap” in HK2 cells 
The optical airyscan sections just above the section at which stress fibers could be observed were used for the 
quantification, with the CellProfilerTM pipeline “Cell/particle counting, and scoring the percentage of stained 
objects” used to score the percentage of EEA1-positive structures colocalizing with F-actin. Briefly, the images 
were converted to greyscale using the module “ColorToGray”. Then the “ObjectIdentification” module was used 
to identify the nuclei, the EEA1-positive and the F-actin stained structures/vesicles. The “RelateObject” module 
was used to establish a parent-child relationship between the stained objects. In this case, a “parent” object 
(endosomes) is one that touches, overlaps or encloses a “child” object (F-actin structures). When Object1 touches 
or overlasp with Object2, they are considered to be colocalized and will be assigned as a parent to the 
corresponding child. The “ClassifyObjects” and “FilterObjects” modules were used to categorize structures that 
were either colocalizing or not-colocalizing, and to calculate the percentage of colocalizing structures on the total 
amount of endosomes per image. Approximately 10 images from each sample were analyzed. 
 
Quantification of “EEA1/actin overlap” in mPTCs 
Z-stack images acquired by confocal microscope were first deconvolved using Huygens (SVI) software in order 
to increase object resolution in x, y and z, to improve the signal, and correct the noise. The final z-stack images 
were loaded into CellProfilerTM, followed by segmentation of images and identification of objects. The process 
is characterized by three main steps: segmentation of actin and endosomes, identification of overlap objects and 
tabulation of measurements. The “ObjectIdentification” and “Filter” modules were used to identify the EEA1+ 
(Endosomes) and the F-actin marked-structures/vesicles. In order to filter out actin fibers and better visualize the 
above subcellular EEA1/actin-positive structures, limits in shape (Eccentricity factor below 0.75) and size (Area 
size in pixel below 80) of the F-actin object were applied. The “RelateObject”, “ClassifyObjects” and 
“FilterObjects” modules were then used as described above to assign colocalization, “parent” and “child” status, 
and ultimately the percentage of colocalizing objects. Approximately 14 images from each sample were quantified. 
The 3D reconstructions of EEA1 positive vesicles and actin were generated in Imaris software (Oxford 
Instruments) using the full confocal z-stacks (around 45) of each imaging region. 
 
Quantification of “stress fiber score” 
The presence of actin fibers in these images was quantified using a custom script in FIJI(ImageJ). Briefly, the 
script measures directionality of signal without tracing fibers as required for detailed analysis of actin organisation 
such as that carried out by Rogge et al (7). It selects the z-slice containing the highest intensity of f-actin labelling 
and applies Laplacian of Gaussian processing with a sigma value of 2 pixels to suppress noise and detect fibers. It 
then divides the image into 576 (24x24) tiles of equal area with an overlap factor of 0.2 at each edge, and convolves 
the tile with each of the 8 Kirsch directional edge detection kernels. The gradient magnitude is the maximum 
magnitude from any of the resulting images, and its direction is determined by the kernel producing the maximum 
response. Since we are interested in fiber direction rather than gradient direction, π/2 is added to the kernel 
direction to give the principal direction of detected edges. The directionality of actin signal is measured as: 
 
tile score =




where E is the set of responses in the 8 gradient directions. This scale normalisation gives a measure of relative 
contribution of the principal direction to the total gradient present in the tile independent of the magnitude of the 
gradient. The tile-based approach allows unbiased analysis of small regions of cells to give a set of local 
measurements representing the degree of directionality of actin signal which can be used to compare the overall 
level of organisation between conditions. 
The script is available on github at https://github.com/gurdon-institute/Stress_Fibre_Scores. 
 
Endocytosis uptake assays. The endocytic capacity of Ocrl mouse proximal tubules was 
examined by measuring Cy5-β-lactoglobulin (L3908, Sigma) uptake as previously described2. The endocytic 
capacity of Ocrl mPTCs was examined by measuring albumin uptake using a pulse-chase assay analysed by either 
immunofluorescence or intracellular fluorescence intensity using a microplate reader8, 9. mPTCs were seeded at 
appropriate densities on either glass coverslips for immunofluorescence experiments or in 96 well plates for plate 
reader experiments, then treated with 10 μM alpelisib for 16 h. For both types of experiment, cells were washed 
three times in PBS, then incubated with 0.2 mg/ml Alexa 488-BSA (A13100, Thermo Fisher Scientific) at 4 o C 
for 1 hour (“pulse”). Following this, cells were rinsed in serum free media and then incubated in standard serum 
containing media for 20 mins at 37 o C (“chase”) to follow the internalization of albumin. For immunofluorescence 
experiments, cells were washed and fixed (using the 4% formaldehyde fix) at the end of the “pulse”, “wash”, and 
“chase” phases of the experiment, labelled for DAPI, and imaged on a laser scanning confocal microscope, then 
the fluorescence intensity of Alexa 488-BSA in individual cells measured. For measurement of internalized 
albumin uptake on the plate reader, cells were lysed with RIPA buffer supplemented with protease inhibitors and 
the fluorescence signal was measured using the microplate reader (Infinite M Plex, Tecan) at an excitation 
wavelength of 493nm and emission wavelength of 520nm. Protein concentration was determined by bicinchoninic 
acid (BCA) protein assay kit (Thermo Fischer Scientific). The albumin uptake was normalized to the protein 
content of the cells in each well. 
 
Western blotting. HK2 cells were lysed in the following buffer: 50 mM Na-HEPES (pH 7.4), 
50 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol. 1% (v/v) Triton X-100, Halt-EDTA protease 
inhibitor tablets for 30 minutes and scraped from the plate. Lysate concentration was determined by BCA protein 
assay (Pierce) and equal samples loaded and ran on 4-20% mini-PROTEAN polyacrylamide gels (Bio-Rad). 
Transfer was performed using the iBlot 2 dry blotting system (Life Technologies), blocking was performed in 5% 
milk-TBST, antibody incubations and washes in 0.5% milk-TBST, and detection was performed using IRDye 
antigen detection (Goat anti-mouse (926-32210) and anti-rabbit (926-32211) IRDye 800CW) and an Odyssey Sa 
reader (all LI-COR Biosciences). Densitometry analysis of band intensity was performed from 3-5 biologically 
independent replicates in Image Studio Lite (software version 5.2.5; LI-COR Biosciences). For mouse work, 
proteins were extracted from mouse kidney tissues or primary culture cells and western blotting was performed as 
previously described3, with the signals revealed using the ChemiDocTM imaging system (Bio-Rad Laboratories) 
and image intensity was measured in FIJI (ImageJ). The primary antibodies used were as follows: rabbit anti-
OCRL ([EP10256], abcam ab 181039) sheep anti-megalin (gift from P. Verroust and R. Kozyraki, INSERM, Paris, 
France), rabbit anti-Aqp1 (ab2219, Millipore), rabbit anti-PI3 Kinase p110α (4249, Cell Signaling), rabbit anti-
PI3 Kinase p110β (3011, Cell Signaling), rabbit anti-PI3 Kinase p110γ (5405, Cell Signaling), rabbit anti-PI3 
Kinase p110δ (Cell Signaling) and mouse anti-α-tubulin (T5168, Sigma-Aldrich - used in mouse experiments or 
Abcam ab7291 - used in HK2 experiments). 
 
Data analysis and Statistics. The quantitative data were expressed as means ± standard error of the mean (SEM). 
Differences between experimental groups were evaluated using one-way analysis of variance (ANOVA) followed 
by Bonferroni test or Kruskal Wallis followed by Dunn’s multiple comparison test, or unpaired or paired two tailed 
Student’s ttest, when appropriate, and as indicated in the figure legends. The sample size of each experimental 
group is described in the figure legends. GraphPad Prism software was used for all statistical analyses. Statistical 
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Deregulation of mitochondrial network in terminally differentiated cells contributes to a broad 
spectrum of disorders. Methylmalonic acidemia (MMA) is one of the most common inherited 
metabolic disorders, due to deficiency of the mitochondrial methylmalonyl–coenzyme A 
mutase (MMUT). How MMUT deficiency triggers cell damage remains unknown, preventing 
the development of disease–modifying therapies. Here we combine genetic and 
pharmacological approaches to demonstrate that MMUT deficiency induces metabolic and 
mitochondrial alterations that are exacerbated by anomalies in PINK1/Parkin–mediated 
mitophagy, causing the accumulation of dysfunctional mitochondria that trigger epithelial stress 
and ultimately cell damage. Using drug–disease network perturbation modeling, we predict 
targetable pathways, whose modulation repairs mitochondrial dysfunctions in patient–derived 
cells and alleviate phenotype changes in mmut–deficient zebrafish. These results suggest a link 
between primary MMUT deficiency, diseased mitochondria, mitophagy dysfunction and 





Mitochondria – the intracellular powerhouse in which energy from nutrients is converted into 
ATP – are highly dynamic, double–membraned organelles that sustain cellular metabolism and 
physiology (1,2). The maintenance of these dynamic and functionally pleiotropic organelles is 
particularly relevant in terminally differentiated cells that are highly dependent on aerobic 
metabolism (3). Genetic dysfunctions of the mitochondrial network and homeostasis might 
therefore confer a potentially devastating vulnerability to many different cells contributing to a 
broad spectrum of diseases (4). 
Mitochondrial diseases are among the most common type of inherited metabolic 
disorders, which often manifest in early childhood and are associated with high morbidity and 
mortality (5,6). Methylmalonic acidemia (MMA; MIM #251000) – the most common form of 
organic aciduria (7,8) – is caused by recessive, inactivating mutations in the MMUT gene 
encoding the mitochondrial enzyme methylmalonyl‒coenzyme A mutase (MMUT) that 
mediates the terminal step of branched–chain amino acid metabolism (9). Complete (mmut 0) 
and/or partial (mmut –) loss of MMUT function results in the accumulation of toxic metabolites 
(e.g. methylmalonic acid [MMA], propionic acid and 2–methylcitric acid) within mitochondrial 
matrix that trigger ultrastructural (e.g. presence of megamitochondria with abnormal cristae; 
ref.10) and/or functional (e.g. abnormal mitochondrial energetic and redox profiling) 
mitochondrial alterations (10, 11), causing severe organ dysfunctions that primarily affect 
brain, liver and kidney (12,13). The mechanisms linking MMUT deficiency to mitochondrial 
dysfunctions and cell toxicity remain largely unknown, restricting therapeutic avenues for this 
devastating disorder to supportive care (14).  
The epithelial cells that line kidney tubules are enriched in mitochondria, whose energy 
production maintains transport functions and overall kidney integrity (15). Disruption of 
mitochondrial homeostasis in inherited mitochondrial cytopathies drives various degrees of 
epithelial (tubular) dysfunction and kidney disease (16). For instance, a systematic study of 42 
patients with mitochondrial disorders showed that 21 patients had kidney tubular dysfunction 
and 8 had renal failure, confirming the underestimated prevalence of kidney involvement in 
these disorders (17). Conversely, modulating mitochondrial function might restore kidney 
function in mouse models of acute (18) and chronic kidney disease (19). 
Cells possess quality control systems to maintain a requisite number of functional 
mitochondria to meet the energy demands (20). These pathways concur to eliminate damaged 
mitochondrial proteins or dysfunctional parts of mitochondrial network by autophagy (aptly 
termed mitophagy; ref. 21). Biochemical and genetic evidences reveal that the PTEN–induced 
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putative kinase1 (PINK1) and Parkin are the key drivers of mitophagy, driven by the loss of 
mitochondrial membrane potential (22). This homeostatic mitochondrial process is particularly 
active in kidney tubular cells (23). Deletion of genes encoding mitophagy–promoting molecules 
damages tubular cells through defective mitochondrial clearance and increased reactive oxygen 
species (ROS) (24). Abnormal mitochondria with disorganized cristae have been described in 
kidney cells (25) and biopsies from MMA patients (10,26), suggesting an involvement of 
mitochondrial quality control mechanisms in the disease. 
In the present study, using MMA as a paradigm of complex mitochondrial dysfunction, 
we decipher a pathway that links loss–of–function of a mitochondrial enzyme, mitochondrial 
abnormalities, defective PINK1/Parkin–mediated quality control and mitochondria–derived 
stress in kidney tubular cells. These insights might offer potential therapeutic avenues for 





MMUT deficiency impairs mitochondria in kidney tubular cells 
As MMUT is robustly expressed within the mitochondria of kidney tubular cells 
(Supplementary Fig. 1a‒e), we first investigated the consequences of MMUT deficiency on 
mitochondrial function and homeostasis in these cells. To this aim, we analyzed the properties 
of mitochondrial network in kidney tubular cells derived from the urine of either healthy 
controls or mut0 MMA patients harboring inactivating mutations in MMUT (Supplementary 
Table 1; ref. 25). Compared to their control cells, the MMA patient–derived tubular cells 
(hereafter referred to as MMA cells) exhibited a marked decrease in MMUT protein (Fig. 1a) 
and in its mitochondrial enzymatic activity (Fig. 1b, c), reflected by the accumulation of 
methylmalonic acid (MMA; Fig. 1d). Transmission electron microscopy (TEM) analyses 
revealed that mitochondria, which appear as an interconnected meshwork of elongated or 
curvilinear organelles in control cells, were fragmented or characterized by a prominent rod–
like shape with perturbed cristae organization in MMA cells (Fig. 1e) and in the kidneys of a 
patient with MMA (Fig. 1f), in line with recent studies showing an abnormal mitochondrial 
ultrastructure in both kidney and explanted livers of patients with MMA (26). Confocal 
microscopy of the mitochondrially‒targeted green fluorescent protein (mito‒GFP) and semi–
automated image analyses confirmed in MMA cells the presence of mitochondria which appear 
circular and robustly fragmented when compared to control cells (Fig. 1g).  
The morphological abnormalities prompted us to examine whether MMUT deficiency 
alters the homeostasis of the mitochondrial network. Using immunoblotting analyses for 
mitochondrial proteins that label outer (e.g. VDAC1) and inner membrane (e.g. SDH, MT–CO2 
and COX IV), intermembrane space (e.g. Cyt C) and matrix (e.g. PDHA1), we noted an 
increased abundance of overall mitochondrial proteins in MMA compared to control cells (Fig. 
2a). These changes were confirmed by measuring the ratio between mitochondrial (mt‒DNA) 
and nuclear (n‒DNA) through quantitative PCR analyses (Fig. 2b) and by quantifying the 
ATP5B‒flagged mitochondrial structures using confocal microscopy (Fig. 2c). These 
mitochondrial alterations did not result from an effect of MMUT deficiency on cell viability 
(Supplementary Fig. 1f) and proliferation (Supplementary Fig. 1g), nor transcriptional changes 
in mitochondrial genes (MFN1/2, DRP1, OPA1) regulating fusion/fission process 
(Supplementary Fig. 1h), which were similar between MMA and control cells. Taken together, 
these data indicate that the deficiency of MMUT alters the homeostasis of the mitochondrial 




Mitochondrial dysfunction drives stress in MMA cells 
As MMUT deficiency alters mitochondrial homeostasis, we next assessed potential 
consequences on mitochondrial function. Consistent with increased numbers of 
morphologically aberrant mitochondria, the mitochondrial membrane potential (m) was 
drastically reduced in MMA cells (Fig. 2d), as evidenced by live cell imaging analyses of the 
mitochondrial network with cell–permeant, fluorescent dye tetramethylrhodamine methyl ester 
(TMRM, that readily accumulates within functional mitochondria) and MitoTracker (a 
fluorescent probe that localizes to mitochondria). These changes were paralleled by a major 
mitochondrial oxidative stress (Fig. 2e), as testified by the elevated production of mitochondria 
(mt)‒derived ROS (MitoSOX, a live–cell permeant indicator of mitochondrial ROS) and 
augmented antioxidant response (SOD1; Fig. 2g). Treatment with the mitochondrial complex I 
inhibitor Rotenone (5M for 24h), which did not alter the cell viability, exacerbated 
mitochondrial alterations (e.g. decreased mitochondrial membrane potential and increased mt‒
ROS levels) to a greater extent in MMA compared to control cells (Fig. 2d, e). Seahorse 
metabolic flux analyses measuring oxygen consumption rate (OCR) confirmed impaired 
mitochondrial bioenergetics in MMUT–deficient cells, as evidenced by a significant reduction 
in the baseline respiration, ATP turnover, and total respiratory capacity (Fig. 2f), suggesting 
that MMUT deficiency impinges on the function and homeostasis of mitochondrial network in 
both normal and stress–evoked conditions.  
Previous studies in transgenic Mmut–deficient mice and in a large cohort of patients with 
MMA (10, 26) showed that mitochondrial dysfunction and oxidative stress are linked to 
increased production of lipocalin–2 (LCN2, also known as NGAL), a small iron–transporting 
protein largely produced by kidney tubular cells following cellular damage (27). In line with 
these observations, we noticed an increase in Lcn2 mRNA and protein expression in MMA 
compared to control cells (Fig. 2g; Supplementary Fig. 1i). The link between compromised 
mitochondria, oxidative stress and LCN2 overproduction was substantiated by loss–of–function 
interventions in primary proximal tubule (PT) cells derived from wild–type mouse kidneys (28). 
Short–hairpin (sh) RNA–induced knockdown of Atg7 encoding an essential protein necessary 
for autophagy causes mitochondrial dysfunction and mitochondrial oxidative stress with 
increased production of LCN2 in these cells (Supplementary Fig. 2a–e). These data indicate a 
functional link between mitochondrial dysfunction, oxidative stress and LCN2 overproduction, 





MMUT deficient phenotypes in model organisms 
To explore the consequences of the MMUT deficiency in vivo, we investigated a Mmut KO/KI 
mouse model carrying a mutant Mmut allele (p.Met698Lys, corresponding to the patient 
mutation p.Met700Lys) and a knock–out Mmut allele (29). The loss of Mmut was reflected by 
the accumulation of MMA (Supplementary Fig. 3a) and distorted kidney mitochondria which 
appear rod–like shape with impaired cristae organization (Supplementary Fig. 3b). Consistent 
with morphologically aberrant mitochondria, the membrane potential (m) was drastically 
reduced in MMA accumulating kidney PT cells derived from MmutKO/KI mice (TMRM staining; 
Supplementary Fig. 3c). These changes were paralleled by a major mitochondrial oxidative 
stress, as testified by elevated mtROS levels (MitoSOX staining; Supplementary Fig. 3d). 
Despite the metabolic and/or mitochondrial alterations (Supplementary Fig. 3a, d), MmutKO/KI 
mice displayed mildly increased levels of urea (Supplementary Fig. 3e); no significant changes 
in kidney function (plasma levels and clearance of creatinine; Supplementary Fig. 3f, g); no 
changes in LCN2 levels in kidneys as well as in plasma and/or urine - even in aged mutant mice 
(Supplementary Fig. 3h–j); and no structural damage (Supplementary Fig. 3k) nor interstitial 
inflammation (Supplementary Fig. 3l, m) in the kidneys compared to control littermates.  
As the MmutKO/KI mouse model does not show key features of kidney disease in MMA, 
we established the first mmut–knockout zebrafish model using CRISPR/Cas9 genome editing. 
We obtained a zebrafish mutant line carrying an 11–bp–CRISPR/Cas9–induced deletion 
(mmutdel11/de111), generating a premature stop codon within exon 3, resulting in a truncated 
protein deprived of its catalytic activity (Supplementary Fig. 4a‒c). Homozygous mmutdel11/del11 
zebrafish larvae, which appear morphologically normal and display no obvious development 
defects (Supplementary Fig. 4d), exhibit accumulation of MMA (Fig. 3a), which was abolished 
by re–expressing wild‒type mmut cDNA in the liver (Supplementary Fig. 4e), validating the 
specificity of the deletion model. When compared to control littermates, both the kidney and 
the liver of mmut–deficient zebrafish exhibited altered mitochondrial morphology characterized 
by increased mitochondrial circularity (Fig. 3b, c) with perturbed cristae organization. Seahorse 
metabolic flux analyses revealed impaired mitochondrial bioenergetics in mmut–deficient 
zebrafish when compared to control larvae (Fig. 3d). These changes were paralleled by a major 
mitochondrial oxidative stress, as testified by in vivo imaging and ratiometric confocal 
microscopy–based analyses of glutathione redox fluorescent signals in liver Grx1‒roGFP2‒
labeled mitochondria (Fig. 3e), demonstrating the evolutionary conservation of this connection. 
Furthermore, mmut‒deficient zebrafish larvae markedly swim over shorter distances (Fig. 3f; 
Supplementary Fig. 3f) and show an excessive mortality (Fig. 3g) compared to control larvae. 
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Both traits were rescued by feeding mmut–deficient zebrafish larvae (Fig. 3f, g) with low 
protein diet–a strategy used in the MMA management care (12). Re–expressing wild‒type 
mmut cDNA in the liver of mmut–deficient zebrafish larvae, which normalized the levels of 
MMA metabolite and blunted the excessive mortality (Fig. 3g; Supplementary Fig. 4e), did not 
rescue the abnormal swimming phenotype (Supplementary Fig. 4g). Collectively, these results 
demonstrate that MMUT deficiency compromises the function and the homeostasis of 
mitochondrial network, both in vitro and in vivo.  
 
MMUT deficiency induces autophagy 
As damaged mitochondria are normally removed by autophagy–lysosome pathways (30), we 
hypothesized that mitochondrial abnormalities in MMA cells might reflect changes in 
autophagy–lysosome degradation systems. We measured autophagy by detecting the 
conversion of the non‒lipidated form of LC3‒I to the lipidated, autophagosome‒associated 
form LC3‒II through immunoblotting and/or by quantifying the numbers of punctate LC3+ 
vesicles through confocal microscopy and/or the abundance of electron microscopy (EM)–
structures compatible with autophagic vacuoles (31). Compared to control cells, we detected in 
MMA cells elevated conversion of LC3–I to LC3–II (Fig. 4a) and higher numbers of punctate 
LC3–positive structures (Fig. 4b), and more EM structures compatible with autophagic 
vacuoles (AVs; Fig. 4c), whose nature was confirmed by correlated light electron microscopy 
(CLEM; Supplementary Fig. 5a).  
An increased number of AVs might arise from the stimulation of autophagosome 
biogenesis or from alteration of their degradation by lysosomes. To distinguish between these 
two possibilities, we treated at two different time points (2h and 4h) control and MMA cells  
with Bafilomycin A1 (BfnA1), a lysosome–proteolysis inhibitor that blocks the cellular 
degradation of autophagosomes that subsequently accumulate. Treatment of MMA cells with 
Bfn A1 further increased the already elevated steady‒levels of LC3‒II and the numbers of 
punctate LC3+ structures at two different time points where any changes would reflect altered 
autophagosome biogenesis (Fig. 4a, b; ref. 31). These cellular alterations were not associated 
with changes in autophagosome trafficking (as measured by LC3/LAMP1–positive structures 
in cells in response to short incubations with non–saturating concentration of BfnA1; 
Supplementary Fig. 5b); nor in autophagosome–lysosome fusion, as testified by augmented 
protein levels of Rab7–a small GTPase protein that regulates autophagosome–lysosome fusion 
(31) (Supplementary Fig. 5c); nor in lysosome dynamics, as scored by the abundance of 
lysosome–associated protein LAMP1 and cathepsin–D (Supplementary Fig. 5c); nor in 
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lysosome–based degradative capacity, as monitored by Bodipy–FL–Pepstatin A, a 
fluorescence–tagged Pep A that binds to the active site of cathepsin–D in acidic lysosomes 
(Supplementary Fig. 5d), implying that the MMUT deficiency stimulates autophagosome 
biogenesis rather than slowing down their degradation.  
The connection between MMUT deficiency and induction of autophagy was substantiated 
by the increased formation of SQSTM1/p62+ aggregates containing polyubiquitinated proteins 
in MMA cells, despite unchanged levels of SQSTM1 and unmodified activity of the proteasome 
(Supplementary Fig. 5e, f). These changes were rescued by treating the MMA cells with the 
mitochondrially‒targeted ROS scavenger mito–TEMPO (MT; 10 M for 24h; Supplementary 
Fig. 5f), in line with recent observations that increased levels of SQSTM1/p62 might enable a 
more efficient autophagy to maintain cellular homeostasis during oxidative stress (32,33). 
Similar findings were observed in human kidney: LC3–marked autophagy vesicles and 
SQSTM1+ aggregates remarkably accumulated in kidney tubules from a patient with MMA 
(Supplementary Fig. 5g).  
Furthermore, the upstream signalling cascade regulating autophagy, such as mTORC1 
complex, was markedly reduced in MMA compared to control cells (Fig. 4d). This was 
paralleled by activation of the ULK1 complex‒the most upstream autophagy machinery 
controlling autophagosome biogenesis, as indicated by increased protein levels of ULK–1 
complex subunits FIP200 and Atg13 (Fig. 4e) and numbers of initiation foci containing ULK–
1 complex subunit Atg13 (Fig. 4f, top panel). In turn, these changes were reflected by the 
heightened production of the autophagy‒relevant pool of PtdIns‒3P (Fig. 4f, middle panel), 
triggering the recruitment of downstream autophagy effector WIPI2 that stimulates the 
biogenesis of autophagosomes (Fig. 4f, bottom panel). Conversely, exposing MMA cells to the 
class III phosphoinositide 3–kinase (PI3K) vacuolar protein sorting 34 (Vps34) kinase inhibitor 
SAR405, which blocks the production of PtdIns‒3P (34), prevented the LC3‒I‒to‒LC3‒II 
conversion, hence the formation of autophagosomes induced by the MUT deficiency 
(Supplementary Fig. 6a, b). Collectively, these data suggest that MMUT deficiency stimulates 
autophagy by regulating, at least in part, upstream signalling cascades that regulate 
autophagosome biogenesis. 
 
MMUT deficiency impairs degradation of damaged mitochondria 
Considering the persistence in MMA cells of dysfunctional (ROS–producing) mitochondria and 
high numbers of autophagic vesicles/autophagosomes, we reasoned that MMUT deficiency 
might sabotage the mitophagy–mediated demolition of MMA damaged mitochondria. To verify 
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our hypothesis, we treated both control and MMA cells with Rotenone to damage mitochondria 
and selectively activate their mitophagy–mediated degradation. After 24h treatment with 
Rotenone, control cells showed a marked decrease in overall mitochondrial proteins (Fig. 5a) 
and in the ratio between mt–DNA and n–DNA (Fig. 5b), whereas both parameters were 
conversely retained in MMA cells. These changes were verified by measuring the overall 
mitochondrial proteins in cells cultured with other mitochondria–damaging compounds such as 
the electron transport chain inhibitors Oligomycin and Antimycin A (4 M and 0.8 M, 
respectively; Supplementary Fig. 7a). The depletion of MMUT did not alter the content of other 
cellular organelles producing ROS, such as peroxisomes, both under normal and 
autophagy/mitophagy–evoked conditions (Supplementary Fig. 7b), nor the dynamics and 
homeostasis of endolysosome system (Supplementary Fig. 5c, d).  
As the loss of MMUT function results in a block of basal and stress–induced mitophagy, 
we hypothesized that MMUT deficiency might paralyse the delivery of MMA damaged 
mitochondria to autophagy–lysosome degradation systems. To tackle this hypothesis, we 
utilized the ratiometric pH–sensitive imaging–based method (22,35) to measure the delivery of 
dysfunctional mitochondria (which were labelled by the mitochondrially targeted–form of a 
fluorescent Keima protein, mt–Keima) to lysosomes. When damaged mitochondria are 
delivered and engulfed within autolysosomes (e.g. mito‒autolysosome), a spectral shift of mt–
Keima occurs owing to the low pH (Fig. 5c). We validated mt–Keima as a bona fide reporter 
of mito–autolysosome formation in autophagy‒deficient PT cells derived from the kidneys of 
Atg7fl/fl mice (adenovirus–mediated, Cre‒induced deletion of floxed Atg7 alleles; 
Supplementary Fig. 7c; ref. 36) or from kidneys of Pink1 or Prkn2 (encoding Parkin) knockout 
(KO) mice (Supplementary Fig. 7e, f), and treated with Rotenone. Compared to controls cells, 
the deletion of Atg7, Pink1 or Prkn2 was reflected by a loss of the expected shift of mt–Keima 
from a green mitochondrial to a red punctate appearance (Supplementary Fig. 7d, g) induced 
by Rotenone. Of note, basal mitophagy was reduced in autophagy (ATG7)–deficient PT cells 
(Supplementary Fig. 7d) whereas it was comparable in wild‒type and Pink1 or Prkn2 KO cells 
(Supplementary Fig. 7g), in line with recent reports suggesting that basal mitophagy might 
occur independently of PINK1 in mouse tissues of high metabolic demand including the 
kidneys (37). 
Next, we similarly expressed mt–Keima in both control and MMA cells (Supplementary 
Fig. 7h) and exposed the cells to Rotenone to follow the delivery of damaged mitochondria to 
lysosomes. After 24h Rotenone treatment, control cells showed a substantial green‒to‒red 
fluorescent shift– indicative of delivery of damaged mitochondria to lysosomes, whereas this 
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shift was abolished in MMA cells (Fig. 5c). Notably, under control conditions, MMA cells 
displayed lower steady‒state mt–Keima red/ green ratio values than controls, suggesting that 
MMUT deficiency compromises the delivery of damaged mitochondria to autolysosomes in 
both normal and stress‒induced conditions (Fig. 5c).  
 
Mitophagy–mediated quality control in COX10 deficiency 
In order to test whether the altered mitophagy associated with the functional loss of MMUT is 
present in other mitochondrial diseases, we investigated the contribution of mitophagy–
mediated removal and quality control systems in a model of impaired cytochrome oxidase 
assembly (COX10 deficiency)–taken as a paradigm of primary mitochondrial disease (38). We 
transduced PT cells derived from the kidneys of floxed Cox10fl/fl mice with Cre–recombinase 
bearing adenoviral particles to conditionally inactivate the floxed Cox10 alleles in vitro 
(Supplementary Fig. 8a, b). The deletion of Cox10 was verified by reverse transcription‒
quantitative PCR (Supplementary Fig. 8c) and indirectly by immunoblotting for mitochondrial 
COX IV (Supplementary Fig. 8d; ref. 39). The Cox10–deleted cells showed significant 
mitochondrial alterations (e.g. decreased membrane mitochondrial potential and increased 
generation of mitochondrial ROS; Supplementary Fig. 8e–f). These alterations were not 
associated with major changes in mitochondrial content as indicated by comparable ratios of 
mt–DNA/n–DNA (Supplementary Fig. 8g) and by similar levels of mitochondrial proteins 
(Supplementary Fig. 8h) between control and Cox10–deleted PT cells. Notably, under normal 
conditions Cox10‒deleted PT cells displayed higher steady‒state mt‒Keima red/green ratio 
values than control cells (Supplementary Fig. 8i), which were reflected by elevated transcript 
levels of mitophagy regulating gene Pink1 (Supplementary Fig. 8j). Treatment with Rotenone 
induced in both control and Cox10–depleted PT cells the green‒to‒red fluorescent shift– 
indicative of delivery and engulfment of damaged mitochondria within autolysosomes 
(Supplementary Fig. 8i). Collectively, these data suggest that mitochondrial alterations 
encountered in Cox10 deficient kidney cells are not linked to anomalies in mitophagy‒mediated 
degradation, in contrast to the defective mitochondrial homeostasis and mitophagy–mediated 
quality control caused by MMUT deficiency in patient–derived kidney cells. 
 
MMUT deficiency skews PINK1/Parkin‒mediated mitophagy 
The PINK1/Parkin‒induced mitophagy maintains the quality of the mitochondrial network by 
priming dysfunctional mitochondria for autophagy‒lysosome degradation pathways (40). 
Therefore, we hypothesized that MMUT deficiency might compromise the PINK1/Parkin‒
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mediated priming of MMA stressed mitochondria to autophagic–lysosomal degradation. Due 
to the lack of commercially available antibodies able to detect endogenous PINK1, we resorted 
to the translocation of Parkin to damaged mitochondria‒a key downstream step following the 
activation of PINK1‒as a bona fide reporter to assess the PINK1/Parkin–priming mechanisms 
(22,41,42). We labelled the mitochondrial network by transducing both control and MMA cells 
with an adenovirus that expresses the mitochondrially–targeted green fluorescent protein (mt–
GFP). 24 hour post‒transduction, we exposed the mt–GFP expressing cells to Rotenone (5 M 
for 4h) and scored the translocation of Parkin to mt–GFP–flagged mitochondria by confocal 
microscopy (42). Using a validated –Parkin antibody (see the below Supplementary Fig. 10e), 
we observed that Rotenone treatment expectedly heightened the numbers of Parkin+ clusters 
and the translocation of Parkin to mt–GFP+–damaged mitochondria in control cells (Fig. 5d‒f), 
indicating a proper PINK1/Parkin–mediated quality control. Conversely, MMA cells displayed 
a decrease in numbers of Parkin+ clusters and translocation of Parkin to damaged mitochondria 
at baseline and in Rotenone‒evoked stress conditions (Fig. 5d‒f). These changes were 
complemented by the lack of engulfment of damaged mitochondria within EM‒compatible 
autophagy vacuoles in MMA cells (Fig. 5g), supporting the concept of defective marking of 
diseased mitochondria for autophagy‒lysosome–based degradation.  
The role of defective PINK1‒mediated quality control systems was further assessed by 
transducing MMA cells with an adenovirus that expresses human hemagglutinin (HA)‒tagged 
PINK1 (Ad‒HA‒PINK1).The functional re‒expression of PINK1 at mt‒GFP‒flagged 
mitochondria in MMA cells markedly increased the numbers of Parkin+ clusters and rescued 
the translocation of Parkin to MMA damaged mitochondria (Fig. 6a‒c), inducing their delivery 
and degradation by autophagy‒lysosome systems, as indicated by mt‒Keima reporter (Fig. 6d; 
Supplementary Fig. 9a) and analyses of mitochondrial proteins (Fig. 6e). In parallel, PINK1 re–
expression improved mitochondrial functions in MMA cells (Fig. 6f–h; Supplementary Fig. 9b, 
c), compared to cells transduced with empty vector.   
 
Mmut deletion damages mitochondria causing stress  
To causally demonstrate the link between MMUT loss, PINK1–directed mitophagy, 
mitochondrial dysfunctions and epithelial stress, we used gain and loss–of–function 
interventions in kidney cells carrying floxed Mmut alleles (Mmutfl/fl). The Mmutfl/fl mice do not 
show any clinical phenotype, have normal growth and display normal metabolite levels (43). 
Primary PT cells derived from Mmutfl/fl mouse kidneys were transduced with adenovirus 
particles bearing Cre–recombinase to conditionally delete Mmut in vitro (Fig. 7a, b).  
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The deletion of Mmut was reflected by augmented levels of MMA (Fig. 7c), and by 
reduced engulfment of damaged and/or dysfunctional mitochondria (e.g. decreased membrane 
potential and altered bioenergetics profiling; Fig. 7d, e) within autolysosomes (as scored by 
reduced mt‒Keima red/green fluorescence ratio; Fig. 7f). Under these conditions, Mmut–
deleted cells showed no significant increase in overall mitochondrial proteins compared to 
control cells (Supplementary Fig. 9d). In line with defective mitochondrial disposal, Mmut–
deleted PT cells exhibited elevated mitochondrial oxidative stress (Fig. 7g) and cell damage 
(LCN2 overproduction; Fig. 7h), which were abolished by restoring PINK1–directed 
mitophagy with an adenovirus expressing (HA)‒tagged PINK1 (Fig. 7g, h; Supplementary Fig. 
9e).  
Conversely, CRISPR/Cas9‒mediated KO of PINK1 or PRKN2 (encoding Parkin) in 
human HAP‒1 cells (Supplementary Fig. 10) led to mitochondrial alterations, i.e. decreased 
mitochondrial membrane potential (Supplementary Fig. 11a), reduced bioenergetics profiling 
and elevated mitochondrial ROS production (Supplementary Fig. 11b, c), that were similar to, 
albeit milder than, those encountered in patient‒and‒in Mmut‒deleted cells. Notably, we did 
not detect differences in mitochondrial morphology between PINK1 and Parkin wild–type and 
KO cells (Supplementary Fig. 11d). Taken together, these data suggest that the deficiency of 
Mmut impedes the PINK1‒induced translocation of Parkin to MMA damaged‒mitochondria, 
halting their delivery and subsequent degradation by autophagy‒lysosome systems. In turn, 
these cellular defects promote the accumulation of dysfunctional (ROS‒producing) 
mitochondria that ultimately trigger epithelial stress and damage. 
 
Drug–disease network perturbations in MMA cells  
We used a drug–disease network–based computational modeling approach (Mantra 2.0; Mode 
of Action by Network Analysis; http://mantra.tigem.it; ref. 44) to identify potential druggable 
pathways to overcome cellular dysfunctions associated with MMA. MANTRA elucidates 
genome–wide targetable candidates by systematically matching disease gene signature 
(Supplementary Fig. 12a), here derived from the comparison of expression profiles between 
MMA and their related control cells (Supplementary Fig. 12b, c; Supplementary Table 2), 
against a library of 1309 small bioactive drug compounds. Predictions for drug–disease pairs 
were based on the hypothesis that, if a drug reverses the disease gene signature, that drug might 
potentially target disease–relevant biological pathways (44). Based on this assumption, the top–
35 drug compounds transcriptionally closer to the inverse disease gene profile were identified. 
To determine the targeted–biological pathways in MMA, we transcriptionally phenotyped the 
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top–35 drug compounds by performing Drug Set Enrichment Analysis (DSEA; ref. 45) – a tool 
identifying, from transcriptional responses, the molecular pathways that are significantly 
modulated by drug compounds in a set. We run DSEA using as pathway databases Gene 
Ontology terms: biological process, molecular function and cellular component. Interestingly, 
DSEA revealed that the top–scored drug compounds modulate redox homeostasis–related 
pathways (Fig. 8a), in line with the mitochondrial oxidative stress encountered in MMA cells 
and with recent mouse transcriptomic profiling denoting a chronic activation of stress–related 
pathways in a transgenic mouse model expressing Mmut in the muscle (26). It also yielded 
candidates affecting pathways that regulate mitochondrial homeostasis and functioning such as 
calcium import, fatty acid –oxidation and cellular respiration; or that control mitochondrial 
dynamics such as fusion; or that modulate cellular responses to mitochondrial stress (Fig. 8a). 
These in silico analyses strongly support that mitochondria–targeting strategies might 
potentially reverse disease phenotype in MMA cells.  
 
Mitochondrial targeting in MMA cells and animal models 
Inspired by the biological evidence and the MANTRA analysis, we tested whether 
mitochondria–targeted interventions might correct phenotypes in MMA. Control and MMA 
cells were cultured in presence and in absence of a mitochondria–targeted antioxidant mito–
TEMPO (MT, 10 M for 24h), which rescues mitochondrial‒based cell dysfunctions associated 
with the lysosome storage disease cystinosis (46). Despite unchanged levels of MMA 
metabolite (Fig. 8b), treatment with MT effectively recovered mitochondrial morphology (as 
scored by presence of curvilinear or elongated mitochondria; Fig. 8c) and partially the 
homeostasis of mitochondrial network (as testified by immunoblotting analyses for 
mitochondrial proteins; Fig. 8d), improved mitochondrial functionality and bioenergetics (Fig. 
8e), lowered the formation of SQSTM1+ aggregates containing polyubiquitinated proteins 
(Supplementary Fig. 5f), and neutralized mitochondrial oxidative stress (Fig. 8f) and LCN2 
overproduction (Fig. 8g) in MMA cells. 
To explore the translational potential of these findings, we treated mmut‒deficient 
zebrafish larvae with low, non–toxic doses of the mitochondrially–targeted antioxidant MitoQ 
(200 nM for 24h). Treatment with MitoQ effectively reduced mitochondrial oxidative stress 
(Fig. 9a), improved the behavioural phenotype (Fig. 9b) and reduced the excessive mortality 
observed in mmut–deficient zebrafish larvae (Fig. 9c), in absence of any significant changes in 
the MMA levels (Fig. 9d). Taken together, these findings suggest that repairing mitochondrial 




The proper functioning of mitochondria is crucial for the homeostasis of specialized cell types, 
for instance those requiring high ATP levels for reabsorptive/transport activities (23, 47–49). 
Inherited defects in mitochondrial–localized proteins and/or enzymes, as exemplified by MMA, 
drive the accumulation of potentially toxic metabolites within mitochondrial matrix, promoting 
ultrastructural and/or functional alterations that ultimately cause life–threatening metabolic 
complications and organ dysfunction (10–13). Here, combining gain–and–loss–of function 
interventions in vitro and in vivo, we decipher the link between mitochondrial abnormalities 
induced by MMUT deficiency and anomalies in PINK1/Parkin–mediated quality control and 
surveillance systems, triggering a level of mitochondrial dysfunction that drives epithelial stress 
and kidney damage in MMA. 
Kidney tubular cells derived from MMA patients and zebrafish lacking MUT exhibit 
mitochondrial fragmentation and lower membrane potential, impaired respiration and ATP 
production, and heightened mitochondrial ROS, generating epithelial stress and cell damage 
(Fig. 10). In particular, MMUT deficiency disables the PINK/Parkin–mediated mitophagy, 
leading to the accumulation of MMA damaged and/or dysfunctional mitochondria that trigger 
cellular stress. Unbiased drug–disease network perturbation modeling predicted targetable 
biological processes including redox homeostasis whose modulation repairs mitochondria in 
patient–derived cells and alleviates disease–relevant phenotypes in a zebrafish model of MMA. 
These findings reveal the importance of mitophagy–mediated organelle quality control systems 
in safeguarding the functioning and homeostasis of the mitochondrial network homeostasis and 
offer potential therapeutic strategies for repairing mitochondrial dysfunctions in MMA and in 
other mitochondrial–related human diseases. 
The epithelial cells that form the kidney tubules are enriched in mitochondria to sustain 
their specialized transport functions and integrity (23). Defects that impair mitochondrial 
protein homeostasis or assembly might drastically lead to kidney tubule dysfunction in various 
types of diseases (50). MMA patient–derived kidney cells show fragmented mitochondria and 
a marked increase in the abundance of mitochondrial DNA and resident mitochondrial proteins, 
suggesting that MMUT deficiency alters the homeostasis of the mitochondrial network. 
Furthermore, MMA cells display decreased mitochondrial membrane potential and reduced 
mitochondrial bioenergetics. These dysfunctions result in the generation of large amounts of 
oxygen radicals and cellular stress, which are observed in other mitochondrial diseases (51). A 
similar accumulation of morphologically aberrant and dysfunctional mitochondria is observed 
in the kidney tubule cells of MmutKO/KI mice, demonstrating the key role of MMUT function 
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for the mitochondrial network homeostasis and function. However, despite the metabolic and 
mitochondrial abnormalities, the MmutKO/KI mice develop no structural changes nor significant 
kidney failure, thus failing to recapitulate the kidney disease associated with MMA. 
To overcome this difficulty, we established the first mmut–knockout zebrafish model 
using CRISPR/Cas9 genome editing. The patterning of the kidney tubule is remarkably 
conserved in the zebrafish pronephros versus mammalian kidney, including junctional 
complexes, endolysosomal apparatus, and receptors and transporters (52). Deficiencies in genes 
encoding receptors, enzymes and transporter that cause tubular dysfunction in humans have 
been shown to trigger similar pathological changes in zebrafish (46,53–55). Further 
characteristics including high fecundity, unrivalled optical transparency, and the possibility of 
housing in multi‒well plates offer unique opportunities to perform (high–throughput) 
phenotypic screens in an in vivo context (56).  
Analogous to the metabolic and mitochondrial alterations encountered in the MmutKO/KI 
and patient–derived kidney cells, the mmut–deficient zebrafish exhibit altered mitochondrial 
morphology and excessive mitochondrial damage, with an exaggerated mitochondrial oxidative 
stress and markedly decreased mitochondrial bioenergetics flux rates when compared to their 
control littermates. The demonstration of this conserved connection will require a more 
comprehensive elucidation of the similarities and differences between zebrafish and human 
mitochondrial biology. The mmut–deficient zebrafish showed an MMA disease‒relevant 
phenotype, including liver/kidney mitochondriopathy, impairment of the behavioural 
phenotypes and an excess of mortality. Of note, these two features are rescued by feeding the 
mutant zebrafish with a low protein diet–a strategy used in MMA patients as it prevents the 
accumulation of methylmalonic acid (14). Intriguingly, our findings revealed that restoring 
mmut activity in the liver, which normalizes the levels of methylmalonic acid metabolite and 
blunts the excessive mortality, does not protect the mmut-deficient zebrafish from the abnormal 
swimming phenotype. The latter observation suggests that mmut–induced mitotoxicity in other 
cell types and organs (e.g. central nervous system, optic nerve and/or muscle) might govern the 
phenotypes encountered in mmut-deficient zebrafish. 
The concept that mitochondrial dysfunctions and uncontrolled cellular stress might 
contribute to the MMA disease is in line with the observed correlation between mitochondrial 
dysfunction, oxidative stress and circulating LCN2 in a cohort of patients with MMA (10, 26). 
LCN2 is a secreted iron–transporting protein produced by kidney tubules following cellular 
damage; it is associated with kidney disease progression (27) and metabolic disease (57). Our 
studies performed on aged MmutKO/KI mice did not show any significant increase in the levels 
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of LCN2, in plasma, urine and kidney. The difference could reflect specific compensatory 
mechanisms (10, 26), or a specific time–course of induction in MmutKO/KI mice (29). 
A central question is how the loss of MMUT enzyme activity disrupts mitochondrial 
network homeostasis and its function. The first line of defense to cope with mitochondrial 
damage is represented by the cellular quality control system (58). The latter involves the 
degradation of dysfunctional mitochondria through an evolutionary conserved, catabolic self–
eating process called macroautophagy (hereafter autophagy; ref. 58) and the renewal of 
components through biogenesis (20). Normally, these homeostatic processes suffice to clean 
the cells of damaged organelles.  
We first noted that MMUT deficiency promotes autophagy. Indeed, MMUT–deficient 
cells show a heightened conversion of LC3–I to LC3–II, with increased autophagosome–
associated LC3+ puncta as well as CLEM and/or EM structures compatible with autophagic 
vacuoles. MMUT deficiency may affect autophagy either by stimulating autophagosome 
biogenesis or by inhibiting the fusion between autophagosomes and lysosomes or by controlling 
the degradative function of lysosomes. These last hypotheses do not sound plausible in view of 
the similar coalescence of LAMP–1–positive and LC3–positive vesicles and the unchanged 
lysosomal dynamics and lysosomal–based cellular degradation under MMUT–depleting 
conditions. Also, treatment with Bfn A1 further increased the already elevated steady‒levels of 
LC3‒II and the numbers of punctate LC3+ structures at two different time points where any 
changes would reflect altered autophagy biogenesis. Furthermore, downstream events 
regulating the degradation of autophagosomes remained unchanged. Several mechanisms may 
account for the stimulation of autophagy in MMUT–deficient cells: (1) reduced mTORC1 
signalling, whose activity downregulates autophagy; (2) increased levels of ULK1 complex 
subunits FIP200 and Atg13 and numbers of initiation foci containing ULK1 complex subunit 
Atg13, whose activation regulates autophagy machinery involved in autophagosome formation; 
(3) augmented abundance of autophagy–relevant pool of PtdIns–3P, which recruits downstream 
autophagy effector WIPI2, hence stimulating autophagosome biogenesis; and (4) redox–
dependent formation of intracellular SQSTM1/p62+ aggregates containing polyubiquitinated 
proteins, whose accumulation might activate autophagy (32). Thus, deficiency of MMUT may 
stimulates autophagy by regulating upstream signalling cascades that regulate autophagosome 
biogenesis, in line with recent studies stating elevated autophagy markers in mitochondria–
related diseases (59) and dysregulation of autophagy–lysosome degradation pathways in tissue 
samples from patients with MMA (26). 
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A growing body of evidence suggests that exhausted mitochondria are selectively 
targeted for autophagy by the PINK1/Parkin–dependent pathways (22). PINK1 and Parkin also 
regulate mitochondrial quality control through other pathways including fusion/fission and 
biogenesis (60). Mitochondrial damage activates the mitochondria‒associated kinase PINK1, 
which recruits and activates Parkin’s E3 ubiquitin ligase activity, forming the basis of multiple 
signalling events that culminate in the engulfment of damaged mitochondria within lysosomes 
(40,41). Considering the accumulation of MMA damaged and dysfunctional mitochondria and 
the stimulation of autophagy, we hypothesized that MMUT deficiency might compromise the 
PINK1/Parkin–mediated priming of MMA stressed mitochondria to autophagy–lysosome 
degradation systems. Indeed, our studies show that MMA cells (1) fail to clear dysfunctional 
mitochondria in both normal and mitophagy (e.g. treatment with Rotenone)–induced 
conditions, as reflected by analyses of mitochondrial proteins and mitochondrial DNA; (2) fail 
to deliver damaged mitochondria to autophagy–lysosome degradation systems, as scored by the 
sensitive mt–Keima imaging–based assay; and (3) show decreased recruitment of Parkin to 
MMA mitochondria–a key downstream step following the activation of PINK1 (22,40,41). The 
dysfunction of the PINK1/Parkin–priming system impacts on the delivery and elimination of 
ROS–producing mitochondria through autophagy–lysosome degradation pathways, triggering 
epithelial stress in MMA. Accordingly, restoring mitophagy–mediated degradation through 
gain–of–function approaches targeting PINK1–mediated priming was sufficient to rescue the 
mitochondrial network, preserving homeostasis in MMA patient–derived cells. Conversely, 
depleting MMUT in PT cells reduces the PINK1–mediated delivery and engulfment of mt–
Keima tagged–mitochondria within autophagy–lysosome degradation compartments, 
promoting mitochondrial stress and cell damage. Of note, when compared to control cells, 
Mmut–deleted PT cells showed no increase in mitochondrial proteins, contrasting with the 
situation observed in MMA patient–derived cells. The difference could reflect effects of chronic 
mitotoxicity on mitochondrial clearance and quality control systems. 
The genetic deletion of PRKN2 (encoding Parkin) or PINK1 in HAP‒1 cells leads to 
mitochondrial alterations similar to, albeit milder than, those encountered in MMA patient 
derived–and in Mmut–deleted kidney cells. Thus, anomalies in PINK1/Parkin–mediated quality 
control might intersect the mitochondrial alterations induced by MMUT deficiency and 
contribute to the pathogenesis of MMA. The latter hypothesis is substantiated by our 
comparative studies of Cox10 deletion – a model that recapitulates a primary mitochondrial 
respiratory chain disease (38). The deletion of Cox10 in PT cells triggered mitochondrial 
alterations that are not linked to anomalies in mitophagy–mediated clearance and quality control 
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systems, in contrast with the dysregulation induced by Mmut deletion. The possibility of a 
cumulative effect of the metabolic and/or mitochondrial perturbations resulting from the 
MMUT deficiency and the loss of PINK1/Parkin–mediated quality control systems is also 
supported by the observation that patients harbouring loss‒of‒function mutations of PINK1 
causing Parkinson’s disease survive in the absence of functional PINK1‒dependent mitophagy 
pathway (61). In these patients, locomotor symptoms do not usually manifest until the second 
and third decades of life, when a sufficient level of mitochondrial dysfunction is coupled to the 
loss of PINK1 to have a detrimental effect on neuron integrity (62). 
The mechanisms by which MMUT deficiency suppresses PINK1 signalling and 
mitophagy remain elusive. We speculate that MMUT deficiency might alter the stability of 
PINK1 by disabling the interaction with yet–to be–defined factors that protect PINK1 from 
processing and degradation (63). Alternatively, MMUT deficiency might trigger stress–related 
posttranslational modification such as S–nitrosylation that inhibits PINK1 kinase activity, 
hence mitophagy (64). Regardless of the mechanism(s) involved, these findings support a role 
of MMUT–beyond its function in metabolism–in maintaining the mitochondrial quality control 
system, hence epithelial integrity and homeostasis. 
There is an urgent need to identify targetable interventions in the early course of MMA. 
Previous studies showed that kidney dysfunction and levels of circulating LCN2 could be 
abrogated in a transgenic mouse model of MMA by administrating ubiquinone, a bioavailable 
form of CoQ10 that acts on mitochondria, and Vitamin E (10). Using an in silico approach 
based on matching gene expression profile from patient–derived cells against a large 
compendium of small bioactive drug compounds, we inferred that targeting mitochondrial 
oxidative stress might reverse disease phenotypes associated with MMUT deficiency. In 
particular, we explored the potential benefit of mitochondria–targeted antioxidants, which are 
clinically tested in a variety of diseases (65). Treatment of MMA cells with mito–TEMPO 
restored partially mitochondrial homeostasis, improved mitochondrial function, normalized 
mitochondrial ROS and autophagy markers, and prevented the overproduction of LCN2. 
Furthermore, treatment with low doses of MitoQ alleviated the mitochondrial oxidative stress 
and ameliorated behavioral phenotypes and blunted the excessive mortality in the mmut–
deficient zebrafish model of MMA. Importantly, both pharmacological interventions did not 
modify the levels of MMA metabolite in either MMA cells or mmut‒deficient zebrafish, 
supporting the concept that mitochondrial targeting acts independently of the elevation of toxic 
MMA metabolites.  
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In conclusion, we identify a pathway that links a genetic deficiency of a mitochondrial 
enzyme with mitophagy dysfunction and accumulation of damaged mitochondria that generate 
epithelial stress and tissue damage. These findings substantiate the role of PINK1/Parkin–
directed mitophagy in safeguarding mitochondrial network homeostasis, which is crucial for 
the properly functioning of specialized epithelial cells. Antioxidant compounds specifically 
targeting mitochondria offer a promising therapeutic strategy for repairing mitochondria in 




Antibodies, reagents and cell lines. Anti‒MMUT (Abcam, ab67869, 1:200), anti‒SDH (Abcam, ab14715, 1:500), 
anti‒PDHA1 (Abcam, ab110334, 1:500), anti‒MT‒CO2 (Abcam, ab110258, 1:500), anti‒VDAC1 (Cell signaling 
technology, 4866, 1:500), anti‒COX IV (Abcam, ab14744, 1:500), anti‒Cytochrome C (Abcam, ab110325, 
1:500), anti‒SOD1 (Santa Cruz Biotechnology, SC-11407, 1:500), anti‒LCN2 (Abcam, ab63929, 1:500), anti‒
ATP5B (Abcam, ab14730, 1:500), anti‒LC3 (MBL, PM036, 1:200), anti‒phospho ULK1 (Ser757; Cell signaling 
technology, 6888, 1:200), anti‒phospho‒S6 Ribosomal Protein (Ser235/236) (Cell signaling technology, 4858, 
1:500), anti‒S6 Ribosomal Protein (Cell signaling technology, 2217, 1:500), anti‒phospho‒4E‒BP1 (Ser65; Cell 
signaling technology, 9451, 1:500), anti‒4E‒BP1 (Cell signaling technology, 9644, 1:500), anti‒ULK1 (Cell 
signaling technology, 8054, 1:200), anti‒FIP200 (Cell signaling technology, 12436, 1:500), anti‒ATG13 (Cell 
signaling technology, 13468, 1:200), anti‒WIPI2 (Abcam, ab105459, 1:200), mCherry‒2XFYVE Ptdins‒3P‒
binding domain (1:100) was kindly provided by Dr. J. Gallop (University of Cambridge), anti‒Parkin (Abcam, 
ab77924, 1:500 for IF and immunoblotting analyses), anti‒Parkin (Santa Cruz Biotechnology, SC-32282, 1:500; 
for immunoblotting analyses), anti‒HA (Roche, 11867423001, 1:500), anti‒‒tubulin (Sigma–Aldrich, T5168, 
1:10000), anti‒RFP (600–401‒379, ROCKLAND), anti‒UMOD (Meridian, K90071C, 1:500), anti‒AQP2 (Santa 
Cruz Biotechnology, sc-9882, 1:500), anti‒CD3 (Abcam, ab16669, 1:200), anti‒Ly6G (Biosciences, 551459, 
1:100), anti‒LAMP1 (Santa Cruz Biotechnology, sc–19992, 1/1000), anti‒PMP70 (Sigma, SAB4200181, 1:500), 
anti‒ubiquitin (Santa Cruz Biotechnology, sc–8017, 1:1000), anti‒SQSTM1/p62 (MBL, PM045, 1:200), anti‒
cathepsin D (Santa Cruz Biotechnology, sc–6486, 1:500), anti‒Rab7 (Abcam, 126712, 1/400), anti‒β‒actin 
(Sigma, A5441, 1/10000), anti‒ATG7 (Sigma, A2856,1/500), anti‒GAPDH (Cell signaling technology, 2118, 
1:1000), Picro Sirius Red staining kit (Abcam, ab150681) were used. Compounds included Bafilomycin A1 (Bfn 
A1; Enzo Life Sciences, ALX-380-030, 250 M), Rotenone (Sigma, R8875, 5 M), mito–TEMPO (Enzo Life 
Sciences, ALX–430–150–M005, 10 M), MG132 (Abcam, ab141003. 50 M), MitoQ (Focus Biomolecules, 10‒
1363, 200 nM), SAR405 (APExBIO, A8883; 5 M), Oligomycin A (Sigma Aldrich, 495455, 4 M) and 
Antimycin A (Sigma Aldrich, A8674, 0.8 M). The HeLa cell line was kindly provided by Dr. L. Borsig 
(University of Zurich) and the Hap‒1 cell line was purchased from Horizon Discovery 
(www.horizondiscovery.com). The cells lines used here do not appear in the database of commonly misidentified 
cell lines (International Cell Line Authentication Committee), except the HeLa cell line that was analysed for the 
detection of Parkin expression in Supplementary Figure 7f. All the cells used in this study were negatively tested 
for mycoplasma contamination using MycoAlert™ Mycoplasma Detection Kit (LT07‒118, Lonza, Switzerland). 
 
Human kidney biopsies.Human kidney biopsies were obtained from an individual patient with clinical diagnosis 
of MMA and from a healthy control (non–transplanted, normal human kidney). Informed consent was obtained, 
and the use of the human biopsy samples was in accordance with the ethical regulations at Bambino Gesù 
Children's Hospital and approved by the EURenOmics consortium (FP7, 2007–2013, grant agreement no. 305608) 
and by the institutional review board at Bambino Gesù Children's Hospital. 
 
Immunofluorescence on human kidney samples. Paraffin blocks of human kidney samples were sectioned into 
consecutive slices with a thickness of 6μm using a Leica RM2255 rotary microtome (Thermo–Fisher Scientific) 
on Superfrost Plus glass slides (12–550–15, Thermo-Fisher Scientific). Before staining, slides were deparaffinized 
in changes of CitriSolv (22–143–975, Thermo‒Fisher Scientific) and 70% isopropanol. Antigen retrieval was 
accomplished by incubating in sodium citrate buffer (1.8% 0.1 M citric acid, 8.2% 0.1 M sodium citrate, in distilled 
water, pH 6.0) in a rice cooker for 30 min. The slides were blocked with PBS blocking buffer (1% BSA, 0.2% 
non‒fat dry milk in PBS) for 30 min and stained with primary antibody specific for LC3 and SQSTM1/p62 in 
blocking buffer overnight at 4°C. After two washes in 0.1% Tween 20 (v/v in PBS), the slides were incubated with 
the corresponding fluorophore‒conjugated secondary antibodies (Life Technologies) diluted in blocking buffer at 
room temperature for 1 h and counterstained with 1g Biotinylated Lotus Tetragonolobus Lectin (LTL; B–1325 
Vector Laboratories) and 1 µM 4’,6–Diamino–2–phenylindole dihydrochloride (DAPI; #D1306, Thermo Fischer 
Scientific). The slides were subsequently mounted in Prolong Gold Anti–fade reagent (Life Technologies) and 
images were acquired using the Leica SP8 confocal laser scanning microscope (Center for Microscopy and Image 




Electron microscopy on human kidney samples. Biopsy specimens were immersed in ice-cold 2.5% 
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) immediately after their extraction and sectioning, and fixed for 
4 h at 4 °C, carefully handling samples to avoid ex vivo artefacts. After washing in cacodylate buffer, kidney 
fragments were then post‒fixed in 1% osmium tetroxide for 1 h, dehydrated through ascending grades of alcohol, 
and embedded in Epon resin (Electron Microscopy Science, Hatfield, PA). Ultrathin sections (70 to 75 nm) were 
cut on an ultramicrotome (Leica reichert ultracut S), stained with uranyl acetate and lead citrate, and examined 
with TEM (Jeol 1400 PLUS). 
 
Enzymatic activity. Crude cell homogenates were sonicated and 1 mM DL‒2‒[methyl-14C] methylmalonyl‒CoA 
(ARC; specific activity 7.03 MBq/mmol in assay) was added in presence (total MMUT activity) and in absence 
(holo‒MMUT activity) of the cofactor Adenosylcobalamin (AdoCbl; 50 µM) in darkroom safelight red conditions. 
The reaction was terminated by the addition of 5N KOH (Merck, Darmstadt, Germany). The samples were 
enriched with succinic acid (Merck, Darmstadt, Germany) to visualize the succinate peak during HPLC separation. 
Succinate and methyl malonate peaks were detected at 210 nm by an UV detector. Quantification of the [14C] 
succinate fraction was performed with Optiphase HiSafe2 counting cocktail (PerkinElmer) in a Tri‒Carc C1 
900TR scintillator spectrometer (Packard). The protein concentration of the cell lysates was determined using the 
Lowry method. The MCM activity is given as pmol succinate which is formed per minute per mg protein 
[pmol/min/mg].  
 
Methylmalonic acid measurement. Mouse tissues or cells were sonicated and lysed in 100 µL of Acetonitrile /10 
mM Ammonium formate 1:1 (v/v). The concentration of methylmalonic acid was measured in an accredited 
laboratory using the standard protocol from Recipe (Recipe, Munich, Germany) with some minor adaptations. 
Briefly, 50 µL of lysate or urine were mixed with 200 µL precipitation reagent containing the internal standard d3-
methylmalonic acid (Recipe, Munich, Germany). After vortexing the sample for 30 s, the protein precipitate was 
removed by centrifugation for 5 min at 16’000 g and the clean supernatant is transferred to a LC‒MS vial, which 
is kept at 10°C in a thermostatic autosampler until LC‒MS analysis. From each vial, 2 µL of sample were loaded 
and separated on an ClinMass column (2.1 x 100 mm, Recipe, Munich, Germany), kept at 25°C using an Ultimate 
3000XRS (Thermo Scientific, Olten, Switzerland) instrument interfaced to a SCIEX TripleQuad 5500 (AB Sciex, 
Zug, Switzerland) mass spectrometer. The chromatography was performed at a flow rate ~700 µL/min by using 
mobile phase A (MPA) and B (MPB) from Recipe (Recipe, Munich, Germany). The elution was achieved using a 
step gradient (100% MPA for 0.3 min, 70% MPA for 0.3 min, 40% MPA for 0.7 min and 0% MPA for 0.1 min 
followed by 1.2 min at 100% MPA). The source parameters were the following: CAD = 7 psi, CUR = 30 psi, GS1 
= 60 psi, GS2 = 70 psi, IS = 4.0 kV, TEM = 550°C. Multiple reaction monitoring (MRM) in negative ion mode is 
used to identify and quantify Methylmalonic acid (quan: 117/73; qual: 117/55) and d3-Methylmalonic acid (quan: 
120/76; qual: 120/58). A collision energy of -12V is used for the 117/73 and 120/76 transitions, while a collision 
energy of -31V is used for the 117/55 and 120/58 transitions. The declustering potential was -40V for all four 
transitions. 
 
Kidney tubule cells from urines of patients with MMA. Tubular epithelial cells were derived from urines of either 
three healthy donors or three muto MMA patients (Supplementary table 1, ref. 25) and cultured in a selective 
medium containing Dulbecco’s Modified Eagle Medium and Ham’s F12 medium, supplemented with dialyzed 
fetal calf serum (FCS), insulin, hydrocortisone, selenite, transferrin, hEGF, NAD and 3,3,5 triiodo‒L‒thyronine. 
The identity of MMUT mutations were confirmed by Sanger sequencing. Confluent cells were sub–cultivated until 
3rd passage and, subsequently, immortalized using pRSVneo vector containing SV40 DNA (pRNS1). Afterwards, 
immortalized kidney tubule epithelial cells were characterized for morphology and expression of kidney markers, 
and MMUT protein and its enzymatic activity as described previously (25). Where indicated, lysosomal proteolysis 
was inhibited by adding Bafilomycin A1 (250nM for 2h and 4h, unless otherwise stated). Where indicated, the 
mitochondrial damage and the activation of mitophagy was triggered by treating the cells with Rotenone (5 M 
for 24h) or with Oligomycin A and Antimycin (O/A; 4 M and 0.8 M, respectively), in fresh culture medium for 
the indicated times. Where indicated, the cells were starved by washing them with Hank’s balanced salt solution 
(55021 C, Sigma‒Aldrich) and placing them in nutrient‒deprived medium. Where indicated, the autophagy was 
inhibited by culturing the cells in presence or in absence of a highly selective PIK3C3/Vps34 inhibitor SAR405 
(5 M in fresh culture medium for 4h). Where indicated, the cells were treated with the proteasome inhibitor 
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MG132 (5 M in fresh culture medium). Where indicated, the cells were treated with the mitochondrially‒targeted 
reactive oxygen species (ROS) scavenger Mito–TEMPO (MT; 10 M in fresh culture medium for 24h, Enzo Life 
Sciences). The cells were processed and analyzed as described below. 
 
Generation of PINK1 and PRKN2 knockout cell lines. PRKN2 (HZGHC003208c002) and PINK1 
(HZGHC000798c008) KO cells were created through CRISPR‒Cas9 gene editing technology and purchased from 
Horizon Discovery (www.horizondiscovery.com). The cells were tested negative for mycoplasma contamination 
and subjected to PCR analysis, followed by Sanger sequencing to identify CRISPR‒Cas9 induced‒deletion. The 
cells were maintained in Iscove’s Modified Dulbecco's Medium (IMDM) supplemented with 10 % dialyzed FCS, 
100 U/mL Penicillin and 100μg/mL Streptomycin. The cells were afterwards processed and analyzed as described 
below. 
 
Generation and maintenance of mmut zebrafish. pT7–gRNA and pT3TS–nCas9n plasmids were obtained from 
Addgene (# 46759 and # 46757, respectively). CRISPR‒Cas9 –targeted site (5’-
GGGCCAGCAGGGTCTGTCTGTGG-3’) contains a restriction site for AlwNI (CAGNNNCTG), which has been 
used for monitoring CRISPR‒Cas9–mediated mutation and genotyping. Oligonucleotides containing sgRNA–
targeting sequence were annealed and cloned into the Esp3I (BsmBI)–digested pT7–gRNA vector (pT7–gRNA–
mmut). The sequence of oligonucleotides is CRISPR–mmut–S: 5’–TAGGGCCAGCAGGGTCTGTCTG–3’ and 
CRISPR–mmut–AS: 5’–AAACCAG ACAGACCCTGCTGGC–3’. XbaI–linearized pT3TS–nCas9n vector was 
used to produce Cas9 mRNA using mMESSAGE mMACHINE T3 kit (Invitrogen). Both sgRNA–mmut and Cas9 
messenger RNAs were co– injected into two or four–cell stage TU zebrafish (Danio rerio) embryos. For detection 
of CRISPR–Cas9–induced deletion, genomic DNA was extracted from 2dpf embryos which developed normally. 
The CRISPR‒Cas9‒injected mosaic TU embryos were raised to adulthood (F0) and outcrossed with wild‒type TL 
zebrafish. The embryos were then raised to adulthood (F1) for screening of heterozygous carriers. We identified a 
heterozygous carrier harboring mmut+/del11 mutation and (F1) generations were crossed again with wild–type TL 
zebrafish to generate (F2) heterozygous zebrafish. Homozygous zebrafish larvae carrying mmutdel11/del11 mutation 
were obtained from incross of (F2) heterozygous zebrafish. Zebrafish were kept at day/night cycle of 14/10 h at 
28°C. Zebrafish larvae were anesthetized by immersion in E3 medium (for 5dpf) or system water (for 10dpf) 
containing 168µg mL-1 tricaine methane sulfonate (MS222, Sigma Aldrich) and analysed as described below. 
Animal care and experimental procedures were approved by the institutional animal care and use committee at 
Canton Zurich in accordance with the ethical guidelines at University of Zurich, Switzerland. 
 
Rescue experiments in mmut zebrafish. A transgenic line expressing mmut‒mCherry was generated under the 
control of the liver fatty acid binding protein (lfabp or fabp10a) promoter. Primers used to clone lfabp promoter 
are lfabp‒Fwd: 5’‒AAATGCAAATTCTGAGCAAATGAC–3’; and lfabp‒Rev: 5’‒
GCTTTCTGGAGAAGCTCAACA–3’. Primers used for amplification of mut cDNA are mut‒Fwd: 5’–
CCCGATGCCTACATAACAACA–3’; and mut‒Rev: 5’–GAACCACCTGATGGTGAGTGA–3’. Stable 
zebrafish line expressing mmut‒mCherry in the liver was established and outcrossed with mmut+/del11zebrafish to 
generate transgenic mutant line, which was crossed with mmut+/del11zebrafish to produce homozygous larvae. Ten 
zebrafish embryos at 5‒dpf or 10‒dpf were pooled and homogenized by sonication in solution containing 50% 
acetonitrile and 10 mM ammoniaformate, and prepared for methylmalonic acid measurements. Where indicated, 
zebrafish larvae were treated at 9‒dpf with system water containing DMSO or MitoQ (200 nM; Focus 
Biomolecules) for 24 hours. The fluorescence signal of reporter protein mito‒Grx1‒roGFP2 (as described below) 
and the larval swimming were analyzed at 10‒dpf. For larval movement tracking, 10‒dpf zebrafish larvae were 
kept individually in fish system water in 24‒well plate. After 10 min of adaptation, the larvae swimming tracking 
is recorded and analyzed in live with zebra box (ViewPoint) with light stimulation during 5min. Where indicated, 
5‒dpf zebrafish were fed with low protein diet (kindly provided by Dr. Carvalho, University of Porto) until to the 
sampled day (14‒dpf), and the distribution of mmut zebrafish larvae was assessed. A range of 100‒120 embryos 
obtained from in‒cross strategies between heterozygous zebrafish were raised to the sampled day, and the 
percentage of wild type, heterozygous and homozygous were determined after genotyping procedure. 
 
Detection of mitochondrial ROS in mmut zebrafish. To measure mitochondrial ROS in zebrafish larvae, we 
generated a transgenic line expressing the reporter protein mito‒Grx1‒roGFP2 under the control of the liver fatty 
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acid binding protein (lfabp) promoter. The plasmid pLPCX‒mito Grx1‒roGFP2 was kindly provided from Dr. 
Dick (Addgene plasmid # 64977). Plasmid DNA pDestTol2CG2‒lfabp::mito‒Grx1‒roGFP2 was co‒injected with 
Tol2 transposase mRNA into zebrafish embryo at 1‒cell stage. Mosaic larvae expressing lfabp::mito‒Grx1‒
roGFP2 were raised to adulthood and then outcrossed with mmut+/del11 zebrafish to produce mmut+/del11 zebrafish 
expressing mito‒Grx1‒roGFP2 in the liver. The fluorescence signal of Grx1‒roGFP2is analyzed by Lightsheet 
microscope (Zeiss, Z.1) after excitation at 405 nm and 488 nm and detected through the same emission filter (505‒
545nm). Imaging settings were maintained with the same parameters for comparison between different 
experimental conditions. The acquired data was processed by Huygens software for deconvolution, and the mean 
fluorescence intensities of randomly selected ROIs were measured and expressed as blue/green fluorescence 
intensity ratio. 
 
Mouse models. The mice were maintained under temperature‒and humidity‒controlled conditions with 12 h 
light/12 h dark cycles with free access to appropriate standard diet in accordance with the institutional guidelines 
of National Institutes of Health Guide for the Care and Use of Laboratory Animals. The mice bearing floxed Cox10 
(Cox10 fl/fl) alleles, in which the exon 6 is flanked by two loxP sequences, were kindly provided by Dr. Moraes 
(Department of Neurology, University of Miami). The mice bearing floxed Atg7 (Atg7 fl/fl) alleles were kindly 
provided by the RIKEN BRC through the National‒Bio‒Resource Project of the MEXT, Japan. The mice bearing 
germline Prkn2 and Pink1 knockout were purchased from Jackson Laboratory. The mice bearing floxed Mmut 
(Mmut fl/fl) alleles, in which the exon 3 is flanked by two loxP sequences, and the mice carrying M698K point 
mutation in the Mmut gene was performed by Polygene (Rümlang, Switzerland) using the C57Bl/6–derived 
embryonic stem cell targeting. To obtain Mmut KO/KI mice, females Mmut WT/KO were crossed to Mmut KI/KI males 
as previously described (29). Mouse genotyping was performed on genomic DNA extracted from ear punch 
biopsies using the primers 5′–GTGGGTGTCAGCACACTTG–3′ (forward) and 5′–
CGTATGACTGGGATGCCT–3′ (reverse) for the KI allele and 5′–ACAACTCCTTGTGTAGGTC–3′ (forward) 
and 5′–CCTTTAGGATGTCATTCTG–3′ (reverse) for the KO allele. All the mice were maintained on a C57BL/6 
background. Animal care and experimental procedures were approved by the institutional animal care and use 
committee at Canton Zurich in accordance with the ethical guidelines at University of Zurich, Switzerland. 
 
Kidney function. The mice were placed overnight in metabolic cages with ad libitum access to food and drinking 
water; urine was collected on ice, body weight, water intake and diuresis were measured (46). Blood (from 
sublingual vein) was obtained after anesthesia with ketamine/xylazine or isoflurane. Urea and creatinine were 
measured using UniCel DxC 800 pro Synchron (Beckman Coulter, Fullerton, CA, USA). The creatinine clearance 
was calculated using the equation Urine (creatinine) × Diuresis/Plasma (creatinine). Plasma and urinary levels of LCN2 
were measured by using an enzyme–linked immunosorbent assay in according to the manufacturer’s instructions 
(EMLCN2, Thermo Fischer Scientific, Waltham, MA).  
 
Picro Sirius Red staining. Picro Sirius Red (ab150681, Abcam) staining was performed on 5 m thick paraffin 
sections from kidneys of MmutWT/KI and MmutKO/KI. Briefly, the sections were deparaffinised, rehydrated and 
subsequently incubated with Picro Sirius Red for 1 hour at room temperature. Sections were then washed twice in 
acidified water (0.05% acetic acid in distilled water), dehydrated and mounted. Images were acquired with a ZEISS 
AxioScan.Z1 slide scanner (ZEISS). 
Primary cultures of mouse proximal tubule cells. The kidneys were harvested from Mmut WT/KI and Mmut KI/KO 
or from Mmut fl/fl or Atg7 fl/fl or Cox10 fl/fl, and from Pink1 or Prkn2 KO and from their corresponding control 
littermates: one kidney was split transversally, and one half was fixed and processed for immunostaining while the 
other half was flash-frozen, homogenized by Dounce homogenizer in 1 mL of RIPA buffer that contains protease 
and phosphatase inhibitors and processed for western blot analysis (46). The contralateral kidney was taken to 
generate primary cultures of mPTCs (46). Freshly micro–dissected PT segments were seeded onto collagen-coated 
chamber slides (C7182, Sigma‒Aldrich) and/or collagen‒coated 6‒ or 24‒well plates (145380 or 142475, Thermo 
Fisher Scientific), and cultured at 37°C and 5% CO2 in DMEM/F12 (21041‒025, Thermo Fisher Scientific) with 
0.5% dialyzed fetal bovine serum (FBS), 15mM HEPES (H0887, Sigma‒Aldrich), 0.55mM sodium pyruvate 
(P2256, Sigma Aldrich), 0.1ml L-1 non‒essential amino acids (M7145, Sigma Aldrich), hydrocortisone, human 
EGF, epinephrine, insulin, triiodothyronine, TF, and gentamicin/amphotericin (Single Quots® kit, CC‒4127, 
Lonza), pH 7.40, 325mOsm kg-1. The medium was replaced every 48 h. Confluent monolayers of mPTCs were 
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expanded from the tubular fragments after 6–7 days, characterized by a high endocytic uptake capacity. These 
cells were negative tested for mycoplasma contamination. All experiments were performed on confluent 
monolayers grown on chamber slides or 24–well or 6–well tissue culture plates. Where indicated, the 
mitochondrial damage and mitophagy were triggered by treating primary cultures of proximal tubule cells with 
Rotenone (5 M in the fresh culture medium for 24h) Oligomycin A and Antimycin (4 M and 0.8 M, 
respectively, in the fresh culture medium for the indicated times). Afterwards, the cells were processed and 
analyzed as described below.  
 
Adenovirus transduction. For RNA interference studies, the adenovirus constructs include scrambled short hairpin 
(Scmb‒shRNA) or shRNAs encoding individually mouse Atg7. For expression studies, adenovirus constructs used 
include CMV (control vector, Ad–CMV–GFP, Vector Biolabs) or an individually carrying Cre–recombinase (Ad–
Cre–GFP, Vector Biolabs) or carrying human hemagglutinin (HA) tagged–PINK1, or carrying mouse green 
fluorescence protein (GFP)‒tagged‒Map1lc3b or expressing green fluorescent protein (GFP) or the coral‒derived 
protein Keima with the mitochondrially‒targeting sequence of the human cytochrome C oxidase subunit VIII 
(COXVIII). All adenovirus constructs were purchased from Vector Biolabs (University City Science Center, 
Philadelphia, USA). The cells were plated onto collagen‒coated chamber slides or 24–well or 6–well tissue culture 
plates. Adenovirus transduction was performed 24 h after plating when the cells reached approximately 70–80% 
confluence. The cells were subsequently incubated for 16 h at 37°C with culture containing the virus at the 
concentration (0.2125×109 PFU mL-1). The cells were afterwards challenged with fresh culture medium every 2 
days, cultured for 5 days (unless otherwise specified) and collected for analyses.  
 
Microarray profiles and drug-disease network modelling. The Affymetrix Gene‒Chip (HG-U113A) 
hybridization experiments were performed in triplicate at the Coriell Genotyping and Microarray Center, Coriell 
Institute for Medical Research, Camden, New Jersey, USA, on total RNA extracted from tubular cells derived 
from three healthy donors and three muto MMA patients (Supplementary Table 1; ref. 25). To identify downstream 
transcriptional effects of loss–of–MMUT function, microarray data were pre–processed using the Bioconductor 
package Affy52 and normalized with the RMA method (66). Differentially expressed (DE) genes between 
conditions (MMA patient–derived versus their control cells) were identified using a Bayesian t-test (67). For each 
P value, the Benjamin–Hochberg procedure was used to calculate the false discovery rate (FDR) to avoid the 
problem of multiple testing. Mode of Action by Network Analysis (MANTRA 2.0, http://mantra.tigem.it) and Drug 
Set Enrichment Analysis (DSEA, http://dsea.tigem.it) were employed to predict either  effective therapeutics or 
druggable biological processes in MMA patient–derived kidney cells. Taking advantage of the connectivity map 
data set –which includes transcriptional profiles following treatment of 1309 small molecules across five different 
cell lines –MANTRA aims to identify compounds transcriptionally similar or different to a disease profile just 
providing as input the ranked list of genes sorted according to their differential expression. This analysis enabled 
us to capture the top–ranked small bioactive molecules that transcriptionally reverse the MMA gene signature 
molecular pathways consistently up– or down–regulated by these set of drugs were then detected using DSEA. 
 
Reverse transcription‒quantitative PCR. Total RNA was extracted from mouse tissues using Aurum TM Total 
RNA Fatty and Fibrous Tissue Kit (Bio-Rad, Hercules, CA). DNAse I treatment was performed to eliminate 
genomic DNA contamination. Total RNA was extracted from cell cultures with RNAqueousR kit (Applied 
Biosystems, Life Technologies). One g of RNA was used to perform the reverse transcriptase reaction with 
iScript 
TM
 cDNA Synthesis Kit (Bio-Rad). Changes in mRNA levels of the target genes were determined by 
relative RT–qPCR with a CFX96TM Real‒Time PCR Detection System (Bio-Rad) using iQ TM SYBR Green 
Supermix (Bio‒Rad). The analyses were performed in duplicate with 100nM of both sense and anti-sense primers 
in a final volume of 20 µL using iQTM SYBR Green Supermix (Bio-Rad). Specific primers were designed using 
Primer3 (Supplementary Tables 3–5). PCR conditions were 95°C for 3 min followed by 40 cycles of 15 sec at 
95°C, 30 sec at 60°C. The PCR products were sequenced with the BigDye terminator kit (Perkin Elmer Applied 
Biosystems) using ABI3100 capillary sequencer (Perkin Elmer Applied Biosystems). The efficiency of each set 
of primers was determined by dilution curves (Supplementary Tables 3–5). The program geNorm version 3.4 was 
applied to characterize the expression stability of the candidate reference genes in kidneys and six reference genes 
were selected to calculate the normalization factor. The relative changes in targeted genes over Gapdh mRNAs 
were calculated using the 2-Ct formula. For the absolute quantification of mitochondrial: nuclear DNA ratio, 
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relative values for ND1 and ACTB (in human cells) or for Nd1 and Hbb (in murine cells) were compared within 
each sample to generate a ratio representing the relative level of mitochondrial DNA per nuclear genome. Primers 
used for mitochondrial DNA: nuclear DNA ratio in human cells are: ND1‒Fwd: 5’‒
ACACTAGCAGAGACCAACCG‒3’; and ND1‒Rev: 5’‒GAAGAATAGGGCGAAGGGGC‒3’; ACTB‒Fwd: 
5’‒ TCACCCACACTGTGCCCATCTACGA ‒3’; ACTB‒Rev: 5’‒CAGCGGAACCGCTCATTGCCAATGG‒
3’. Primers used for mitochondrial DNA: nuclear DNA ratio in murine cells are: Nd1‒Fwd: 5’‒ 
TAGAACGCAAAATCTTAGGG ‒3’; and Nd1‒Rev: 5’‒ TGCTAGTGTGAGTGATAGGG ‒3’; Hbb‒Fwd: 5’‒ 
AGGCAGAGGCAGGCAGAT ‒3’; Hbb‒Rev: 5’‒ GGCGGGAGGTTTGAGACA ‒3’. 
 
Lysosomal‒based degradation activity. The detection of lysosomal activity was performed in live in kidney cells 
by using Bodipy‒FL‒PepstatinA (P12271, Thermo Fischer Scientific) according to the manufacturer's 
specifications. The cells were pulsed with 1μM Bodipy‒FL‒Pepstatin A in Live Cell Imaging medium (A14291DJ, 
Thermo Fischer Scientific) for 1h at 37°C, fixed and subsequently analyzed by confocal microscopy (46). The 
numbers of PepA‒positive structures per cell were quantified by using the open‒source cell image analysis 
software CellProfilerTM as described below. 
 
Mitochondrial membrane potential measurement. The mitochondrial membrane potential () was measured in 
accordance with the manufacturer's specifications. The cells were pulsed with 50 nM Tetramethylrhodamine 
Methyl Ester Perchlorate (TMRM, T668 Thermo Fisher Scientific ) and 1 M MitoTracker Red FM 
(Invitrogen, M22426) for 30 min in live cell imaging at 37°C. After washing, the cells were subsequently analysed 
by confocal microscopy (46) in a chamber heated to 37°C at 5% CO2. Images were acquired using Leica SP8 
confocal laser scanning microscope (Center for Microscopy and Image Analysis, University of Zurich) and the 
fluorescence intensity was quantified by the open source image processing Fiji (which is just ImageJ, NIH) as 
described below. 
 
Mitochondrial ROS detection. The cells were pulsed with 2.5 M MitoSOX Red Mitochondrial Superoxide 
Indicator (M36008, Thermo Fisher Scientific) and 1 M MitoTracker Green FM (Invitrogen, M7514) for 10 min 
in live cell imaging at 37°C. After washing, the cells were subsequently analysed by confocal microscopy in a 
chamber heated to 37°C at 5% CO2. Images were acquired using Leica SP8 confocal laser scanning microscope 
(Center for Microscopy and Image Analysis, University of Zurich) and the fluorescence intensity was quantified 
by the open source image processing Fiji (which is just ImageJ, NIH) as described below. 
 
mt‒Keima mitophagy assay. Cells expressing mt‒Keima were treated in presence and in absence of mitochondrial 
complex I inhibitor Rotenone or electron transport chain inhibitors Oligomycin A and Antimycin as previously 
described and analysed by confocal microscopy in a chamber heated to 37°C at 5% CO2. mt‒Keima protein was 
excited both at 458nm (neutral, pseudo‒coloured in green) and 561nm (acidic, pseudo‒coloured in red) and 
detected through the same emission filter (570‒695nm). Laser power was set up at the lowest output which would 
enable the clear visualization of the mt‒Keima signal, and were individualized for each experimental condition. 
Imaging settings were maintained with the same parameters for comparison between different experimental 
conditions. Images were acquired using Leica SP8 confocal laser scanning microscope (Center for Microscopy 
and Image Analysis, University of Zurich) and the fluorescence intensity was quantified by the open source image 
processing software Fiji (ImageJ, NIH) as described below. 
Extracellular flux analysis and metabolic measurement. Oxygen consumption rate (OCR) in mouse or human 
kidney tubule cells and in zebrafish larvae was measured with XFp Extracellular Flux Analyzers (Agilent Seahorse 
Biosciences). The cells were incubated with XF-Base Medium (non-buffered RPMI 1640 containing either 
2mM L-glutamine, 1mM sodium pyruvate and 10mM glucose, pH 7.4). Three measurements were assessed 
under basal conditions and upon addition of 2μM Oligomycin (Oligo), 0.5μM FCCP, and 1μM Rotenone 
(ROT)/Antimycin‒A (ANT). All the reagents were provided by XFp Cell Mito Stress Test Kit (Agilent Seahorse 
biosciences). OCR measurements were normalized to the numbers of cells (TC10TM automated cell counter, 
Bio-Rad). The zebrafish larvae were anesthetized with 125mg/L of MS222 and placed individually into the wells 
of a 24‒wells microplate, filled with 500 mL of E3 media (pH 7.4) containing anesthesia solution MS222 and 
covered by capture screens. After incubation in a non‒CO2 incubator at 28.5°C for 20 min, the metabolic 
measurements were analyzed in live. One measurement cycle consisted of a brief wait period to acclimate the 
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plate, 2 min mix, 1 min wait, and 2 min data acquisition. Eight measurement cycles were performed to establish 
the average value. 
 
Detection of PtdIns‒3P. PtdIns‒3P staining was performed according to previously established protocols (68). 
Briefly, kidney cells were fixed for 15 min in 2% PFA and permeabilized for 5 min with 20 μM digitonin in buffer 
A (150 mM NaCl, 20 mM Hepes, pH 7.4, and 2 mM EDTA). Cells were subsequently incubated for 45 min with 
buffer A supplemented with 5% goat serum and mCherry‒2×FYVE PtdIns‒3P‒binding domain and 
immunostained with the anti‒RFP antibody to amplify the detection of mCherry probe. The cells were washed and 
post‒fixed with 2% PFA for 5 min, and analyzed by confocal microscopy and quantified by using the open‒source 
cell image analysis software CellProfilerTM as described below. 
 
Immunofluorescence and confocal microscopy. Fresh mouse kidneys were fixed by perfusion with 50–60 mL of 
4% paraformaldehyde in PBS (158127, Sigma–Aldrich), dehydrated and embedded in paraffin at 58C. Paraffin 
blocks were sectioned into consecutive 5m‒thick slices with a Leica RM2255 rotary microtome (Thermo–Fisher 
Scientific) on Superfrost Plus glass slides (Thermo-Fisher Scientific). Before staining, slides were deparaffinized 
in changes of CitriSolv (22–143–975, Thermo–Fisher Scientific) and 70% isopropanol. Antigen retrieval was 
accomplished by heating the slides at 95°C for 10 min in 10 mM sodium citrate buffer (pH 6.0). The slides were 
quenched with 50 mM NH4Cl, blocked with 3% BSA in PBS Ca/Mg (D1283, Sigma‒Aldrich) for 30 min and 
stained with primary antibodies specific for Mutase, UMOD, AQP2, CD3, Ly6G diluted in blocking buffer 
overnight at 4°C. After two washes in 0.1% Tween 20 (v/v in PBS), the slides were incubated with the 
corresponding fluorophore‒conjugated Alexa secondary antibodies (Invitrogen) diluted in blocking buffer at room 
temperature for 1h and counterstained with 1g Biotinylated Lotus Tetragonolobus Lectin (LTL; B–1325 Vector 
Laboratories) and 1µM 4’,6-Diamino-2-phenylindole dihydrochloride (DAPI; D1306, Thermo Fischer Scientific). 
The slides were mounted in Prolong Gold Anti‒fade reagent (P36930, Thermo Fisher Scientific) and analyzed by 
confocal microscopy. The images were acquired using Leica SP8 confocal laser scanning microscope (Center for 
Microscopy and Image Analysis, University of Zurich) equipped with a Leica APO 63x NA 1.4 oil immersion 
objective at a definition of 1,024 x 1,024 pixels (average of eight or sixteen scans), adjusting the pinhole diameter 
to 1 Airy unit for each emission channel to have all of the intensity values between 1 and 254 (linear range). The 
micrographs were processed with Adobe Photoshop (version CS5, Adobe System Inc., San Jose, USA) software. 
Quantitative image analysis was performed by selecting randomly 5‒10 visual fields per each slide that included 
at least 3‒5 PTs (LTL–positive), using the same setting parameters (i.e., pinhole, laser power, and offset gain and 
detector amplification below pixel saturation). The numbers of CD3 or Ly6G positive structures per field were 
manually counted.  
The cells were fixed for 10 min with 4% PFA in PBS, quenched with 50 mM NH4Cl and permeabilized for 20 min 
in blocking buffer solution containing 0.1% Triton X-100 and 0.5% BSA dissolved in PBS. Subsequently, cells 
were incubated overnight with the appropriate primary antibodies at 4°C. After repeated washing with PBS, the 
slides were incubated for 45 min with the suitable fluorophore-conjugated Alexa secondary antibodies 
(Invitrogen), counterstained with 1µM DAPI for 5 min, mounted with the Prolong Gold Anti-fade reagent and 
analyzed by a Leica SP8 confocal laser scanning microscope (Center for Microscopy and Image Analysis, 
University of Zurich) using the settings described above. Quantitative image analysis was performed by selecting 
randomly 5 visual fields pooled from biological triplicates, with each field including at least 10–15 cells, using the 
same setting parameters (i.e. pinhole, laser power, and offset gain and detector amplification below pixel 
saturation). The quantitative cell image analyses of mitochondrial morphology (69) were performed using 
mitochondrial morphology plug in of the open‒source cell image software Fiji. The quantitative cell image of 
mitochondrial membrane potential, production of mitochondrial ROS and mt‒Keima red/green signal, the analyses 
of fluorescence were performed following background subtraction over cellular regions of interests (ROIs) and 
quantified using the multi‒measure plug‒in of Fiji. Mean fluorescence intensity ratios of selected ROIs matching 
cells were determined and expressed as TMRM/MitoTracker, MitoSOX and mt‒Keima red/green ratios, 
respectively. The quantitative cell image analyses of subcellular structures were determined by using the open‒
source cell image analysis software CellProfilerTM (70). In particular, the specific module “Measure‒Object‒
Intensity‒Distribution” was used to score the number of ATP5B, PtdIns‒3P, ATG13, WIPI2, Parkin, LC3, and 
PMP70 or Pep−A+ structures. The pipeline “Cell/particle counting and scoring the percentage of stained objects” 
was used to score either the fractions of Lamp1/LC3+ or mito‒GFP/Parkin+ structures. 
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Electron microscopy. Animal tissue samples and cultured cells were fixed in 2.5 % glutaraldehyde in 100 mM 
sodium cacodylate, at pH=7.43 for 1 h at room temperature, post‒fixed in 1% osmium tetroxide, 1.5% potassium 
ferrocyanide in 0.1 M cacodylate for 1 hour on ice. After washing in distilled water, the samples were stained with 
0.5% uranyl acetate in water overnight at 4°C. The samples were finally dehydrated in a graded ethanol series, 
embedded in Epon 812 and finally cured at 60°C for 48 hours. Ultrathin (70‒90nm) sections were cut using a 
Leica Ultracut UCT ultramicrotome and collected on copper grids, stained with uranyl acetate and Sato’s lead 
citrate before been  imaged with a FEI Talos 120kV transmission electron microscope (FEI Company, 
Netherlands) and images were acquired by a 4k×4K Ceta CMOS camera. Autophagic vacuoles (AVs) were 
identified and categorized as autophagosomes or autolysosomes according to conventional criteria (31). 
Autophagosome should have a double membrane (completely or partially visible), absence of ribosomes in the 
outer membrane, luminal density comparable to the surrounding cytosol and identifiable organelles or regions of 
organelles in their lumen; autophagolysosomes should have single membrane, luminal density lower than 
surrounding cytosol with luminal material partially recognizable as specific organelles or heterogeneous 
amorphous material. Primary and secondary lysosomes were excluded from the quantification. The term 
autophagic vacuole was used for identifying both autophagosomes and autophagolysosomes structures. At least 
20 random selected cellular profiles were acquired and analysed using ImageJ software. For the quantification of 
content of AVs, the percentage of cytosolic area occupied by autophagic vacuoles was calculated. For the 
quantification of the morphology of mitochondrial network, the cross‒section area (A) and perimeter (P) derived 
from each mitochondrion was measured and circularity (c) was calculated according to the formula circularity = 
4 (area/perimeter^2). 
 
Correlative light electron microscopy. The cells were grown on finder grids and prepared for confocal microscopy 
analyses. Z‒stacks of cells of interest were taken with the PerkinElmer Ultra View ERS confocal microscope. The 
coordinates of the cells on the finder grid were determined by bright‒field microscopy. Cells were fixed in 1% 
glutaraldehyde in 0.1 M cacodylate buffer (Sigma) and post‒fixed with 1.5% potassium ferricyanide, 1% OsO4 in 
0.1M cacodylate buffer. Cells were stained overnight with 0.5% uranyl acetate, dehydrated in ethanol, and 
embedded in epon. After baking for 48 h at 60 °C, the resin was released from the glass coverslip by temperature 
shock in liquid nitrogen. Serial sections (70–90 nm) were collected on carbon‒coated formvar slot grids and 
imaged with a  FEI Talos 120kV transmission electron microscope (FEI Company, Netherlands) and images were 
acquired by a 4k×4K Ceta CMOS camera. LM and EM images were aligned using Ec‒CLEM Icy plugin and 
overlaid using Photoshop software. 
 
Soluble and insoluble fractionation. The cells were lysed in buffer containing 50 mM Tris‒HCl, pH 7.5, 150mM 
NaCl, 0.1% SDS, 1% Triton X‒100, 1% sodium deoxycholate supplemented with protease (1836153001, Roche) 
and phosphatase inhibitors (04906845001, PhosSTOP Sigma), and centrifuged at 16,000 g at 4°C for 20 min, to 
collect the soluble fraction (supernatant). The pellet was suspended in a buffer containing 4% SDS and 20 mM 
HEPES, pH 7.5, protease and phosphatase inhibitors, and further centrifuged at 18,000 g at room temperature for 
10 min, to collect the insoluble fraction (supernatant). The samples were boiled at 95 °C for 5 min and analyzed 
by western blotting. 
 
Immunoblotting. Proteins were extracted from mouse tissues or cultured cells, lysed using a buffer which contains 
protease (1836153001, Roche) and phosphatase inhibitors (04906845001, PhosSTOP Sigma), followed by 
sonication and centrifugation at 16,000xg for 10 min at 4°C. The samples were thawed on ice, normalized for 
protein (20g/lane), dissolved in Laemmli sample buffer and separated by SDS–PAGE under reducing conditions. 
After blotting onto PVDF and blocking with 5% non‒fat milk (1706404, Bio–Rad Laboratories), the membranes 
were incubated overnight at 4°C with primary antibody, washed, incubated with peroxidase–labeled secondary 
antibody, and visualized with enhanced chemiluminescence (WBKLS0050, Millipore, Life technologies). Signal 
intensity was assessed by measuring the relative density of each band normalized to -actin, GAPDH or α-tubulin 
with ImageJ software. 
 
Cell viability assay. Cell viability was determined by the Cell Counting Kit‒8 (CCK‒8) assay (Dojindo, Rockville, 
USA). Cells were seeded at a density of 5000 cells/well of 96 well plates and grown until they reached 90% 
confluence. The cell medium was replaced by water‒soluble tetrazolium salt solution and incubated for 30 min at 
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37°C according to the manufacturer’s protocol. The amount of formazan dye generated by dehydrogenase activity 
was measured at 450 nm in a TECAN infinite 200 reader (Männedorf, Switzerland) in according to the 
manufacturer's specifications. 
 
Cell proliferation. To measure cell proliferation, the cells were seeded in 24‒well plates at a density of 2.0 × 104 
cells per well. The cells were cultured for 2 days and cell medium was renewed daily. Where indicated, the cells 
were treated with Rotenone (24h at the indicated concentrations), then trypsinized every 24 h and quantified using 
the Countess automated cell counter TC10 automated cell counter (BIO-RAD). The time–course experiments were 
repeated three times. 
 
Data analysis and Statistics. The plotted data were presented as mean ± standard error of the mean (SEM). 
Statistical comparisons between experimental groups were determined by using one‒way analysis of variance 
(ANOVA) followed by Bonferroni or Dunnet post hoc test or Kruskal Wallis followed by Dunn’s multiple 
comparison test, when appropriate. When only two groups were compared, two tailed Student’s t–tests or 
nonparametric Mann Whitney t tests were used as appropriate. Statistical comparisons between untreated and 
MitoQ treated–mmut zebrafish in Figure 9c was determined by Chi–square goodness of fit test. The sample size 
and reproducibility for each figure were denoted in figure legends. Experiments in Figure 9c were performed once. 
All of the other experiments reported here were independently performed two to three times or more as indicated 
in the legends. The investigators were not blinded to allocation during the experiments and outcome assessment. 
Graph Pad Prism software v. 7.0a (GraphPad software) was used for all statistical analyses and the p values are 
indicated in each figure legend along with the statistical tests.  
 
Data Availability.The Source data underlying figs 1a–b, 1d, 1e, 1g, 2a–g, 3a–g, 4a–f, 5a–f, 6b–h, 7b–h, 8b–g, 9a–
d, and Supplementary Figs 1a–c, 1f, 1i, 2a–e, 3a, 3c–j, 3l–m, 4c, 4e, 4g, 5b–f, 6a–b,7b, 7d–e, 7g–h, 8c–j, 9d–e, 
10b, 11a–d are provided in the Source Data file. Microarray data that support the findings of this study are provided 
in the Supplementary Table 2, and the latter have been deposited in NCBI Gene Expression Omnibus (GEO) under 
the accession number GSE120683 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120683]. 
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Figure 1 Abnormal mitochondrial network in MMA kidney cells. (a) Immunoblotting and quantification of MMUT protein levels and (b) MMUT enzyme activity in control and MMA kidney cells, n=3 independent experiments. β–actin used as 
loading control. (c and g) Cells were transduced with adenoviral particles bearing the mitochondrially‒targeted green fluorescent protein (Ad‒mito‒GFP, green). (c) After 24h post‒transduction, the cells were immunostained for MMUT (red) and 
imaged by confocal fluorescence microscopy. Yellow indicates the colocalization. (d) Quantification of methylmalonic acid (MMA) levels by liquid chromatography tandem mass spectrometry (LC–MS/MS, n=3 independent experiments). (e) 
Representative electron micrographs and quantification of the shape (expressed as circularity) of the mitochondrial network in control and MMA kidney cells; n=527 mitochondria pooled from 24 control cells and n=310 mitochondria pooled from 20 
MMA cells. The experiments were performed twice. Dotted yellow squares contain images at higher magnification. (f) Representative electron micrographs showing the mitochondrial network in kidney biopsies from an individual healthy control 
subject and a patient with MMA. (g) Representative inverted confocal micrographs (left) and quantification of shape (expressed as circularity, top right) or  interconnectivity (bottom right) of the mitochondrial network in control and MMA kidney 
cells; each point representing the average values for circularity or interconnectivity in a cell, n=10 cells per each condition pooled from two independent experiments. Plots represent mean ± SEM. Two tailed Student’s t test, *P<0.05, ***P<0.001 and 








Figure 2. Mitochondrial dysfunctions in MMA kidney cells. (a) Representative immunoblotting and quantification of the indicated mitochondrial proteins; n=5 independent experiments. (b) The ratio between mitochondrial DNA (ND1) and nuclear 
DNA (ACTB) was analysed by quantitative PCR; n=4 independent experiments. (c) Cells were immunostained for ATP5B (red) and imaged by confocal microscopy. Representative confocal micrographs and quantification of numbers of ATP5B+ 
structures per cell (each point representing the number of ATP5B+ structures in a cell; n=27 control cells and n=40 MMA cells pooled from three independent experiments;). Nuclei counterstained with DAPI (blue). (d‒e) Cells were exposed to 
mitochondrial complex I inhibitor Rotenone (Rot, 5 µM). After 24 h of treatment, the cells were loaded (d) with tetramethylrhodamine methyl ester (TMRM; green; mitochondrial membrane potential fluorescent probe, 50 nM for 30 min at 37°C) and 
MitoTracker (red; fluorescent probe that localizes to mitochondria; 1 M for 30 min at 37°C) or (e) with MitoSOX (green; mitochondrial ROS indicator, 2.5 µM for 25 min at 37°C) and MitoTracker (red), and analysed by confocal microscopy. 
Representative confocal micrographs and quantification of (d) membrane potential and (e) mitochondrial ROS (both calculated as ratios between TMRM and MitoTracker or MitoSOX and MitoTracker fluorescence intensities, with each point 
representing the average fluorescence intensity ratio in a cell). TMRM/MitoTracker: n=21 untreated and Rot−treated control cells, n=22 untreated MMA cells and n=18 Rot−treated MMA cells. MitoSOX/MitoTracker: n=31 untreated control cells and 
n= 40 Rot−treated control cells n=36 untreated MMA cells and n= 31 Rot−treated MMA cells. Data were pooled from three independent experiments. (f) Oxygen consumption rate (OCR) and individual parameters for basal respiration, ATP production 
and maximal respiration. OCRs were measured at baseline and upon the sequential addition of Oligomycin (Oligo, 1 µM), FCCP (0.5 µM) and Rotenone (Rot; 1 µM) + Antimycin A (Ant; 1 µM), n=3 independent experiments. (g) Immunoblotting 
and quantification of the indicated proteins; n=3 independent experiments. Plots represent mean ± SEM. Two tailed Student’s t test, *P<0.05, **P<0.01, ***P<0.001 and #P<0.0001 relative to untreated control or to Rot−treated control cells or to 






Figure 3. Mitochondrial abnormalities and phenotypic changes in mmut–deficient zebrafish. (a) Quantification of MMA levels by LC–MS/MS; n=8 mmut+/+ and n=12 mmutdel11/del11 zebrafish. (b−c) Representative electron micrographs and 
quantification of the mitochondrial shape (expressed as circularity) in (b) livers and in (c) kidneys of 10‒dpf–mmut zebrafish (n=9 and n=15 randomly selected fields of views pooled from three mmut+/+ and mmutdel11/del11 zebrafish livers, respectively; 
n=10 and n=13 randomly selected fields of views pooled from three mmut+/+ and mmutdel11/del11 zebrafish kidneys, respectively). Dotted yellow squares contain images at higher magnification. (d) Oxygen consumption rate (OCR) and individual 
parameters for basal respiration in 10‒dpf–mmut zebrafish, n= 6 mmut+/+ and 12 mmutdel11/del11 zebrafish. (e) Zebrafish expressing mito‒Grx1‒roGFP2 in the liver were outcrossed with mmut +/del11 zebrafish. Quantification of ratios between 405 (blue) 
and 488 (green) fluorescence intensities, with each point representing the average fluorescence intensity ratio in a zebrafish liver; n=11 mmut+/+ and n=12 mmutdel11/del11 zebrafish. (f) Tracking analyses of motor behavior in 10‒dpf–mmut zebrafish fed 
with a high or low protein diet (HP or LP, respectively). Quantification of the covered distance, with each point representing the average distance covered by an individual zebrafish; n=28 HP‒fed mmut+/+, n=26 LP‒fed mmut+/+, n=23 HP‒fed 
mmutdel11/del11 and n=27 LP‒fed mmutdel11/del11 zebrafish. (g) Distribution of mmut zebrafish (calculated as percentage of the total larvae) in HP or LP‒fed at 5 and 14‒dpf or in mmut zebrafish stably expressing mmut in the liver; n≥3 independent 
experiments, with each containing ~100 mmut zebrafish larvae. Plots represent mean ± SEM. Two tailed Student’s t test, *P<0.05, **P<0.01 and #P<0.0001 relative to mmut+/+ or HP-mmutdel11/del11 in a, b, c, d and e. One‒way ANOVA followed by 







Figure 4. MMUT deficiency stimulates autophagy in MMA cells. (a‒b) Cultured cells were exposed to lysosome‒based proteolysis inhibitor Bafilomycin A1 (Bfn A1, 250 nM for the indicated time). Representative immunoblotting and 
quantification of LC3‒II protein levels; n=3 independent experiments. Two tailed Student’s t test, *P<0.05 and **P<0.01 relative to untreated control or MMA cells. (b) Representative inverted confocal micrographs and quantification of numbers of 
punctate LC3+ structures, with each point representing the average number of LC3+ structures in a cell; n= 122 untreated control cells, n= 127 Bfn A1−treated control cells, n= 127 untreated MMA kidney cells and n=77 Bfn A1−treated MMA kidney 
cells. Data were pooled from three independent experiments. One‒way ANOVA followed by Bonferroni’s post hoc test, ***P<0.001 relative to untreated control or MMA cells. (c) Representative electron micrographs and quantification of 
cytoplasm area occupied by autophagy vacuoles (AV; expressed as percentage of the total area); n=43 control cells and n=45 MMA cells. Data were pooled from two independent experiments. Arrowheads indicate EM–compatible AV. (d–e) 
Immunoblotting and quantification of (d) phosphorylated and total forms of mTORC1 substrates and (e) of FIP200 and ATG13 protein levels, n=3 independent experiments. (f) Representative inverted confocal micrographs and quantification of 
numbers of ATG13+ (top panel) or PtdIns‒3P+ (middle panel) or WIPI2+ (bottom panel) structures, with each point representing the average number of positive structure in a cell. Number of ATG13+ structures: n= 86 control cells and n=118 MMA 
cells. Number of PtdIn‒3P+ structures: n= 41 control cells and n=141 MMA cells. Number of WIPI2+ structures: n=71 control cells and n=253 MMA cells. Data were pooled from three independent experiments. Plots represent mean ± SEM. Two 
tailed Student’s t test, *P<0.05, **P<0.01, ***P<0.001 and #P<0.0001 relative to control cells in c, d, e and f. β‒actin was used as loading control in a, d and e. Scale bars are 10 m in b and f, and 1 m and 250nm in c (left and right panel, 






Figure 5. Impaired mitophagy‒mediated degradation of MMA diseased mitochondria. (a−f) Cells were exposed to Rotenone (5 µM) for the indicated time. (a) Immunoblotting and quantification of indicated mitochondrial proteins; 
n=3 independent experiments. GAPDH used as loading control. (b) The ratio between mitochondrial (ND1) and nuclear DNA (ACTB) was determined by qPCR; n= 4 independent experiments. (c) Workflow of the strategy used to monitor the cellular 
delivery of damaged mitochondria to lysosomal compartments. Cells were transduced for 24h with adenoviral particles bearing the mitochondrially–targeted form of Keima (mt‒Keima). Representative confocal micrographs and quantification of ratios 
of red/green fluorescence signal, with each point representing the average red/green fluorescence intensity ratio in a cell; n=46 untreated control cells and n=52 Rotenone−treated control cells, and n=51 untreated MMA cells and n=53 Rotenone−treated 
MMA cells. (d‒f) Cells were transduced with adenoviral particles bearing the mitochondrially‒targeted green fluorescent protein (Ad‒mito‒GFP). After 24h post‒transduction, the cells were exposed to Rotenone for 4h, immunostained for with Parkin 
(magenta) and analyzed by confocal microscopy. (d) Representative confocal micrographs and quantification of numbers of (e) Parkin+ and (f) GFP/Parkin+ structures. Number of Parkin+ structures, with each point representing the number of positive 
structures in a cell: n=30 untreated and Rotenone−treated control cells, n=39 untreated MMA cells and n=52 Rotenone−treated MMA cells. Number of GFP/Parkin+ structures (expressed as percentage of total mitochondria): n=5 randomly selected 
fields of views per condition, with each containing ~10 cells. (g) Representative electron micrographs (EM) showing the engulfment of mitochondria within EM‒compatible, double membrane‒autophagic vacuoles in control but not in MMA kidney 
cells. Data were pooled from three independent experiment in c, e and f. Plots represent mean ± SEM. Two tailed Student’s t test, *P<0.05, **P<0.01 and ***P<0.001 relative to untreated control cells or to Rotenone‒treated control cells in a, b and 
in f. One‒way ANOVA followed by Bonferroni’s post hoc test, *P<0.05 and ***P<0.001 relative to untreated control cells or to Rotenone‒treated control cells in c and e. Scale bars are 10 µm in c and in d, and 250nm in g. NS, non‒significant. 







Figure 6. Rescue of mitochondrial function and homeostasis by re‒expressing PINK1 in MMA kidney cells. (a‒c) Cells were transduced with adenovirus expressing mitochondrially‒targeted GFP (green) and subsequently with adenovirus 
bearing Null (Ad‒Null) or HA−PINK1 (red). (a) Representative confocal micrographs and (b) quantification of numbers of Parkin+ structures in a cell. Numbers of control cells transduced with Ad−Null (n= 25) or Ad−PINK1 (n=39) and of MMA 
cells transduced with Ad−Null (n= 57) or HA−PINK1 (n=55). (c) Quantification of mito‒GFP/Parkin+ structures (expressed as percentage of total mitochondria); n≥4 fields of views for control and MMA cells. Nuclei counterstained with DAPI 
(blue). (d‒e) Null and HA‒PINK1 expressing cells were transduced with adenovirus particles bearing mt‒Keima and analysed by confocal microscopy. (d) Quantification of red/green fluorescence intensity ratio in a cell. Numbers of control cells 
transduced with Ad−Null (n=46) or HA−PINK1 (n=38) and of MMA cells transduced with Ad−Null (n=51) or HA−PINK1 (n=54). (e) Representative immunoblotting and quantification of the indicated mitochondrial proteins; n=5 independent 
experiments. (f‒g) Cells were loaded with (f) TMRM (green) or (g) MitoSOX (green) and MitoTracker (red), and analysed by confocal microscopy. Quantification of TMRM/MitoTracker or MitoSOX/MitoTracker fluorescence intensity ratio in a 
cell. Numbers of control cells transduced with Ad−Null (n=43) or HA−PINK1 (n=62) and of MMA cells transduced with Ad−Null (n=83) or HA−PINK1 (n=84) for TMRM/MitoTracker. Numbers of control cells transduced with Ad−Null (n=38) or 
HA−PINK1 (n=56) and of MMA cells transduced with Ad−Null (n=59) or HA−PINK1 (n=64) for MitoSOX/MitoTracker. (h) Oxygen consumption rate (OCR) and individual parameters for basal respiration, ATP production and maximal 
respiration. OCRs were measured at baseline and upon the sequential addition of Oligomycin (Oligo, 1µM), FCCP (0.5 µM) and Rotenone (Rot; 1µM) + Antimycin A (ANT; 1µM). Data in a−h were pooled from three independent experiments. 
Plots represent mean ± SEM. One‒way ANOVA followed by Bonferroni’s post hoc test, *P<0.05 and ***P<0.001 relative to control or MMA cells transduced with Ad‒Null in b, d, f and g. Two tailed Student’s t test, *P<0.05, **P<0.01, 







Figure 7. MMUT deletion damages mitochondria and blunts PINK1–directed mitophagy triggering epithelial stress in kidney cells. (a‒i) mPT cells from floxed Mmut kidneys transduced with adenovirus bearing Empty (Ad‒Empty) 
or Cre recombinase (Ad‒Cre) for 5 days. (a) Workflow of strategy used to generate the floxed Mmut alleles. (b–c) Validation of Mmut deletion by (b) immunoblotting (n=4 independent experiments) and (c) by LC–MS/MS analysis of MMA levels, 
n=9 samples pooled from three independent experiments. (d) Cells were loaded with TMRM (green) and MitoTracker (red) and analysed by confocal microscopy. Quantification of fluorescence inten sity ratio in a cell. Numbers of cells transduced 
with Ad−Empty (n=25) or Ad−Cre (n=45). (e) Oxygen consumption rate (OCR) and individual parameters for basal respiration, ATP production and maximal respiration. OCRs were measured at baseline and upon the sequential addition of Oligomycin 
(Oligo), FCCP and Rotenone (Rot) + Antimycin A (Ant); n=3 independent experiments. (f) Mmut cells were transduced for 24h with an adenovirus expressing mitochondrially–targeted form of Keima (mt‒Keima) and exposed to Rotenone (Rot, 5 
M for 24h). Representative confocal micrographs and quantification of red/green fluorescence intensity ratio in a cell. Numbers of untreated (n=68) and Rot−treated (n=57) control cells, and of untreated (n=51) and Rot−treated (n=58) Mmut deleted 
cells. (g‒h) Control and Mmut‒deleted cells were transduced with an adenovirus expressing Null or HA–PINK1 for 24 h. (g) Cells were loaded with MitoSOX (green) and analysed by confocal microscopy. Representative confocal micrographs and 
quantification of MitoSOX fluorescence intensity, n≥4 randomly selected fields of views, with each containing ~ 10cells. (h) Representative immunoblotting and quantification of LCN2 levels, n=4 independent experiments. ‒actin used as loading 
control. Data in d, f and g were pooled from three independent experiments Plots represent mean±SEM. Asterisks denote non‒specific bands in b and h. Two tailed Student’s t test, *P<0.05, **P<0.01, ***P<0.01 and #P<0.0001 relative to control cells 
in b, c, d and e or relative to control or Mmut‒deleted cells transduced with Ad‒Null in h . One‒way ANOVA followed by Bonferroni’s post hoc test, **P<0.01and ***P<0.001 relative to untreated control cellsor relative to control or Mmut‒deleted 







Figure 8. Mitochondrially‒targeted ROS scavenger mito–TEMPO repairs mitochondrial functions in MMA cells. (a) Gene ontology (GO) annotations significantly upregulated (red) and downregulated (green) by the in silico‒prioritized hits 
according to Drug Set Enrichment Analysis (DSEA). (b‒g) Cells were treated with mito‒TEMPO (MT; 10m for 24h). (b) Quantification of MMA levels by LC–MS/MS; n=6 samples pooled from three independent experiments. One‒way ANOVA 
followed by Bonferroni’s post hoc test, ***P<0.001 relative to untreated control or MMA cells (c) Cells were transduced with adenovirus bearing the mitochondrially‒targeted GFP (green). After 24h post‒transduction, the cells were  treated with MT, 
and analysed by confocal microscopy. Representative inverted confocal micrographs and quantification of circulari ty (expressed as circularity) and interconnectivity of the mitochondrial network. Circularity: n= 15 cells per each condition. 
Interconnectivity: n=15 untreated and MT−treated control cells, n=15 untreated MMA cells and n=13 MT−treated MMA cells. Data were pooled from three independent experiments. One‒way ANOVA followed by Bonferroni’s post hoc test, *P<0.05 
and ***P<0.001 relative to untreated control or MMA cells. (d) Representative immunoblotting and quantification of the indicated mitochondrial proteins, n=3 independent experiments. −tubulin used as loading control. (e) Oxygen consumption rate 
(OCR) and individual parameters for basal respiration, ATP production and maximal respiration. OCRs were measured at baseline and upon the sequential addition of Oligomycin (Oligo), FCCP and Rotenone (Rot) + Antimycin A (Ant), n=3 
independent experiments. (f) Cells were loaded with MitoSOX (2.5 M for 25 min at 37°C and MitoTracker (red; 1M for 25 min at 37°C), and analysed by confocal microscopy. Representative confocal micrographs and quantification of mitochondrial 
ROS (calculated as ratio between MitoSOX and MitoTracker fluorescence intensities; each point representing the average fluorescence intensity ratio in a cell. Numbers of untreated (n=36) or MT−treated (n=28) control cells and of untreated (n=51) 
or MT−treated (n=28) MMA cells. Data were pooled from three independent experiments. One‒way ANOVA followed by Bonferroni’s post hoc test, ***P<0.001 relative to untreated control or MMA cells. (g) Representative immunoblotting and 
quantification of LCN2 levels, n=4 independent experiments. ‒actin used as loading control Plots represent mean ± SEM. Two tailed Student’s t test, *P<0.05, **P<0.01 and ***P<0.001 relative to untreated control or MMA cells ind, e and g. Scale 






Figure 9. Mitochondrially‒targeted ROS scavenger MitoQ rescues the MMA–associated phenotypes in mmut–deficient zebrafish. (a‒d) Zebrafish were treated with vehicle or with the mitochondria‒targeted ROS scavenger MitoQ (200 nM 
for 24h). (a) Representative confocal micrographs and quantification of ratios between 405 (blue) and 488 (green) fluorescence intensities in mmut zebrafish expressing mito‒Grx1‒roGFP2 in the liver. Each point represents the average fluorescence 
intensity ratio in a zebrafish liver; n= 6 untreated mmut+/+ zebrafish and n=7 untreated mmutdel11/del11 zebrafish, and n=5 MitoQ‒treated mmutdel11/del11 zebrafish. Kruskal‒Wallis followed by Dunn’s multiple comparison test, *P<0.05 and **P<0.01 
relative to vehicle‒treated mmut+/+ or mmutdel11/del11 zebrafish. (b) Tracking analyses of motor behavior in 10‒dpf mmut zebrafish. Quantification of covered distance, with each point representing the average distance covered by an individual zebrafish; 
n=28 vehicle‒treated mmut+/+ and n=27 vehicle‒treated mmutdel11/del11 and n=31 MitoQ‒treated mmutdel11/del11. One‒way ANOVA followed by Bonferroni’s post hoc test, *P<0.05 and **P<0.01 relative to vehicle‒treated mmut+/+ or to mmutdel11/del11 
zebrafish. (c) Distribution of mmut zebrafish (calculated as percentage of total larvae) after treatment with vehicle or MitoQ. Chi–square goodness of fit test, ***P<0.001 and #P<0.0001 relative to vehicle−treated mmut+/+ or mmutdel11/del11 zebrafish. 
Data derived from one experiment (n≥77mmut zebrafish per each group). (d) Quantification of MMA levels by LC–MS/MS; n= 5 vehicle−treated mmut+/+ zebrafish and n=9 vehicle−treated mmutdel11/del11 zebrafish and n=8 MitoQ‒treated mmutdel11/del11 
zebrafish. Plots represent mean ± SEM. Kruskal‒Wallis followed by Dunn’s multiple comparison test, **P<0.01 relative to vehicle‒treated mmut+/+ or mmutdel11/del11 zebrafish. Scale bars, 100 m. NS: non‒significant. Source data are provided as a 







Figure 10. Proposed model depicting the link between mitochondrial dysfunction and epithelial stress in MMA. In wild type kidney cells (left), mitochondrial stress (e.g. treatment with Rotenone) stimulates PINK1‒induced translocation of 
Parkin to damaged mitochondria. This triggers the activation of mitophagy and the subsequent disposal of dysfunctional mitochondria through autophagy–lysosome degradation systems, hence safeguarding the homeostasis and function of the 
mitochondrial network. By contrast, in MMA–affected kidney cells (right), the impaired PINK/Parkin‒mediated mitophagy impedes the delivery of damaged mitochondria and their degradation by autophagy‒lysosome systems. This leads to the 
accumulation of diseased mitochondria and exacerbates the mitochondrial alterations induced by MMUT deficiency, including accumulation of toxic metabolites, collapsed mitochondrial membrane potential (m), and abnormal energetic profiling 
and increased mitochondrial ROS. These mitochondrial defects trigger epithelial stress, causing ultimately cell damage (e.g. LCN2 overproduction). Drug–disease network perturbation modeling, based on gene expression profiles from MMA patient‒
derived kidney cells against a large compendium of gene expression signatures derived from 1309 small bioactive drug compounds, identifies targetable disease–relevant biological pathways. The modulation of the identified targets (e.g. treatment 
with mitochondria‒targeted ROS scavengers MT or MitoQ) repairs mitochondrial dysfunctions, neutralizes epithelial stress and cell damage in MMA cells, and improves disease–relevant phenotypes in mmut–deficient zebrafish. 
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Supplementary Figure 1 
 
 
Supplementary Figure 1. Tissue, nephron–segment and intracellular compartmentalization of the enzyme MMUT, and characterization of MMA patient‒derived cells.(a) Transcript and (b) protein expression of the enzyme Mmut in mouse 
tissues were determined by reverse transcription‒ quantitative PCR (RT‒qPCR; n=3 mice) and by immunoblotting (n=4 mice), respectively. Protoblue was used as loading control. (c) Transcript levels of Mmut in nephron specific segments were 
measured by RT−qPCR. The abundance of each segment–related gene (GLOM=Nphs2; PCT=Scl5a2; PST=Slc38a3; TAL=Slc12a1; DCT=Slc12a3 and CD=Aqp2) defines the purity of each segment fraction. Quantification of all segment specific 
marker genes was performed in comparison with Gapdh as an endogenous control (n=3 mice). (d) Representative images showing the segment‒specific compartmentalization of Mmut (red) in LTL+ (green, left) proximal tubules or in UMOD+ (green, 
middle) thick ascending limb tubules or in AQP2+ (green, right) collecting duct. G denotes glomerulus. (e) Cells were transduced with adenoviral particles expressing the mitochondrially‒targeted green fluorescent protein (Ad‒mito‒GFP). After 24h 
post‒transduction, the cells were immunostained for MMUT (red) and imaged by confocal microscopy. Yellow indicates the coloca lization. Dotted white squares represent regions of the respective panels magnified. (f) Cell viability was assessed by 
Cell Counting Kit‒8 (CCK‒8) assay; n=6 replicates pooled from three biologically independent experiments. (g) Growth curves in control and MMA kidney cells, n=3 biologically independent experiments. (h‒i) Transcript levels of (h) MFN1, MFN2, 
DRP1 and OPA1 or (i) LCN2 were measured by RT−qPCR; n=6 replicates in h and n=9 replicates in i. Values in h and i are pooled of three biologically independent experiments. Plots represent mean ± SEM. Two tailed Student’s t test, ***P<0.001 
relative to control cells. Nuclei counterstained with DAPI (blue) in d and e. Dotted white squares represent regions of the respective panels magnified in d and e. Scale bars are 30 m in d and 10 m in e. GLOM, glomerulus; PCT, proximal convoluted 




Supplementary Figure 2 
 
 
Supplementary Figure 2. Autophagy deficiency leads to mitochondrial dysfunctions in kidney tubule cells. (a–e) Primary cultures of proximal tubule cells derived from mouse kidneys were transduced with adenovirus particles carrying scrambled 
or Atg7 short hairpin RNA (shRNA) for 5 days. (a) Transcript levels of Atg7 and Gapdh were measured by RT‒qPCR; n=6 replicates pooled from three biologically independent experiments. (b‒c) Cultured cells were loaded with (b) 
tetramethylrhodamine methyl ester (TMRM, green; mitochondrial membrane potential fluorescent probe, 50 nM for 30 min at 37°C) and MitoTracker (red; fluorescent probe that localizes to mitochondria, 1 µM for 30 min at 37°C) or with (c) MitoSOX 
(green; mitochondrial ROS indicator, 2.5 µM for 30 min at 37°C) and MitoTracker (red), and analyzed by confocal microscopy. Representative images and quantification of (b) membrane potential and (c) mitochondrial ROS production (both 
calculated as ratio between TMRM and MitoTracker or MitoSOX and MitoTracker fluorescence intensities, with each point representing the average fluorescence intensity ratio in a cell). TMRM/MitoTracker: n=24 control cells and n=23 Atg7-deleted 
cells. MitoSOX/MitoTracker: n=24 control cells and n=21 Atg7-deleted cells. Values are pooled from three biologically independent experiments. (d) Oxygen consumption rate (OCR) and individual parameters for basal respiration, ATP production, 
proton leak and maximal respiration. OCRs were measured at baseline and after the sequential addition of Oligomycin (Oligo, 1 M), FCCP (0.5 M) and Rotenone (Rot; 1µM) + Antimycin A (Ant; 1 M); n=11 replicates pooled from four biologically 
independent experiments (for cells transduced with Ad−Scmb shRNA) and n=18 replicates pooled from six biologically independent experiments (for cells transduced with Ad−Atg7 shRNA). (e) Immunoblotting and quantification of Lcn2, n=4 





Supplementary Figure 3 
 
 
Supplementary Figure 3. Mitochondrial and kidney phenotypes in Mmut KO/KI mice. (a) Quantification of MMA levels in the urines of 32‒36‒ week‒old MmutWT/KI and MmutKO/KI using LC–MS/MS; n=6 animals per each group. (b) Representative 
electron micrographs showing the mitochondrial network in 20‒week‒or 36‒week‒old kidney tubules of MmutWT/KI and MmutKO/KI mice. (c‒d) Primary cultures of proximal tubule cells derived from 20 week‒old kidneys of Mmut WT/KI and Mmut KO/KI 
mice were loaded (c) with tetramethylrhodamine methyl ester (TMRM; green; mitochondrial membrane potential fluorescent probe, 50 nM for 30 min at 37°C)  and MitoTracker (red; fluorescent probe that localizes to mitochondria; 1 M for 30 min 
at 37°C) or with (d) MitoSOX (green; mitochondrial ROS indicator, 2.5 M for 25 min at 37°C) and MitoTracker (red), and analyzed by live confocal fluorescence microscopy. Representative confocal m icrographs and quantification of TMRM or 
MitoSOX fluorescence intensities; n=3 randomly selected fields of views, with each containing ~10 cells (for TMRM) and n4 randomly selected fields of views, with each containing ~10 cells (for MitoSOX). Data are pooled from three independent 
experiments. (e‒f) Quantifications of (e) urea and (f) creatinine, and measurements of (g) creatinine clearance in 32‒36 ‒week‒old Mmut mice, n=8 animals per group. (h‒i) Levels of Lcn2 (h) in plasma or (i) urine harvested from 32‒36‒ week‒old 
Mmut mice were measured by ELISA, n= 5 MmutWT/KI and n= 4 MmutKO/KI. (j) Immunoblotting and quantification of Lcn2 protein levels in whole‒tissue lysates harvested from kidneys of 32‒36 ‒week‒old Mmut mice (n=3 mice per each group). ‒
tubulin used as loading control. (k) Representative micrographs and detection of collagen deposition by Picro Sirius Red staining in kidneys of 32‒36 ‒week‒old Mmut mice. (l‒m) Representative confocal micrographs and quantification of numbers 
of (l) CD3+ cells (marker of T cells; red) or (m) Ly6G+ (marker of granulocytes, monocytes and neutrophils; red) in kidneys of 32‒36‒ week‒old Mmut mice. Proximal tubules labelled by Lotus Tetragonolobus Lectin (LTL; green); n=30 randomly 
selected fields of views. Data are pooled from three mice. Dotted yellow squares contain images at higher magnification. Arrowheads indicate the CD3 or Ly6G positive cells. Plots represent mean ± SEM. Two tailed Student’s t test, *P<0.05, **P<0.01 
and ***P<0.001 relative to MmutWT/KI. Nuclei counterstained with DAPI (blue). Scale bars are 1m in b, 10 m in c and d, 1mm in k and 20m in l and m. NS: non‒significant. 
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Supplementary Figure 4. Generation, validation and characterization of mmut knockout zebrafish model. (a) CRISPR‒Cas9‒induced deletion (green) generates a frameshift of the open reading frame, resulting in a premature stop codon (TGA) 
within the exon 3 of mmut gene (middle panel) that produces a truncated protein of 141 amino acids. The underlined sequence represents the AlwNI site used for the detection of the deletion. (b) AlwNI digestion of PCR products after the amplification 
of the CRISPR‒Cas9 targeting region using genomic DNA extracted from caudal of wild‒type (+/+), heterozygous (+/del11) and homozygous (del11/del11) zebrafish. Wild type allele: two lower bands 333bp + 120bp correspond to PCR products cut 
by AlwNI. Mutant allele: upper band 453bp, resistant to AlwNI digestion. (c) Transcript levels of mmut in zebrafish kidneys was determined by RT‒qPCR; n=5 animal per each group. (d) Representative images of mmut+/+and mmutdel11/del11zebrafish 
embryos at 5‒dpf. (e) Quantification of MMA levels in mmut zebrafish by LC–MS/MS; n=8 mmut+/+ zebrafish and n=16 mmutdel11/del11 zebrafish and n=5 mmutdel11/del11 zebrafish expressing mmut in the liver. (f) Tracking analyses of motor behavior in 
10‒dpf–mmut zebrafish larvae fed high or low protein diet. (g) Quantification of mean covered distance, with each point representing the mean distance covered by an individual zebrafish;  n=36 mmut+/+ zebrafish and n=34 mmutdel11/del11 zebrafish and 
n=33 mmutdel11/del11 zebrafish expressing mmut cDNA in the liver. Plots represent mean ± SEM. Two tailed Student’s t test, #P<0.0001 relative to mmut +/+ in c. One‒way ANOVA followed by Bonferroni’s post hoc test, ***P<0.001 relative to mmut +/+ 




Supplementary Figure 5 
 
 
Supplementary Figure 5. Dysregulation of autophagy in MMA kidney cells. (a) Cells were transduced with GFP‒tagged Map1lc3b (Ad–GFP‒Map1lc3b) bearing adenoviral particles for 24h. The punctate GFP‒LC3+ structures were imaged by 
live confocal fluorescence microscopy. Selected cells were further processed, and serial sections were analyzed by electron m icroscopy. (b) Cells were cultured in presence or in absence of Bafilomycin A1 (Bfn A1, 250 nM for 4h). Representative 
confocal micrographs and quantification of numbers of LC3/LAMP1+ structures (expressed as percentage of total lysosomes; n= 4 randomly selected fields per condition, with each containing ~10 cells. Data are pooled from two independent 
experiments. Yellow indicates colocalization. (c) Immunoblotting and quantification of LAMP1, Cathepsin D (CtsD) and RAB7 protein levels; –actin used as loading control. Two tailed Student’s t–test, #P<0.0001 relative to control cells, n=3 
independent experiments. (d) Cells were loaded Bodipy‒FL‒Pep A (1 M, for 1h at 37°C), fixed and analysed by confocal microscopy. Quantification of numbers of Pep A+ structures, with each point representing the number of Pep A+ structures in a 
cell; n= 30 cells pooled from three independent experiments. (e) Transcript levels of SQSTM1 and GAPDH in control and in MMA cells were measured by RT‒qPCR; n=6 pooled from three independent experiments. (f) Control and MMA kidney cells 
were treated with the mitochondrially‒targeted ROS scavenger mito–TEMPO (MT, 10 m for 24h) or with the proteasome inhibitor MG132 (50 m for 16h). Representative immunoblotting and quantification of ubiquitin, SQSTM1 and GAPDH 
protein levels in the soluble and insoluble fractions obtained from control and MMA cells. Two tailed Student’s t–test, *P<0.05 relative to untreated control or MMA kidney cells, n=3 independent experiments. Asterisk denotes the presence of non–
specific bands. (g) Representative confocal micrographs of LC3 (top panel, red) and of SQSTM1 (bottom panel, red)  in kidney biopsy samples from an individual healthy control subject and patient with MMA. Kidney proximal tubules labelled by 
LTL (green). Nuclei counterstained with DAPI. Scale bars are 10m (left panel) and 2m (middle panel) and 250nm (right panel) in a, 10m in b and d, and 30m in g. NS: non‒significant.  
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Supplementary Figure 6. Inhibition of Vps34‒induced PtdIns‒3P production blocks autophagosome biogenesis. (a‒b) Cells were exposed to the highly selective Vps34 inhibitor SAR405 (5 M for 4h). (a) Representative inverted confocal 
micrographs and quantification of numbers of PdtIns‒3P+ structures, with each point representing the average number of PdtIns‒3P+ structures in a cell; n=45 untreated control cells, n= 93 SAR405−treated control cells, n=141 untreated MMA cells 
and n=114 SAR405−treated MMA cells. Data are pooled from three independent experiments. One‒way ANOVA followed by Bonferroni’s post hoc test, **P<0.01 and ***P<0.001 relative to untreated control or MMA cells. (b) Representative 
immunoblotting and quantification of LC3 protein levels, n=4 independent experiments. ‒actin used as a loading control. Two tailed Student’s t test, *P<0.05 and ***P<0.001 relative to untreated control or MMA cells. NS: non‒significant. 
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Supplementary Figure 7 
 
Supplementary Figure 7. Mitophagy in MMA cells or in proximal tubule cells derived from floxed Atg7 or from Pink1 or Prkn2 knockout mice. (a) Cells were exposed to Oligomycin (4 M) and Antimycin (0.8 M) for the indicated times. 
Immunoblotting of the indicated mitochondrial proteins, n=2 independent experiments. (b) Cells were cultured under normal growth (fed) or nutrient‒deprived (starve) conditions or exposed to Rotenone (Rot, 5 m for 24h) and immunostained for 
PMP70 (red), and analysed by confocal microscopy. Representative confocal micrographs and quantification of PMP70+ structures per cell, with each point representing the number of PMP70+ structures in a cell; n= 142 fed control cells, n=181 starved 
control cells and n= Rot−treated control cells, n=189 fed MMA cells, n=196 starved MMA cells and n=212 Rot−treated MMA cells. Data are pooled from three independent experiments. One‒way ANOVA followed by Bonferroni’s post hoc test, 
***P<0.001 relative to fed control or MMA cells. Nuclei counterstained with DAPI (blue). (c‒d) Primary cultures of proximal tubule cells derived from kidneys of floxed Atg7 mice were transduced with Empty (Ad‒Empty) or Cre recombinase (Ad‒
Cre) bearing adenoviral particles for 5 days. (c) Validation of the deletion of Atg7 by immunoblotting, n=4 independent experiments. (d) Control and Atg7‒deleted cells were transduced for 24h with adenoviral particles bearing mitochondrially–
targeted form of Keima (mt−Keima), and exposed to Rot. Representative confocal micrographs and quantification of ratios of red/green fluorescence signal, with each point representing the average red/green fluorescence intensity ratio in a cell; n=54 
untreated control cells, n=55 Rot−treated control cells, n=46 untreated Atg7 deleted cells and n=44 Rot−treated Atg7 deleted cells. Two tailed Student’s t test, #P<0.001 relative to untreated or Rot−treated control cells. (e) Transcript levels of Pink1 
and Gapdh were assessed by RT‒qPCR in 12‒week‒old brain of Pink1 WT and KO mice; n=4 WT brains and n=3 KO brains. (f) Immunoblotting of Parkin in Prkn2 WT and KO kidneys or in HeLa cells. (g) WT, Pink1 and Prkn2 KO cells were 
transduced for 24h with adenoviral particles bearing mitochondrially–targeted form of Keima (mt−Keima). After 24h post−transduction, the mt−Keima expressing cells were exposed to Rotenone for 24h and analysed by confocal microscopy. 
Representative confocal micrographs and quantification of ratios of red/green fluorescence signal, with each point representing the average red/green fluorescence intensity ratio in a cell; n=50 untreated control cells and n=41 Rot−treated control cells, 
n=82 untreated Pink1 KO cells and n=79 Rot−treated Pink1 KO cells, and n=55 untreated Prkn2 KO cells and n=44 Rot−treated Prkn2 KO cells. One‒way ANOVA followed by Bonferroni’s post hoc test, ***P<0.001 relative to untreated WT cells or 
to Rotenone‒treated WT cells. (h) Transcript levels of mt‒Keima and GAPDH in control and MMA kidney cells were measured by RT‒qPCR; n=5 independent experiments. –tubulin or ‒actin was used as loading control. Plots represent mean ± 
SEM. Scale bars are 10m. NS: non‒significant 
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Supplementary Figure 8 
 
 
Supplementary Figure 8. Mitochondrial abnormalities in Cox10‒deficient kidney cells are not linked to deficient mitophagy. (a‒j) Primary cultures of proximal tubule cells derived from kidneys of floxed Cox10 mice were transduced with 
Empty (Ad‒Empty) or Cre recombinase (Ad‒Cre) bearing adenoviral particles for 5 days. (a–b) Workflow of strategy used (a) to generate floxed Cox10 alleles and (b) to delete Cox10 gene in vitro in primary cultures of proximal tubule cells derived 
from floxed Cox10 kidneys. (c‒d) Validation of Cox10 deletion (c) by RT‒qPCR (n≥ 8 pooled from four independent experiments) and (d) by immunoblotting, n=3 independent experiments. (e−f) Cultured cells were loaded (e) with 
tetramethylrhodamine methyl ester (TMRM; green; mitochondrial membrane potential fluorescent probe, 50 nM for 30 min at 37°C) and MitoTracker (red; fluorescent probe that localizes to mitochondria; 1M for 30 min at 37°C) or (f) with MitoSOX 
(green; mitochondrial ROS indicator, 2.5 M for 25 min at 37°C) and MitoTracker (red), and analysed by live confocal fluorescence microscopy. Representative confocal micrographs and quantification of (e) membrane potential and (f) mitochondrial 
ROS production (both calculated as ratios between TMRM and MitoTracker or MitoSOX and MitoTracker fluorescence intensities, with each point representing the fluorescence intensity ratio in a cell). TMRM/MitoTracker: n=60 cells transduced 
with Ad−Empty and n=95 cells transduced with Ad−Cre. MitoSOX/MitoTracker: n=74 cells transduced with Ad−Empty and n=56 cells transduced with Ad−Cre. Data are from three independent experiments. (g) Ratio between mitochondrial DNA 
(Nd1) and nuclear DNA (Hbb) was determined by quantitative PCR; n=9 pooled from 3 independent experiments. (h) Immunoblotting and quantification of the indicated mitochondrial proteins; n=5 independent experiments. (i) Control and Cox10 
deleted cells were transduced for 24h with adenoviral particles bearing mt‒Keima and exposed to Rotenone (5M for 24h). Representative confocal micrographs and quantification of ratios of red/green fluorescence signal, with each point representing 
the average red/green fluorescence intensity ratio in a cell; n=39 untreated control cells and n=35 Rot−treated control cells, and n=40 untreated Cox10 deleted cells and n=45 Rot−treated Cox10 deleted cells. One‒way ANOVA followed by Bonferroni’s 
post hoc test, *P<0.05 and ***P<0.001 relative to untreated control cells or Cox10‒deleted cells. (i) Transcript levels of Pink1 and Gapdh in Cox10 cells were determined by RT‒qPCR, n= 9 pooled from three independent experiments. Two tailed 
Student’s t–test, **P<0.01 and #P<0.0001 relative to cells transduced with Ad‒Empty in c, d, e, f, g, h and j. Plots represent mean ± SEM. Scale bars are 10m. NS: non‒significant. 
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Supplementary Figure 9 
 
 
Supplementary Figure 9. Re‒ expression of PINK1 restores mitophagy in patient‒derived and Mmut deleted kidney tubular cells. (a‒c) Representative micrographs of experiments plotted in figure 6d, 6f and 6g. (d) Immunoblotting and 
quantification of the indicated mitochondrial proteins; n=3 independent experiments.(e) Control and Mmut deleted cells expressing Ad‒Null or Ad‒HA‒PINK1 were subsequently transduced for 24h with adenoviral particles bearing matrix 
mitochondrially–targeted form of Keima (mt‒Keima), and analyzed by live confocal microscopy. Representative confocal micrographs and quantification of ratios of red/green fluorescence signal, with each point representing the average red/green 
fluorescence intensity ratio in a cell; n= 57 control cells transduced with Ad‒Null and n= 65 control cells transduced with Ad‒HA‒PINK1, and n= 55 Mmut deleted cells transduced with Ad‒Null; n= 59 Mmut deleted cells transduced with Ad‒HA‒








Supplementary Figure 10. Generation and validation of PINK1 or PRKN2 knockout HAP‒1 cells. (a) CRISPR‒Cas9‒induced deletion (green) generates a frameshift of the open reading frame, resulting in premature stop codon (TGA) within the 
exon 2 of PINK1 gene, which ultimately produces a truncated protein of 148 amino acids. (b) Validation of the PINK1 deletion by RT‒qPCR, n=8 pooled from 4 independent experiments. Plots represent mean ± SEM. Two tailed Student’s t–test, 
#P<0.0001 relative to WT cells. (c) CRISPR‒Cas9‒induced deletion (green) generates a frameshift of the open reading frame, resulting in premature stop codon (TGA) within the exon 3 of PRKN2 gene, which ultimately produces a truncated protein 










Supplementary Figure 11. Deficiency of PINK1 or PRKN2 leads to mitochondrial alterations in HAP‒1 cells. (a and c) Cultured cells were loaded (a) with MitoSOX (green; mitochondrial ROS indicator, 2.5 M for 25 min at 37°C) and 
MitoTracker (red; fluorescent probe that localizes to mitochondria; 1M for 30 min at 37°C) or with tetramethylrhodamine methyl ester (TMRM; green; mitochondrial membrane potential fluorescent probe, 50 nM for 30 min at 37°C) and MitoTracker 
(red), and analysed by live confocal fluorescence microscopy. Representative confocal micrographs and quantification of (a) mitochondrial ROS production and (c) membrane potential (both calculated as ratios between TMRM and MitoTracker or 
MitoSOX and MitoTracker fluorescence intensities, with each point representing the fluorescence intensity ratio in a cell). MitoSOX/MitoTracker: n=93 WT cells, n=143 Pink1 KO cells and n=113 Prkn2 KO cells in a; TMRM/MitoTracker: n=114 
WT cells, n=141 Pink1 KO cells and n=147 Prkn2 KO cells in c. Data are pooled from four independent experiments. One‒way ANOVA followed by Dunnett’s post hoc test, ***P<0.001 relative to WT cells in a and c. (b) Oxygen consumption rates 
(OCR) and individual parameters for basal respiration ATP production, proton leak and maximal respiration. OCRs were measured  under basal level and after the sequential addition of Oligomycin (Oligo, 1M), FCCP (0.5M) and Rotenone (Rot; 
1M) + Antimycin A (Ant; 1M). Two tailed Student’s t–test *P<0.05 and **P<0.001 relative to WT cells, n=12 pooled from four independent experiments. (d) Representative electron micrographs and quantification of the shape (expressed as 
circularity) of the mitochondrial network; n=173 mitochondria pooled from 21 WT cells and n=77 mitochondria pooled from 10 PINK1 KO cells and n=158 mitochondria pooled from 16 PRKN2 KO cells. The electron microscopy data are representative 
of two independent experiments. Plots represent mean ± SEM. Scale bars are 10m. NS: non‒significant. 
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Supplementary Figure 12. Transcriptome profiling of control and MMA kidney cells. (a) The MANTRA 2.0 tool concept. The connectivity map, which includes transcriptional profiles following treatment of 1309 small molecules across five 
different cell lines, is compared against the disease gene signature obtained from the comparison of gene expression profiles between control and MMA cells. This analysis enables to capture compounds transcriptionally closer to the inverse MMA 
gene signature in order to identify potential drug compound–targeted biological pathway candidates. (b) Hierarchical–clustering and heat map: representation of the 360 genes identified as differentially expressed between control and MMA kidney 
cells, n=3 per each group. Expression levels are color−coded and indicate the fold change in pairwise comparisons; upregulated and downregulated genes are shown in red and green, r espectively. (c) Volcano plot of transcriptome−wide analyses 
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 Discussion and perspectives 
Rare kidney diseases represent a group of at least 150 different disorders, with an overall 
prevalence of about 60–80 cases per 100 000 in Europe and in the USA. Inherited kidney 
disease is one of the cause of kidney transplantation for 10% of the adults and for almost all 
children and it is the fifth most common cause of end-stage-kidneys disease after diabetes, 
hypertension, glomerulonephritis, and pyelonephritis. The progress in kidney transplantation is 
improving the survival of these patients; however, they often have compromised health linked 
to a poor quality of life. Patients with inherited kidney diseases have multisystem complications 
as the kidney is involved in the regulation of essential homoeostatic processes (Devuyst et al. 
2014). Mechanistic studies in different models and cells systems, as performed in this thesis, 
have allowed better characterization of pathways involved in rare diseases and offer novel 
therapeutic perspectives.  
 
New mechanistic insights and therapeutic approaches for Lowe syndrome and Dent 
disease  
The generation and characterization of a new OCRL-deficient mouse model for Lowe 
syndrome/Dent disease 2 allowed us to investigate the renal and extra-renal manifestations 
encountered in patients affected by these diseases. The loss of Ocrl in mouse kidney induces 
PT dysfunction characterized by LMW proteinuria and albuminuria and muscular defect 
associated with dysfunctional locomotricity and reduced growth, as observed in patients 
carrying a mutation in OCRL. The impairment of PT function observed in this mouse model is 
reflected by defective receptor-mediated endocytosis caused by the reduced expression of the 
apical endocytic receptor megalin. This mouse model did not show glycosuria, phosphaturia 
nor calciuria, mimicking the partial renal Fanconi syndrome observed in patients with Lowe 
syndrome/Dent disease 2. 
  The lack of models available for Lowe syndrome/Dent disease was one of the major 
restrictions to assess the cellular and molecular mechanism of OCRL in kidney cells. The first 
developed Ocrl KO mice did not exhibit kidney, eye or brain phenotype due to to the 
compensatory role of INPP5B, the closest paralogue of OCRL in mice and humans (Jänne et 
al. 1998). The conditional double Ocrl and Innp5b KO mouse model (Inoue et al. 2017) showed 
a generalized kidney PT dysfunction reflecting the renal phenotype observed in patients. 
However, this mouse model does not allow the discrimination between the individual role of 
OCRL and INPP5B in the pathophysiology of the disease. To overcome this concern, we used 
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here a novel humanized mouse model expressing human INPP5B in OcrlY/+; Inpp5b-/- or in 
OcrlY/-; Inpp5b-/- background (hereinafter referred to as OcrlY/+ or OcrlY/- respectively). The 
genetic architecture of this humanized mouse line allowed us to investigate directly the 
functional consequences associated with the single loss of OCRL activity. The reinsertion of 
the human INPP5B in the OcrlY/+; Inpp5b-/- background was fundamental for survival 
(Bothwell et al. 2011; Festa et al. 2019). The differences between the humanized OcrlY/- mice 
and the conditional double Ocrl and Innp5b KO (Inoue et al. 2017) were evident when 
comparing the defective tubular endocytic phenotypes. In fact, the single lack of Ocrl in the 
transgenic mice results in a selective dysfunction of the clathrin receptor-mediated endocytosis, 
as evidenced by the specific defective uptake of the low-molecular-weight protein β-
lactoglobulin and the unchanged internalization of dextran, a fluid phase marker (Festa et al. 
2018). By contrast, the conditional deletion of Ocrl and Inpp5b resulted in an unspecific 
impairment of both clathrin-dependent and clathrin-independent endocytosis, as showed by a 
decreased of β-lactoglobulin and dextran uptake (Inoue et al. 2017). 
We were able to reconstitute critical aspects of the disease in vitro by establishing 
differentiated and polarized proximal tubular cell cultures (mPT cells) from OcrlY/- mouse 
kidneys. OCRL coordinates the progression of internalized endocytosis cargo along the 
endosomal pathway by maintaining the PI(4,5)P2 homeostasis. The deficient degradation of 
PI(4,5)P2 by the 5 phosphatase OCRL in early endosomes triggers an aberrant F-actin 
polymerization. The abnormal actin dynamics impairs consequently the trafficking of various 
classes of receptors, including those that pass through the early endosomes to be rapidly 
recycled back to the plasma membrane such as the endocytic receptors cubilin and megalin. 
The trapping of megalin in early endosomes, and hence its defective endosomal trafficking, 
might partly link the OCRL deficiency to kidney tubule dysfunction associated with Lowe 
syndrome. These defects in receptors recycling appear as a potential therapeutic target for 
rescuing the PT dysfunction associated with the disease. Altogether, these findings provide new 
insights into the mechanisms of endocytosis as well as into the molecular pathogenesis of Dent 
disease/Lowe syndrome.  
Recent exciting discoveries demonstrated that the defective endocytic uptake caused by 
OCRL deficiency is rescued by targeting the actin machinery with latrunculin B, an inhibitors 
of actin polymerization, or with the selective depletion of PI(4,5)P2 (Vicinanza et al. 2011). 
Other studies showed that actin polymerization is arising not only from PI(4,5)P2 but also from 
other phosphoinositide lipids. For example, it has been shown that PI(3)P acts in conjunction 
with PI(4,5)P2 in a curved vesicles and triggers actin polymerization (Gallop et al. 2013). PI(3)P 
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is produced by the phosphorylation of PI via Vps34 - a class III PI3K- and it is enriched in 
endosomes, where it is essential for their function (Figure 10) (Gillooly et al. 2000). In an 
OCRL-deficient retinal pigmented epithelial (RPE) cell line, inhibition of PI(3)P production by 
treatment  with PI3K inhibitors wortmannin and Vps34-IN1 reduces the actin comet (Daste et 
al. 2017). All these data suggested that PI3K inhibitors might be a therapeutic strategy in Lowe 
syndrome/Dent disease 2. Additionally, PI3K inhibitors that have been developed for cancer 
therapy, are approved for clinical use, and are thus available for drug repurposing (Yang et al. 
2019). For instance, Alpelisib, a PI3K inhibitor which target p110α, has shown clinical benefit 
in children with PROS/CLOVES syndrome (Venot et al. 2018), a rare overgrowth syndrome 
resulting from the activation PIK3CA gene. 
 We showed that alpelisib treatment on PT cells derived from Ocrl mice alleviates the 
aberrant actin polymerization at endosome by reducing levels of PI(4,5)P2 and PI3P. These 
changes were paralleled by an improvement of the endocytic machinery and absorptive 
capacity in both cellular and mouse model for Lowe syndrome/Dent disease 2. These results 
confirmed the link between phosphoinositide lipids homeostasis, actin polymerization and 
endocytic trafficking in the pathophysiology of Lowe syndrome. Alpelisib might be a 
promising candidate for drug repurposing in the context of this disorder, as there is currently 
no treatment.  
Loss of LMWP in urine is the main feature observed in patients with Lowe 
syndrome/Dent disease 2. These proteins, which are quantified and detected more consistently 
and earlier than the other solutes such as glucose, phosphate and amino acids, offer faithful 
biomarkers of defective receptor-mediated endocytosis in PT (De Matteis et al. 2017). In our 
studies, we showed that alpelisib, a class IA PI3K inhibitor, restores megalin expression at the 
plasma membrane and consequently rescues the apical endocytic uptake capacity of PT cells 
in vitro and in vivo. This effect is reflected by the decrease of CC16 and albumin loss in OcrlY/- 
mice treated with the PI3K inhibitor. Mice treated with alpelisib did not show major toxic 
effects, except glycosuria. This effect is in line with alpelisib administration being known to 
interfere with insulin pathway and induce an increase of glucose in the blood, and could be 
considered as a biomarker for drug dosing. However, mice in both groups (vehicle and treated) 
gained body weight, suggesting that the drug does not affect their development. 
The rescue of endocytosis by alpelisib is explained by its action on the actin machinery. 
Alpelisib rebalances the levels of PI(4,5)P2 and PI(3)P, which results in a decreased of actin 
polymerization in endosome compartment and improvement of the endocytic flux. Moreover, 
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this treatment improves the absorptive capacity of PT cells by restoring the level of megalin at 
the plasma membrane. Our data indicates a bispecific effect of alpelisib on phosphoinositide 
production: on the production of PI(3,4,5)P3 and its conversion to PI(3)P, and on production of 
PI(4,5)P2. PI3K is involved in many cellular pathways including cell growth, survival, 
metabolism and autophagy. Therefore we cannot exclude that the improvement of the endocytic 
capacity is due to effects on PI(3,4,5)P3 directly and the combined effect on other pathways 
modulated by this kinase.  
This study focused on the PT function as it is first affected in paediatric patients with 
Lowe syndrome/Dent disease 2, and because progressive kidney disease is the primary cause 
of morbidity and mortality in these individuals. In fact, the study of urinary solutes is easily 
accessible and quantify, while the measurement of muscular or behavioural defect requires 
more complex investigations, sometimes invasive. Therefore, more work is needed to evaluate 
the potentially beneficial effects of alpelisib on other organs involved in the disease such as 
muscle and eyes.  
Alpelisib may be particularly suitable for long-term use in patients, as it does not 
completely block PI3K activity and thus maintains functions of the signalling pathway. The 
hyperglycaemia induced by alpelisib, observed in mouse and in patients, may be manageable 
by dietary changes. Proximal tubule dysfunction is the first manifestation of kidney disease in 
Lowe syndrome/Dent disease 2 patients; alpelisib intervention in early stage might slow down 
the onset and progression of chronic kidney disease and therefore have a significant impact on 
lifespan and quality of life. Collectively, these data highlight the importance of drug 
repurposing for treating PT dysfunction in Lowe syndrome/Dent disease 2.  
 
Deciphering the pathogenic cascade from MMUT deficiency to mitochondrial 
alterations and cell damage offers promising therapeutic avenues 
The development of kidney tubular cells derived from the urine of patients with MMA and the 
establishment of a new zebrafish mutant line lacking for mmut enabled us to study the link 
between MMUT deficiency and epithelial cell dysfunction. The loss of MMUT induces an 
accumulation of damaged and dysfunctional mitochondria, which results in the production of 
a large amount of ROS, generating epithelia stress and cell damage. In particular, MMUT 
deficiency impairs the PINK/Parkin-mediated mitophagy, leading to an accumulation of altered 
mitochondria that trigger cellular stress. We used an unbiased drug–disease network modeling 
approach as a prioritization tool to identify plausible druggable targets. Our in silico analyses 
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strongly suggest that mitochondria–targeted strategies to correct imbalances in redox 
homeostasis might reverse disease-relevant pathways in MMA. 
The epithelial cells from the kidney tubules are enriched in mitochondria to sustain their 
specialized transport functions. Impairment of mitochondrial homeostasis or assembly might 
lead to kidney tubule dysfunction in various types of diseases (e.g. mutations in genes encoding 
for electron carriers proteins or assembly factors) (Emma et al. 2016). The presence of 
fragmented mitochondria and an increase of mitochondria DNA in MMA patient-derived 
kidney cells suggest that MMUT deficiency alters mitochondria network. Furthermore, 
energetic study showed a reduction of mitochondrial membrane potential as well as a reduction 
of baseline respiration, total respiration capacity and ATP turnover in MMA cells. These altered 
and dysfunctional mitochondria trigger the production of ROS, associated with an increase of 
Lipocalin 2 (LCN2), a marker of cellular damage. The abnormal mitochondria are also 
observed in mouse kidney tubule cells conditionally inactivated for the floxed Mmut alleles in 
vitro and in the kidney of mice carrying a mutant Mmut allele (p.Met698Lys, corresponding to 
the patient mutation p.Met700Lys) and a knock-out Mmut allele (hereafter referred to as 
MmutKI/KO mice), confirming the importance of MMUT to maintain the mitochondria 
homeostasis and function. Despite the elevated levels of MMA metabolite and mitochondria 
abnormalities, these mutant mice showed no significant alterations in kidney function, neither 
structural damage nor interstitial inflammation in the kidneys compared to the control mice, 
thus failing to recapitulate the kidney disease associated with MMA. 
To overcome this difficulty, we developed the first mut knock-out zebrafish model using 
CRISPR/Cas9 genome editing. The zebrafish has become a significant model system for 
studying kidney disease as the patterning of the kidney tubule is well conserved in zebrafish 
pronephros, with the expression of junctional complexes, endolysosomal apparatus, and 
receptors and transporters that are required for performing their absorptive functions. The 
modifications of mitochondria morphology and function described in Mmut KO/KI and patient-
derived kidney cells were observed in the zebrafish model. Moreover, in contrast to the mouse 
model, the mutant zebrafish show a more complete disease-relevant phenotype, including liver 
mitochondriopathy, behavioural abnormalities and an excess of mortality. Interesting, these 
features are rescued when the fish are feeding with a low protein diet, a strategy currently used 
in MMA patients to prevent the accumulation of methylmalonic acid. These results demonstrate 
the key role of MMUT in preserving the mitochondrial network and homeostasis and the 
probable involvement of mitochondria quality control system in the disease.  
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Autophagy is an evolutionarily conserved process that degrades malfunctioning cellular 
constituents within a double-membrane structure called an autophagosome (Choi, Ryter, and 
Levine 2013). This quality control pathway is essential to maintain cellular homeostasis and 
function. Using a comprehensive series of autophagy‒based assays, we were able to describe 
the downstream consequences of the MUT deletion on autophagy. Surprisingly, we observed 
an increase of autophagic vesicles due to the stimulation of autophagosome biogenesis. 
Furthermore, upstream signalling cascades involved in the regulation of autophagy biogenesis, 
such as mTORC1 and ULK1 complexes, were downregulated and upregulated respectively. 
Collectively, these data suggest that MUT deficiency stimulates autophagy by regulating, at 
least in part, upstream signalling cascades involved in autophagosome biogenesis. 
It is known that the selective degradation of damaged and/or dysfunctional mitochondria 
occurs via a process called mitophagy (Palikaras, Lionaki, and Tavernarakis 2018). This 
process is selectively induced by the recruitment and activation of the mitochondrial 
serine/threonine protein kinase PINK1 and E3-ubiquitin-protein ligase Parkin to the outer 
mitochondrial membrane. This pathway drives mitochondria to be sequestered within 
autophagosomes and delivered to the endolysosome for degradation. Here, we used different 
pharmacological and genetics approaches to investigate the consequence of the loss of MMUT 
function on the selective degradation of damaged mitochondria. Rotenone treatment on control 
and MMA cells damages the mitochondria and triggers their selectively degradation by 
mitophagy. Parkin, which translocates to damaged mitochondria in physiology condition, was 
reduced in MMA cells in both normal and mitophagy induced conditions.  The consequence of 
the defective PINK1-PRKN mechanism is the impairment of the mutant cells to deliver the 
dysfunctional mitochondria to the autophagy-lysosome degradation systems. This observation 
was monitored with mt-Keima, a ratiometric pH-sensitive probe used to measure the delivery 
of damaged mitochondria (which were labelled by the mitochondrial targeted form of a 
fluorescent Keima protein, mt-Keima) to the lysosomes (Katayama et al. 2011). These cellular 
defects compromise the clearance of mitochondria; trigger accumulation of mitochondria as 
shown by a marked increase of mitochondrial proteins and DNA. Expression of PINK1 in 
mutant cells activates mitophagy-mediated degradation of damaged mitochondria, improves 
the function of the mitochondrial network and homeostasis, and thereby averting mitochondria-
derived epithelial distress and cell damage. 
We used MANTRA, an in silico tool, to identify plausible druggable targets in the MMA 
context (Carrella et al. 2014). These in silico analyses suggested that targeting mitochondrial 
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function and homeostasis might reverse disease phenotypes associated with MMUT deficiency. 
Taking in account the MANTRA predictions, we used compounds targeting mitochondria, such 
as mito–TEMPO (MT) and MitoQ and tested their potential benefits in vitro and in vivo. 
Consistent with in silico predictions, MT rescues the morphology and homeostasis of the 
mitochondrial network and improves its function, neutralizing thereby mitochondria–derived 
oxidative stress and cell damage in MMA kidney cells. We applied this strategy in mut–
deficient zebrafish model: treatment with a low, non–toxic dose of MitoQ alleviated the 
mitochondrial oxidative stress and improved the behavioural phenotype of the fish model. The 
in silico predictions were validated by exposing MMA cells to either merbromin or lycorine, 
the two top drug candidate compounds that obtained a similar transcriptional responses but 
have distinct structure. This treatment of MMA cells improved the morphological abnormalities 
of the mitochondrial network (e.g. circularity and mitochondrial interconnectivity) as well as 
its functioning (e.g. membrane mitochondrial potential and production of mitochondrial ROS). 
On the other hand, merbromin and lycorine did not modify the levels of methylmalonic acid in 
MMA cells, supporting the concept that mitochondrial targeting acts independently from the 
elevation of toxic MMA metabolites. These results support the concept that targeting 
mitochondria, in order to improve their function and homeostasis, might represent a valid 
therapeutic perspective in MMA. 
Taking all together, the studies reported in this thesis support the importance to develop 
new models, in vivo and vitro, to decipher the cellular and molecular pathway involve in rare 
genetic diseases. The development of news tools, such as in silico analysis, are essential to 
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